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Computed tomography (CT) and positron emission tomography (PET) are routinely
used in (pre)clinical research and practice. The radiation burden inflicted on subjects
from both modalities needs to be addressed to keep exposures as low as possible.
While the focus in literature is on human dosimetry, few studies investigate the
animal dosimetry in preclinical studies. This doctoral thesis aimed to quantify the
radiation burden imposed on subjects by CT and PET in clinical and especially
preclinical case studies using both experimental data and Monte Carlo simulations.
We derived the biodistribution of three 18F-radiopharmaceuticals (18F-UCB-H, 6-
[18F]fluoro-L-DOPA and 2-[18F]fluoro-L-Tyrosine) in mice using the gold standard
method organ harvesting, as well as dynamic microPET imaging and the new tech-
nique of hybrid imaging, where microPET activities are cross-calibrated with the
activity remaining in post-scan harvested organs. The radiation dosimetry in hu-
mans was calculated and results of all methods were compared. For the newly
developed tracer 18F-UCB-H, a first-in-human clinical study was conducted and the
radiation dosimetry was compared to preclinically obtained data. Additionally, the
preclinically obtained human dosimetry of 6-[18F]fluoro-L-DOPA was compared to
clinical values available in the literature. The derived biodistributions of the three
tracers were also applied to mouse S-factors to calculate absorbed doses in mice.
Furthermore, the radiation dosimetry of the small animal microCT GE eXplore 120
was experimentally investigated ex vivo in a custom built phantom and in vivo in rats.
A model of the imaging system was built using Monte Carlo simulations to further
investigate the radiation dosimetry non-invasively.
The preclinical study of the three 18F-radiopharmaceuticals in mice showed that
hybrid imaging produces equivalent results compared to labour intensive organ har-
vesting while being more efficient from an ethical, economical, and scientific point
of view. Sole dynamic microPET imaging produced poor results due to partial vol-
ume effects and quantification errors in small volumes. Clinically and preclinically
derived data of 18F-UCB-H and 6-[18F]fluoro-L-DOPA agreed roughly regarding total-
body absorbed dose and effective dose, but significant differences were revealed in
organ absorbed doses for both tracers. The experimentally derived radiation dosime-
try of microPET and microCT imaging in mice showed that animals are exposed to
significant amounts of radiation in preclinical studies. Monte Carlo simulations of
the GE eXplore 120 were in good agreement with experimental results and provided
a deeper insight into the spatial dose distribution.
Based on our analysis, hybrid imaging could serve as a replacement for the cur-
rent gold standard of organ harvesting in preclinical dosimetry. Preclinically ob-
tained estimates of human dosimetry showed relatively poor accuracy and should
be used with caution for the calculation of injection limits in first-in-human studies.
We demonstrated that excessive radiation doses are inflicted on small animals in
preclinical imaging, especially in dual-modality longitudinal studies. The radiation
should be addressed in advance to avoid critical exposures that might compromise
the outcome of the study.
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C H A P T E R 1
Introduction
1.1 Motivation
In the last two to three decades the use of computed tomography (CT) and positron
emission tomography (PET) increased constantly and they are now essential for
routine clinical use, as well as preclinical and clinical research [1, 2], e.g. in on-
cology [3]. Due to advances in technology in the past decade, stand-alone PET
scanners have almost disappeared from modern hospitals and have been substituted
for the dual-imaging modality PET/CT [3]. The combined system exhibits several
advantages, such as intrinsically spatially co-registered images as well as faster and
qualitatively better transmission scans for attenuation correction [4]. The main clin-
ical applications of PET/CT imaging are staging, restaging and assessment of tumor
response in oncological applications [3], with 2-deoxy-2-[18F]fluoro-D-glucose (18F-
FDG) being the currently most used radiopharmaceutical [5]. Other applications
consist of the target volume definition for highly accurate radio therapy treatment
[6], the assessment of myocardial viability and perfusion in cardiology [7, 8], and
the diagnosis of neurological pathologies such as Alzheimer’s [9], epilepsy [10], and
Parkinson’s [11]. One common application of preclinical micro positron emission
tomography (microPET) imaging, which is often combined with micro computed
tomography (microCT) imaging for anatomical referencing, is in the field of drug
development as it allows for dynamic, pharmacological, longitudinal observations
on the same animal [12]. Using suitable radiopharmaceuticals microPET imaging
enables researchers to non-invasively monitor biological processes, disease progres-
sion and therapy response in small animals providing a potential translational model
for human medicine [13]. Because of the widespread use of PET/CT and the ever-
increasing number of applications, the radiation exposure of subjects undergoing a
single PET or CT imaging session and especially a combined PET/CT scan needs to
1
2 Chapter 1. Introduction
be addressed to keep the radiation burden as low as possible. The focus of past dosi-
metric considerations in the literature has mainly been human applications. With the
emergence of preclinical microPET and microCT of small animals in the last decade,
however, there is a need for further investigations into the radiation burden of ani-
mals. Since longitudinal studies are commonly conducted in preclinical imaging and
often involve dual-modality microCT/microPET or micro single photon emission
computed tomography (microSPECT) scans [14, 15], the radiation exposure needs
to be quantified to rule out any influence on the outcome of the study [16].
1.2 Units of radiation and biological effects
The amount of radiation received by any subject from any type of ionizing radiation
in nuclear medicine and radiology is quantified using the absorbed dose (D). It is





where dε is the mean deposited energy induced by the ionizing radiation to the
matter in the volume element of mass dm. In radiology the term absorbed dose
is used interchangeably with the term dose, however, in nuclear medicine as dose
could possibly refer to other quantities D is always referred to as absorbed dose.
Physical processes caused by ionizing radiation depositing the energy within matter
will be described in Section 2.4. The SI unit of the absorbed dose is gray (Gy) with
1 Gy being equal to 1 J
kg
. Other units for the same quantity exist but are outdated
and erg
g
or rad will not be used here. In diagnostic nuclear medicine and radiology it
is under all circumstances the aim to keep the absorbed dose as low as possible to
avoid any biological effects in living tissue. Nonetheless, the overall aim is to acquire
diagnostically useful images and the subject should not be exposed to radiation
unnecessarily.
Radiobiology differentiates between two types of effects caused by ionizing radi-
ation: stochastic effects and deterministic effects. Stochastic effects resulting from
exposure to ionizing radiation are carcinogenesis and hereditary effects, whose sever-
ity are independent of the received absorbed dose and may, or may not, manifest
many years or even decades after exposure [18, 19]. However, their probability of
occurrence increases with the absorbed dose. Deterministic (or non-stochastic) ef-
fects occur only above a certain threshold of radiation exposure and are usually not
of concern in diagnostic imaging opposed to radiation therapy (nuclear medicine
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or external beam), which aims at producing deterministic effects in pathological tis-
sue [19]. Below this threshold deterministic effects do not manifest, but beyond the
threshold their severity increases with the absorbed dose. Because of inter-individual
differences the threshold may vary. Manifestations of deterministic effects after acute
exposure are i.e. erythema (reddening of the skin), epilation (loss of hair), depres-
sion of bone marrow cell division, NVD (nausea, vomiting, diarrhea), central nervous
system damage, and damage to unborn children. However, in diagnostic imaging
patients, whether in nuclear medicine or radiology, only stochastic effects are of
concern due to the low absorbed doses.
Since the absorbed dose does not take into account the type of radiation or the
type of target material, there is the need for other quantities in medical dosimetry as
different materials, especially biological tissues, are more radiosensitive to different
types of radiation than others [17, 19]. The International Committee of Radiation
Protection (ICRP) publishes regularly recommendations on radiation protection and
has defined the quantity of the effective dose [20], which is a sex, age, and dose
rate (delivered dose over time) independent quantity. It is a measure of the resulting
stochastic risk to a subject by a non-uniform radiation. As the effective dose is ap-
plicable to many situations (i.e. medical imaging including patient and practitioner,
aviation exposures, etc.) one must account for different types of radiation and bio-
logical tissues. Before giving the definition of the effective dose the equivalent dose
(or radiation-weighted dose) is to be considered. The equivalent dose is accounting
for the different types of radiation (i.e. photons, electrons/positrons, neutrons, pro-
tons etc.) and their relative biological effectiveness in producing biological damage.
Therefore, the equivalent dose H to a specific tissue or organ T is the weighted sum





where wR is the weighting factor for the radiation type R and DT,R the absorbed
dose to tissue T from that particular radiation. The weighting factors were pub-
lished first in ICRP publication 26 [21], and were most recently updated in ICRP
publication 103 [20] in 2007. As the weighting factor wR for radiations produced
in diagnostic nuclear medicine and radiology are equal to unity, the equivalent dose
can be interpreted as the physical absorbed dose in photons or electrons that has
the same biological effect to an organ or tissue. However, since the quantity is
committee-defined, the unit was assigned to be sievert (Sv) instead of gray (Gy).
Heavier particles like protons, alpha particles or neutrons have higher weighting
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factors as they are more potent in producing biological damage. In order to estimate
the stochastic risk to a subject from any given ionizing imaging modality, all types
of radiation must be known and therefore the equivalent dose H to all tissues. Addi-
tionally, the respective radiosensitivity of all tissues must be taken into account, as
they vary for different organs and tissues. Their intrinsic radiosensitivity is reflected
in the tissue weighting factor wT , which allows for calculation of the effective dose





The weighting factors wT were first published in ICRP publication 26 [21] and
were updated twice in ICRP 60 [22] and the most recent publication 103 [20]. The
first weighting factors from ICRP 26 reflected mortality risk only, but due to the
advancement in knowledge of radiosensitivity, the weighting factors of ICRP 60 and
103 reflect the following quantities: probability of attributable fatal cancer, weighted
probability of attributable non-fatal cancer, weighted probability of severe hereditary
effects, and relative amount of time lost [19]. The sum of all tissues / organs (with
a known weighting factor) results in the effective dose for the whole body, which is
commonly used in diagnostic nuclear medicine to assess the exposure risk. According
to the EANM dosimetry committee the most recent weighting factors from ICRP 103
should not be applied yet, as they are phantom specific (male and female, published
in [23]) and specific absorbed fractions for those phantoms were not published at the
moment this manuscript was prepared [24]. Controversially, many studies apply the
tissue weighting factors from ICRP 103 to effective dose calculations based on the
standard hermaphroditic phantom [25–29] as was requested by reviewers during
the publication process of Paper I in Appendix A. The effective dose based on ICRP
103 was also added in Paper II in Appendix B. We were made aware of that widely
spread misconception during the review of Paper IV in Appendix D and therefore the
reader is advised to focus on effective doses based on tissue weighting factors from
ICRP 60, which are displayed exclusively in Chapter 3 to 5. The use of the effective
dose for assessing radiation risk from medical exposures is contentious anyway, as
the value is averaged over sex and age, and neglects the impact of absorbed dose
rate [19, 30]. Many still recommend the use of absorbed doses for patient specific
dosimetry as it only reflects deposited energy per mass [30, 31].
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1.3 Typical clinical and preclinical exposures
Typical radiation exposures of patients undergoing PET imaging highly depend on
the administered radiopharmaceutical, the amount of activity necessary to obtain
a diagnostically useful image and partially on the scanners sensitivity towards sig-
nal detection. Therefore, every newly developed radiopharmaceutical needs to be
investigated regarding its radiation burden to the subject. In CT imaging however,
it depends exclusively on the technical properties of the scanner itself, such as beam
geometry, collimation, detector size and sensitivity, and the noise reduction tech-
niques applied in image reconstruction [32]. Mettler et al. published in 2008 a
literature review on effective doses in radiology and nuclear medicine [33] based
on over 150 peer-reviewed scientific publications. They reported average effective
doses for several types of clinical CT examinations including head CT (2 mSv, range
0.9 to 4 mSv), chest CT (7 mSv, range 4 to 18 mSv), and coronary angiography (16
mSv, range 5 to 32 mSv). For PET imaging using 18F-FDG they stated an average
effective dose of 14.1 mSv based on an administered activity of 740 MBq, however,
injected activities are less using high sensitivity state of the art PET/CT scanners.
Brix et al. studied the radiation exposure of patients undergoing whole-body dual-
modality 18F-FDG PET/CT examinations in four different German hospitals using
their hospital specific routine protocols and arrived at the conclusion of an average
effective dose of 25 mSv (range of 23.7 to 26.4 mSv) [34]. Another study conducted
by Huang et al. presented the radiation dosimetry of whole-body PET/CT scanning
using different CT protocols and an injected activity of 370 MBq of 18-FDG. They
reported an effective dose of 13.45 mSv to 31.91 mSv depending on the chosen CT
imaging protocol [35]. There are far fewer studies published about the radiation
dosimetry of small animals in either single PET or CT scans, or in dual-imaging
PET/CT and SPECT/CT. Taschereau et al. published two separate studies on mi-
croCT [36] and microPET imaging in mice [37], reporting an average whole body
absorbed dose of 93 mGy from microCT and an average whole body absorbed dose
of 106 mGy for an injection of 7.4 MBq 18F-FDG from microPET. Since there are no
existing radiation or tissue weighting factors for mice, absorbed doses can only be
reported. Absorbed doses from preclinical microCT scanners tend to be much higher
than clinically used CT scanners due to the trade-off that has to be made between
the resolution (typically 50 to 100 µm) and the X-ray dose to achieve a sufficient
signal-to-noise ratio in images [38].
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1.4 Regulations for new radiopharmaceuticals
When planning a first-in-human clinical trial with a newly developed radiopharma-
ceutical, assessing the dosimetry preclinically in animals first is a prerequisite in
order to rule out any overexposure of the subjects [39–41]. First injection limits pro-
jected from preclinically derived dosimetry data can be estimated and aim to keep
the radiation exposure of subjects in clinical trials in acceptable ranges, while still
producing diagnostically useful images. The regulations for the maximum allowed
radiation burden to voluntary subjects in clinical trials for new radiopharmaceuticals
depend on the country and agency. In Europe, guidelines adopted from ICRP publi-
cation 62 [42, 43], suggest different radiation exposures depending on the benefit of
the radiopharmaceutical used compared with the detriment caused by the involved
radiation. In other words, the more substantial the benefit is, the higher the allowed
radiation burden to the subject might be, which is summarized in risk categories
[40]. Their radiation exposure limits are based on the effective dose, neglecting any
specific organ absorbed doses [43]. For a radiopharmaceutical with a minor level
of expected societal benefit, which is categorized as simply increasing knowledge
of e.g. a disease, an effective dose below 0.1 mSv is allowed with the risk category
being trivial (1 in a million have a direct consequence linked to the radiation bur-
den) [42]. When the expected level of societal benefit of the radiopharmaceutical is
substantial, radiations above 10 mSv are allowed and direct consequences (such as
cancer) for 1 out of 1000 are considered to be acceptable. However, the radiation
must be kept below deterministic thresholds except for therapeutic experiments. In
the United States of America the agency describing the radiation limits for research
studies is the Food and Drug Administration (FDA). They follow a different approach
and use specific organ doses limiting the maximum injectable dose based on the
equivalent dose and specify a single scan and an annual limit. For the whole body,
blood forming organs, lens of the eye, and gonads 30 mSv should not be exceeded
per scan with the annual limit being 50 mSv. For all other organs 50 mSv per scan
and an annual limit of 150 mSv should not be exceeded [43, 44].
1.5 Specific aims
The primary goal of this doctoral thesis was to assess the radiation burden inflicted
on subjects in clinical and preclinical case studies involving newly developed PET
radiopharmaceuticals. These case studies involve PET imaging and often CT imaging
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for localisation and/or for attenuation correction of PET data. Therefore the focus
was on the quantification of the radiation exposure of both imaging modalities.
Specifically, several aims were defined:
I. Preclinically derived human radiation dosimetry of newly developed
(or unpublished) radiopharmaceuticals in PET imaging. The well-known
methodology of biodistribution assessment in small animals using organ
harvesting and dynamic microPET imaging was experimentally applied to-
wards radiopharmaceuticals. A newly developed compound [18F]UCB-H (18F-
UCB-H) with a presently unknown biodistribution and radiopharmaceuticals,
whose preclinically derived radiation dosimetry was not available in litera-
ture (6-[18F]Fluoro-l-DOPA (18F-FDOPA) and 2-[18F]Fluoro-l-Tyrosine (18F-
FTYR)) at the time, were studied . A third method of activity quantification,
which aims to combine the advantages of organ harvesting and dynamic mi-
croPET imaging while possibly eliminating their disadvantages, was applied
for the first time to mice experiments. Human radiation dosimetry calcula-
tions based on the preclinicially derived data using all three methods were
performed and presented for the first time.
II. Clinically derived human radiation dosimetry of 18F-UCB-H and com-
parison to preclinical results. The human radiation dosimetry for the newly
developed radiopharmaceutical 18F-UCB-H was derived for the first time
based on a clinical study conducted within the frame of this thesis. The re-
sults were compared to preclinically derived results.
III. Small animal radiation dosimetry of newly developed (or unpublished)
radiopharmaceuticals in microPET imaging. The experimentally obtained
kinetic biodistributions were used to calculate the radiation dosimetry for
all three radiopharmaceuticals in mice. The results, presented for the first
time for the three specific tracers, and based on the different methods for
assessing the biodistribution, were compared and discussed.
IV. Experimental X-ray dose quantification of the GE eXplore 120 microCT.
The radiation dose delivered by several relevant imaging protocols of the GE
eXplore 120 micro CT was quantified for the first time. It was assessed ex vivo
using a custom built phantom and in vivo in sacrificed rats. The dosimetry
was presented in the standard clinical measure of computed tomography
dose index and organ doses inflicted on the animal.
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V. Simulation of X-ray dose of the GE eXplore 120 microCT using Monte
Carlo simulations. The X-ray source and the geometry of the GE eXplore
120 microCT was modelled in the Monte Carlo simulation (MCS) software
package Geant4 Application to tomographic emission (GATE) and the energy
deposition of the radiation was quantified in the same custom built phantom
used in the experiments. Additionally the dose was derived for rats and mice
and compared to the experimental results.
1.6 Structural outline
Chapter 2 provides the basic scientific background for readers unfamiliar with the
topic to fully comprehend the published / unpublished publications this thesis is
based on. A brief insight into medical imaging (PET and CT), radiopharmaceuticals,
radiation transport in matter, and absorbed dose quantification techniques is given.
References to in-depth information on each topic for the interested reader are sug-
gested as covering all topics in detail is far beyond the scope of this manuscript. In
Chapter 3 and subsections all performed studies dealing with one of the specific
aims mentioned in Section 1.5 are introduced, their results are briefly discussed and
links are established between the different studies. The full detailed (published /
unpublished) manuscripts are provided as Appendix A to F for the interested reader.
They offer in-depth descriptions of all involved methods, results and their discussion.
Chapter 4 consists of a comprehensive discussion of all results and their impact on
the field of preclinical and clinical dosimetry. Conclusions drawn from the discussion
are summarized in Chapter 5.
C H A P T E R 2
Scientific background
In this chapter a basic overview of the involved imaging techniques is presented with
the focus on their respective production of ionizing radiation leading to the absorbed
dose in matter. A basic physical overview of radionuclides and their radioactive
decay, photon interactions with matter, the subsequent energy deposition due to
interactions of charged particles with matter and ways of quantifying it, is covered.
The mathematical basics of absorbed dose calculations in radiology and nuclear
medicine are presented to provide the necessary background to comprehend the
journal publications involved in this manuscript.
2.1 Positron Emission Tomography
PET imaging exploits the positron emission for imaging purposes, which is part of the
radioactive decay of the isotope bound to a radiopharmaceutical. The subsequent
annihilation of the positron with an electron is followed by the emission of two
almost opposite photons [45]. The interactions of all emitted particles with matter
inside the subject cause the radiation burden, which will be described in Section 2.4.
The detection of the two opposing photons is called coincidence detection, which
represents a line of response as the photons emitted under approximately 180◦ orig-
inate from an annihilation event on the straight line between the opposite detectors.
The first coincidence detection technique with positron emitters was reported in
1951 by Wrenn et al. [46] for localization of brain tumors. There are a broad variety
of radiopharmaceuticals available for use in e.g. oncology, neurology or cardiology
and an overview of common radiopharmaceuticals, their use and production can be
obtained here [5]. The radiopharmaceutical, which is often an analog to a natural
occurring compound in the human body, is introduced to the blood circulation of
the subject by injection (or inhalation for special tracers [47]) and distributes inside
9
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the organism according to its physiological task making PET imaging a functional
imaging technique. Since the radioactive isotope used for labelling of the tracer
constantly decays, the coincidence detection can be used to spatially quantify the
dynamic distribution of the isotope inside the subject as every detected event can
be related to a nuclear disintegration. The PET scanner consists of a cylindrical de-
tector array located around the subject, which dynamically detects the coincidence
events in its field of view. The detected photons are considered a coincidence event,
if they fulfil certain requirements. They need to be detected in both detectors within
a certain timing window to ensure they originate from the same annihilation event
and with an energy corresponding to the energy window of the detectors. There
are several events that can lead to a coincidence event detection, i.e. the “true”,
the “scatter”, the “random” and the “multiple” [48]. Only a true event is a correctly
detected line of response, where two photons are detected originating from a single
annihilation located on the line of response between the two opposite detectors. The
scatter, random and multiple events are falsely detected lines of response due to
scattering, absorption of photons or annihilation events at the same time (for details
see [45, 48]). In order to obtain quantitative data from PET imaging, one has to
account for these falsely detected lines of response during data processing. With
increasing amount of radioactivity inside the field of view, the dead time of the de-
tectors (non-responsiveness during and after detecting an event) play an important
role in quantification as well, which needs to be corrected for. Since the annihilation
events occur inside matter that attenuates photons, only a fraction of the emitted
photons reach the detector. In order to account for the attenuation and to allow for
accurate quantification, an attenuation scan is performed before (or sometimes af-
ter) the PET emission scan. In older clinical PET stand-alone systems (or preclinical
stand-alone systems) the attenuation scan is performed by acquiring a blank scan
without the object present and the transmission scan with the object present using
a rotating source of a gamma or positron emitter (57Co or 68Ge). The ratio between
blank and transmission scan results in the attenuation correction factors to correct
the emission data [48]. In state of the art PET/CT systems, the attenuation correc-
tion factors are derived from the CT scan [49]. For details on image reconstruction
the reader is referred to [48], with special focus on the filtered back projection [48]
and the iterative list mode time-of-flight algorithm [50], since they were used for
reconstruction in the presented publications. For most applications of PET imaging,
especially dosimetry, accurate quantification of the radiopharmaceutical is essential.
However, the spatial resolution of the imaging system is limited by physical effects
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related to the radioactive isotope [51], the physics of the detection process [52] and
the image reconstruction process [53], which impairs the quantification in small
objects [54]. The finite spatial resolution, generally described by the system’s point
spread function, results in the partial volume effect (PVE) altering the intensities of
voxels inside the image, which is more apparent in small objects and boundaries be-
tween adjacent structures having different intensities [53]. Additionally, due to the
image representation in a spatially finite voxel grid, two structures could be present
within the same voxel forming an average intensity of the two distinct structures.
Accounting for these impairments of quantification is essential in dosimetry.
2.2 Computed Tomography
After the first publication of a clinical head scan using an EMI head scanner by
Hounsfield and Ambrose in 1972 [55], CT gradually became indispensable in clini-
cal routine. It was the first imaging technique to produce images of the inside of the
human body without falsification through superposition of anatomical structures as
present in radiography, which produces a planar projected 2D image. CT and radiog-
raphy both image a structure using X-rays, which are of electromagnetic nature with
a wavelength approximately between 10−8 m and 10−13 m (photon energies of 100
eV to 10 MeV). In diagnostic medicine, X-ray quanta with energies between 40 and
140 keV are used. Due to their short wavelength and high energy they penetrate
matter as first observed by Wilhelm Conrad Roentgen in 1895, who received the
Nobel Prize for Physics in 1901 for his discovery. X-rays are produced inside an X-ray
tube. Electrons are accelerated in a vacuum towards a rotating solid metal anode by
applying a high voltage between the anode and a wire filament acting as a cathode.
After entering the anode the electrons interact with matter and two physical effects
lead to the emission of photons in the energy range of X-rays. These effects will be ex-
plained more detailed in following chapters and can be found here [19, 56]. Briefly,
in one effect the electrons interact with the Coulomb field of the atoms inside the
anode material and consequently are slowed down. The deceleration of the charged
particle creates an electric dipole emitting electromagnetic waves in the range of
X-rays with a continuous energy spectrum called Bremsstrahlung. The other effect
occurs during the direct interaction of the fast electron with an atomic electron of
the anode material. If the atomic shell electron is removed from the shell by the
collision, the atom is ionized and an electron from a higher energetic shell fills the va-
cant position. The energy difference between the shells is emitted as X-ray radiation,
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leading to a characteristic energy spectrum with peaks according to the difference
in energy of the specific shells, which is singular to the material(s) of the anode.
Both spectra superimposed lead to the specific energy spectrum of the X-ray tube.
In Figure 2.1 typical X-ray emission spectra are displayed (all produced with the
X-ray spectrum simulator provided by Siemens, Link to X-ray toolbox). Figure 2.1a
represents unfiltered spectra of materials and tube voltages used in mammography,
and Figure 2.1b displays filtered spectra of tungsten as used in CT. The sharp peaks
in all spectra can be related to the characteristic energy spectrum of the respective
material and the underlying continuous spectrum to Bremsstrahlung.
Figure 2.1: X-ray emission spectra of (a) Molybdenum (Mo), Rhodium (Rh) and
Tungsten (W) at 40 kVp and (b) of W at 80, 110 and 140 kVp
The exposure of the subject to X-ray radiation and the subsequent interaction
of the photons with matter of the subject cause the radiation burden as will be
described later. In medical imaging the energy spectrum is usually filtered before
the exposure of the patient to remove low energy X-ray quanta, which reduces the
dose, and artifacts due to the energy dependence of the X-ray attenuation in the
image reconstruction. The fact that X-ray absorption inside matter depends on their
energy and atomic number Z of the material can be exploited to acquire the image
of the inside of an object by exposing it to X-rays. In CT the X-ray source and a
detector array at fixed geometry and distance rotate around the subject and collect
spatially dissolved X-ray attenuation data of the subject at every angle referred to
as projections. These projections plotted over all angles represent the sinogram of
the respective axial image slice, which is ultimately the raw data that is used for
reconstructing a 2D image of the X-ray attenuation inside the slice of the subject, i.e.
a tomogram. Reconstructing an image out of projection data is an inverse problem
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and involves complex physics, mathematics and computer science, which is far out
of scope of this manuscript. The basics of image reconstruction in CT imaging can
be found here [56] as well as a more detailed description of the whole CT imaging
technique. All CT images presented in this manuscript have been reconstructed using
Feldkamp’s filtered backprojection [57].
2.3 Radionuclides
In this section the physical basics of radioactive nuclei used in diagnostic nuclear
medicine, their decay scheme including the emitted particles and radiations are cov-
ered. Since every radiopharmaceutical used throughout this manuscript was labelled
with the same isotope, the decay scheme of 18F is explained only. Knowledge of the
emitted particles, the resulting radiation and the interaction of both with matter
are essential for dosimetric calculations. There are several ways for an unstable
nucleus to decay depending on the type of nucleus. For therapeutic and diagnostic
nuclear medicine only α, β and γ decay are of particular interest, however, there
are also internal conversion, spontaneous emission of a single proton or neutron,
and spontaneous fission. As 18F is a β particle emitter, specifically a β+ emitter, only
the β+ decay scheme will be discussed. 18F is a proton enriched isotope of fluorine
having an excessive number of protons and consequently an excessive neutral elec-
tric charge for its mass. It will try to reach a more energetically favourable state by
making a transition to another nuclear state or nucleus. This transition, i.e. nuclear
decay, can take place as two different decays, the positron decay and the electron








+ + ν +Q(+e-). (2.1)
The proton enriched parent nucleus X decays into the energetically more favourable
daughter nucleus Y by emitting the positron β+ and a neutrino ν, which has a very
small mass and no charge. After the nuclear transition described in 2.1, the daughter
nucleus Y has an atomic number Z− 1, which is one less than the parent nucleus X.
In order to keep the electrical charge balanced, an orbital electron of the daughter
nucleus must be ejected from the atom, which is achieved by a process called internal
conversion. The nucleus supplies energy (Q(+e-)) to overcome the binding energy
of the orbital electron, which can leave the atom with residual kinetic energy to
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balance charge. On a subnuclear spatial level the decay can be described as the
conversion of a proton into a neutron n, a positron β+, and a neutrino ν
1
1p→ 10n + 01β+ + ν. (2.2)
Since during the positron decay a positron is ejected from the nucleus and an elec-
tron from the atom to keep the electrical charge balanced, the requirement for
the positron decay to take place is that the parent atom must be heavier at least
by double the electron/positron rest mass of 2me (1.022 MeV) than the daughter
nucleus.
The competing process to positron decay is electron capture, which is possible
due to the spatial overlap between the nuclear volume and the wavefunction of an
orbital electron, especially the K-orbital of high-A nuclei due to their larger nuclear
radii. The process takes place as follows on an atomic level
A
ZX + e
- → AZ−1Y + νe. (2.3)
The proton-rich parent nucleusX absorbs an inner atomic electron e− thereby chang-
ing a proton to a neutron and emitting a neutrino. Since the proton is changed into a
neutron, the atomic mass remains unchanged while the number of protons decreases
transforming the parent nucleus into the daughter nucleus Y . The missing electron
on the K-shell is replaced by an electron from a higher orbital, which results in the
emission of the difference in binding energy of both shells in form of X-ray radiation.
Electron capture is possible when the parent nucleus is heavier than the daughter
nucleus, however, when the mass difference exceeds 1.022 MeV, β+ decay becomes
possible. For 18F electron capture occurs only 3.1% of the time, the remaining decay
is ruled by positron decay. The branching ratio (or branching fraction) represents
the fraction of particles which decay by an individual decay mode with respect to
the total number of decaying particles. Therefore, the branching ratio of 18F is 0.969,
since decay by positron emission occurs 96.9% of the time.
After emission of the positron from the nucleus to reach the energetically more
favourable nuclear state, the positron will have an initial energy with a dynamic
distribution up to a maximum value. The particle will lose kinetic energy along
its travelling path by different types of interactions with other nuclei. These types
of interactions will be described in detail in a later section. In general, there are
four different types of interactions: inelastic collision with atomic electrons, elastic
scattering with atomic electrons, inelastic scattering with a nucleus, and elastic
scattering with a nucleus. For elastic scattering kinetic energy and momentum are
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conserved, but for inelastic scattering the kinetic energy of the positron is reduced.
The particle is deflected by every interaction making an estimation of the travelling
range of the positron difficult.
Eventually, after the kinetic energy is sufficiently reduced, the positron combines
with an electron when both are essentially at rest leading to the annihilation event.
The event sends off electromagnetic radiation in the form of two photons of the
energy of 0.511 MeV, which is equal to the rest mass of each particle. The particles
are emitted under an angle of 180◦ to conserve the momentum, however, due to the
momentum being only close to zero and not strictly zero, many pairs are emitted
with a slightly smaller angle in accordance to momentum preservation laws.
In PET imaging the measured signal consists of the coincidence detection of the
photon pair with opposed directions. Usually one is interested in the distribution
of the radiopharmaceutical inside the human body. However, due to the travelling
path of the positron outside of the atom, the location of the annihilation process
is not equal to the location of the positron emitting atom, which produces an un-
certainty between the signal detection in PET imaging and the true localization of
the radiopharmaceutical. The positron range increases with the initial energy of the
positron as it may take longer for the kinetic energy to be reduced sufficiently for
the annihilation process to take place. The positrons emitted by the β+-decay of 18F
have with a mean energy of 249.8 keV (maximum energy of 633.5 keV) a relatively
low energy and the isotope has a favourable half-life time of 109.8 min. The trav-
elling path of the positron in water has a mean of only 0.6 mm (max. of 2.4 mm
for 18F; in contrast 11C has max of 4.1 mm and mean of 1.1 mm) and the relatively
long half-life makes an on-site cyclotron redundant. Additionally, the fluorine atom
has a similar atomic radius to hydrogen and a high electronegativity, allowing it
to closely mimic the behaviour of a carbon-hydrogen bond in an organic molecule
when bound to carbon [5]. These properties make 18F the ideal positron emitting
candidate for PET tracer development, handling of the tracer, and resulting image
resolution.
The probability of the occurrence of the nuclear transition in form of positron
emission with subsequent annihilation in the time interval dt is proportional to λdt.
The proportionality constant (or physical decay constant) λ is singular to the specific
nuclear species and to the respective decay mode with units of reciprocal time. The
probability of the transition occurring is equal to the proportion of radioactive decays
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By integrating with initial conditions of N0 as the number of nuclei at time t = 0,
the number of remaining un-decayed nuclei at time t can be calculated as
N(t) = N0e
−λt. (2.5)
By rearranging 2.5 it becomes apparent that the transition rate dN
dt
is proportional
to the number of radioactive nuclei
N(t) = λN(t). (2.6)
The absolute value of the transition rate (the number of decays per unit time) is
called activity, A(t), which has the unit of Becquerel (Bq). Substituting 2.5 into 2.6
(with A0 ≡ λN0) yields the function of activity, which lets one calculate the activity
of the nuclide after a time t
A(t) = A0e
−λt. (2.7)
The physical decay constant λ is related to the nucleus stability and the half-life









As one is interested in the temporally dynamic distribution of a radiopharmaceutical
in living organisms in nuclear dosimetry, the distribution will not be exclusively
ruled by the physical half-life of the radioactive nucleus, but also by biological pro-
cesses resulting in the washout or the clearance of the radiopharmaceutical from
the tissue / organism. Therefore, one can define the effective half-life describing the
temporal activity distribution inside an organ, assuming the biological process can
be described by an exponential function as well
λeff,i = λphys + λbiol,i, (2.9)
with λphys being the physical decay constant and λbiol,i being the biological rate
constant of the biological process i.
To be able to calculate the absorbed dose to a certain organ in nuclear dosimetry
one is interested in the total number of disintegration in a source region, which is
equal to the time-integrated activity in the source region (formerly referred to as
cumulated activity ) [58], and can be calculated from the time-activity distribution
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Although being a pure number, Bq ∗ s is currently used as unit for this quantity. This
usage is based on practical considerations when making the various calculations
leading to the absorbed dose.
2.4 Particle interactions with matter
The reason for radiation depositing energy inside matter, which is the definition
of the absorbed dose as previously described, is the interaction of particles with
the matter it is traversing. There are various interaction processes that can take
place depending on the type of particle, its energy and the physical properties of
the medium. All interactions are of stochastic nature, allowing for the interactions
to be described by probability density functions (PDFs), the so called cross-sections
of interaction and energy transfer, which are important for radiation transport and
energy deposition calculations. The particles to be considered in PET and CT imaging
are photons, electrons and positrons. They can be divided into uncharged particles,
i.e. the photon, whose interaction mechanisms are described in Section 2.4.1, and
charged particles, i.e. the electron and the positron, whose interactions with matter
are covered in Section 2.4.2. A brief summary is provided here, for more detailed
mathematical derivations the reader is referred to [19, 59, 60].
2.4.1 Photon interactions
When photons travel through matter of any kind, they will discretely interact with
atoms and nuclei of the medium. There are elastic interactions and inelastic inter-
actions with the former transferring no energy leading only to a deflection of the
photon. The latter leads to a partial or full energy transfer to an atomic electron,
since the electrons subsequently impart energy to the matter. Since photons are elec-
trically neutral, they are far more penetrating than charged particles and can travel
a significant distance inside matter. The type of photon-electron interaction depends
fully on the photon energy, the polarization and the atomic and nuclear properties
of the medium. In this section, the basic physical mechanisms of the interactions will
be discussed. Since the photon energies in radiology and diagnostic PET imaging
using 18F are limited to the range between 1 keV and 511 keV, the mechanisms
relevant for image formation and dosimetry in this energy window will be discussed
only.
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2.4.1.1 Rayleigh or Thomson scatter
Rayleigh or Thomson scatter is an elastic scattering event between an incident pho-
ton, considered as an electromagnetic wave, and an electron (Thomson) or an en-
semble of electrons (Rayleigh), transferring no energy to the matter. Since there is
no energy transferred to the electron, only the direction of the incident electromag-
netic wave is changed after the interaction while the wavelength is preserved. It can
be observed if the wavelength of the incident radiation is large compared with the
diameter of the scattering nucleus. The electric field of the incoming beam sets a
strongly bound electron into oscillation creating a dipole. Due to the acceleration
during oscillation the electron radiates electromagnetic energy with the same fre-
quency of the incident wave with the angular distribution of an electric dipole [56].
The effect is never dominating throughout the relevant energies in nuclear medicine
or radiology but occurs the most in low and high Z materials between 10 keV and
100 keV.
2.4.1.2 Compton Scattering
Compton scattering of a photon is the incoherent scatter of a photon with a loosely
bound electron, i.e. bound on an outer shell of the atom. The incident photon is
deflected by an angle θγ with reduced energy (increase in wavelength), while the
electron recoils at an angle θe having a kinetic energy of the difference between
incident and scattered photon following the laws of momentum and energy con-
servation. This effect is important in dosimetric calculations, as the recoil electron
subsequently deposits energy inside matter. The maximum energy transfer to the
recoil electron occurs for a backscattered photon with an angle θγ = 180◦. The
probability of the occurrence of Compton scattering depends on the energy of the
incident photon, the scattering angles and is given by the Klein-Nishina equation
[48]. However, as the formulas were derived under the assumption of the electron
being at rest and free, i.e. no momentum and no binding energy, the formula only
yields accurate results for photons with incident energy of above 1 MeV and for
low-atomic number materials. In reality electrons have a momentum distribution
and are bound (even if loosely) to the atom prior to the interaction with the photon,
which alters the scattering angle and the transferred energy. Depending on Z of
the traversing medium, Compton scattering becomes the dominant effect in photon
attenuation above approximately 40 keV in carbon and 700 keV in lead.
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2.4.1.3 Photoelectric absorption
In the photoelectric absorption process a bound atomic electron absorbs the incident
photon and is subsequently ejected. The photons energy k, minus the binding energy
and the kinetic energy of the recoil nucleus, is transferred to the kinetic energy of
the electron. The photoelectric absorption has a strong dependence on the atomic
number of the medium (Z5) and on the incident photon energy (k-7/2). If the incident
photon energy k is below the binding energy (EB)K of the K-orbital, photoelectric
absorption in the K-orbital cannot take place and the energy transfer is essentially
negligible except for high Z materials. For low Z materials like carbon photoelectric
absorption is the dominant effect to photon energies of up to 40 keV and up to
700 keV in high Z materials like lead. Due to the ejection of the atomic electron
from the atom, a vacancy in the specific shell where the absorption took place is
created, leaving the atom in an excited state. Thus, an atomic electron from a higher
orbital fills the vacancy to remove the excess of energy, while the difference between
the electron binding energies of the orbitals is emitted as X-ray radiation. This can
entail a cascade of subsequent vacancies including their filling by electrons from
higher orbitals and emission of photons if the radiation energy is large enough. This
effect is responsible for the characteristic X-ray emission spectrum of any material,
as it possesses an X-ray peak at the specific energies corresponding to the difference
of binding energies between the orbitals. However, the excess of energy that is
produced by the ejection of the electron from the atom can also be directed to
eject one or more atomic electrons from outer orbits. This non-radiative process is
called Auger effect and the ejected electron is called the Auger electron. Both effects
contribute to dosimetry, as the emitted X-ray radiation will be absorbed or the Auger
electron will be slowed down along its respective travelling path and therefore both
will deposit energy in the medium.
2.4.1.4 Attenuation coefficient
The overall probability, so the combination of all interaction cross-sections, of a
photon undergoing an interaction per unit distance travelled by any of the above
processes is expressed by the linear attenuation coefficient µ in 1
cm
, which depends
on the energy of the incident photon and the density of the medium. The mass atten-
uation coefficient equals the linear attenuation coefficient divided by the mediums
density and its unit is cm
2
g
. As one is interested in the energy transfer in dosime-
try, the energy transfer cross-sections of Compton effect and photoelectric absorp-
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tion are added up to form the total mass energy-transfer coefficient. Some of the
energy, transferred from the incident photons to the atomic electrons, is carried
away by subsequent radiative relaxation processes. The subtraction of the radia-
tive relaxation processes from the total mass energy-transfer coefficient leads to
the mass energy-absorption coefficient, which quantifies the total amount of energy
transferred to atomic electrons enabling the calculation of the amount of energy
imparted to the matter. In Figure 2.2 the mass attenuation coefficient and the mass
energy-absorption coefficient are displayed for carbon, oxygen, soft tissue and bone
(material definitions from ICRP and tabulated data taken from NIST Standard Ref-
erence Database 126, Link NIST data).
Figure 2.2: Mass attenuation coefficient (Mass) and mass energy-absorption coeffi-
cient (Mass energy) of (a) carbon (C) and oxygen (O) and (b) soft tissue (ST) and
bone (B)
2.4.2 Charged particle interactions
Moving charged particles, originating from either the radioactive decay described
in Section 2.3 or the interaction of photons with matter as described in the previous
Section, are the cause of the absorbed dose. As in PET and CT imaging only light
particles like electrons and positrons are of concern, heavy particles like protons
and ions will not be discussed. The energy deposition of heavy particles is due to
their increased mass slightly different to those of light particles and their path inside
matter is different due to less scattering. When charged particles travel through
matter, they transfer energy to the medium by coulombic interactions with atomic
electrons and nuclei. In contrast to photons, which can travel a significant distance
before interacting discretely leading to partial or total energy transfer to an atomic
2.4. Particle interactions with matter 21
electron, charged particles undergo far more discrete interactions and slow down
faster due to coulombic interactions making them less penetrating than photons.
The particular way and amount of energy transferred to the medium by charged
particles is described by the total stopping power, which is subdivided into collisional
and radiative stopping power with both having the unit of MeV
m
. Both describe the
energy loss of charged particles along a unit path length. The quantity of interest
for dosimetry is the mass stopping power in MeV ∗m
2
kg
, which is equal to the stopping
power divided by the density of the medium. For mathematical descriptions and a
more detailed picture the reader is referred to [19, 59, 60], as only a brief summary
will be provided within the manuscript.
The collisional mass stopping power describes the coulombic interaction of the in-
cident electron with atomic electrons. It combines the contributions from two types
of collisions, which depend on the perpendicular distance b between the trajectory
of the charged particle and the radius of the scattering atom. If the distance is large
(b  ratom), the particle will interact with the atom as a whole, which is referred
to as a soft collision. The probability of the event is high, however, the net energy
transfer per interaction is small leading to a temporal polarization or excitation of
an atomic electron into empty quantum states. If the distance is approximately as
small as the radius of the atom (b ≈ ratom), the charged particle will interact with
a single atomic electron, being referred to as a hard collision. The probability is
lower than for a soft collision, but the net energy transfer is substantially higher,
leading to an approximately equal energy transfer from both, soft and hard collision,
from a global point of view. The hard collision with an atomic electron can result in
ionization of the atom including subsequent radiative relaxation processes as previ-
ously described for photoelectric absorption. The ejected electron, which is called a
δ−ray, can carry energy a significant distance away from its origin, making this an
important feature for dosimetry considerations. The collisional mass stopping power
is below an energy of 0.5 MeV antiproportional to energy, i.e. the slower the incident
electron the higher the energy deposition, while it flattens out for higher energies
and becomes approximately independent for higher energies. It is largely indepen-
dent of Z. However, higher Z materials have greater binding energies for inner shell
electrons, leading to an increased excitation energy, which in turn decreases the
collisional mass stopping power for higher Z materials slightly.
If the distance is smaller than the atomic radius (b ratom), the charged particle
will interact with the nucleus of the atom, leading to a strong deflection of the
particle’s path or to complete deceleration. The deceleration of the charged particles
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creates an electric dipole emitting electromagnetic waves in the frequency range of
X-rays known as Bremsstrahlung. The maximum bremsstrahlung photon energy is
equal to the kinetic energy of the incident charged particle resulting from the full
stop of the particle and conversion of the complete kinetic energy into radiation. This
effect is summarized in the radiative mass stopping power, which is not contributing
to the locally deposited energy, as the energy is carried away by radiation. The
radiative mass stopping power is in general proportional to Z2 and the energy of
the charged particle. In Figure 2.3 the collision, radiative and total mass stopping
power of electrons in soft tissue and compact bone (material definitions from ICRP
and tabulated data taken from NIST Standard Reference Database 124, Link NIST
data) are displayed.
Figure 2.3: Collision, radiative and total mass stopping power of electrons in (a)
soft tissue and (b) bone
In general, positrons and electrons are assumed to show similar behaviour re-
garding collisional and radiative stopping power, since they have the same mass but
opposite charge. This however holds only true for high energies. The collisional stop-
ping power of positrons is slightly greater below energies of 0.5 MeV and less above
that threshold. The radiative stopping power of positrons is significantly different to
electrons at low energies. The ratio of the radiative stopping power of electrons and
positrons is unity at about 10 MeV but only 0.5 at 10 keV [19].
In summary, the collisional mass stopping power is the predominant contributor
to the total mass stopping power at low energies and becomes essentially indepen-
dent of energy at about 0.5 MeV. For high Z materials like lead, the collisional mass
stopping power is approximately lower by a factor of 2 compared to water. The ra-
diative mass stopping power is negligible at low energies compared to the collisional
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mass stopping power and only becomes the dominant energy transfer mechanism
at about 10 MeV in lead and 100 MeV in water, which are energies far outside of
the medical diagnostic energy window. However, the radiative mass stopping power
is proportional to Z2 and energy. Another important quantity for dosimetry is the
electron range, i.e. how far electrons travel inside a medium in order to be able to
predict the position of the energy deposition. Since the energy loss of a charged
particle due to collisions is a stochastic process, the energy distribution of a mo-
noenergetic electron beam after traversing a certain depth of medium is varying
and consequently the range of the electron. This effect is called energy and range
straggling.
2.5 Monte Carlo simulations in medical physics
This section aims to introduce the method of Monte Carlo simulations (MCS), their
purpose in medical physics and the specific application of radiation dosimetry will
be discussed. The numerical method known as MCS can be described as a statistical
simulation method involving sequences of random numbers to solve problems of
stochastic nature [61]. MCS is useful in medical physics because of the stochastic
nature of radiation emission, its transport and detection, since deterministic methods
and experimental measurements are infeasible. However, the applications of this
method varied greatly and its use for medical physics increased only after the review
paper by Raeside [62] in 1976. The method will be described only briefly, as a
detailed description of the mathematics involved can be obtained elsewhere [62–
64].
2.5.1 General concept
The most common, very simple example to explain the basic idea of MCS is the
problem of Buffon’s needle, based on the following question: What is the probability
(P ) of a thin needle of length d being randomly thrown onto an array of equally
spaced parallel lines, which are separated by a distance D (with d < D), to intersect
with one of the lines? The probability P for the needle hitting a line is equal to 2d
πD
,
which can be derived by the two probability density functions for the distance of
the needle centre to the parallel lines and the orientation angle between lines and
the needle. If the needle is randomly thrown N times (N being a large number),




. The idea that π can be
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approximated with a large enoughN can serve as the basis for a Monte Carlo compu-
tation. When putting that into relation with medical imaging, it becomes clear that
three inputs for MCS are essential [61]. One input is the PDFs of all possible particle
interactions (cross-sections of interactions) in matter for all involved particles of the
particular imaging process. The other important input is the random numbers in the
interval [0, 1] to sample from the PDFs. All random number generators (RNG) used
in MCS are based on mathematical algorithms. Since they are created deterministi-
cally, they are pseudo-random, which is defined as appearing random but exhibiting
a repeatable pattern. As many as 107 to 1012 random numbers are used in a typical
simulation and even slight patterns or correlations could alter the outcome of the
simulation [65]. There are many RNGs that have been suggested for the use in MCS
and will not be discussed further, however, summaries of available pseudorandom
number generators were published [66]. The last important input parameter is the
sampling rules, i.e. how to sample from the pdfs. Therefore, in an oversimplified
way, by using a large amount of random numbers (N) to sample from the PDFs one
can reach a solution to a specific physical problem such as energy deposition in a
complex system.
2.5.2 GATE package
The dedicated medical imaging Monte Carlo package GATE was first publicly re-
leased in 2004 [67], and combines a wide and accurate physics modelling ability
with a user-friendly way of modelling complex scanner geometry and imaging con-
figurations [68]. It is based on the Geant4 libraries written in C++, which were
developed by Conseil Européen pour la Recherche Nucléaire (CERN) to simulate
interactions of particles with matter over a very wide energy range for i.e. the Large
Hadron Collider [69]. GATE encapsulates the libraries to achieve a modular, widely
applicable and scripted simulation toolkit focused on medical imaging applications.
The end-user of GATE does not have to perform any C++ coding, every simulation
can be defined and run using script language. The user can freely define the source
of radiation, the scanner geometry, the detectors, the phantom (voxellized images
are also possible) and can set the various physical phenomena involved. For the
physical processes to be simulated, the user can choose several sets of cross-sections
in form of PDFs depending on the energy window and the involved physics.
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2.5.3 PET dosimetry using Monte Carlo simulations
Although not performed in the frame of this work, Monte Carlo simulations are
essential for dosimetry in PET imaging. Assuming two cubic sources filled with
a homogeneous amount of 18F, radiation transport of emitted particles and their
subsequent energy deposition in each of them can be simulated. The knowledge
of how much energy per nuclear disintegration is deposited in each of the cubes
can be used to calculate the absorbed dose for any given amount of activity in this
specific static geometrical arrangement. Replacing the simple cubic arrangement
by the much more complex geometry of a biological body, one is able to calculate
for each organ, being a source of activity, the energy that is imparted to the source
organ itself (self-radiation) and the surrounding organs (cross-radiation). Figure
2.4 represents a simple example of the two cubes filled with 18F. Both cubes act as
a source and a target at the same time. Black arrows symbolize the self-radiation
of source 1 and green arrows the self-radiation in source 2. Red and pink arrows
represent the cross-radiation from source 1 to target 2 (pink arrows) and from
source 2 to target 1 (red arrows).
Figure 2.4: Self- and cross-radiation in a cubical arrangement
Due to the additive nature of the absorbed dose, it is possible to derive factors,
called absorbed dose rate per unit activity or simply S-factor, for all sets of organs
allowing for the calculation of absorbed doses for a static geometry. Since the calcu-
lation of these S-factors is computationally very expensive, a population averaged
phantom with precalculated S-factors is used for absorbed dose calculations in clini-
cal routine instead of patient specific dosimetry. For human dosimetry calculations
performed in the frame of this work, the commercially available software package
OLINDA/EXM [70] was used, which includes the phantom of Cristy and Eckerman
[71] and S-factors released by Stabin et al. [72]. The software also provides a urinary
excretion module, as obtaining experimental data including voiding of the bladder
and activity data over several hours is often not feasible. The module was used for
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the calculation of the urinary bladder wall absorbed dose (self-irradiation) and the
contribution of the activity to surrounding organs (cross-radiation). Inputs for the
model are the amount of activity, a voiding interval and the biological half-life of the
activity inside the body. For mouse absorbed dose calculations the MOBY phantom
developed by Segars et al. [73] was used in combination with the S-factors derived
recently by Mauxion et al. [74].
2.5.4 CT dosimetry using Monte Carlo simulations
In CT dosimetry the energy deposition inside the subject only depends on the energy
spectrum produced by the X-ray tube (therefore the properties such as tube voltage,
tube current and anode material) and the exposure times of the applied protocol.
Consequently, precalculated factors cannot be directly derived, since the dosimetry is
not only subject dependent but also machine dependent. However, Monte Carlo sim-
ulations can be used to simulate the photon transport of the emitted X-ray quanta of
the specific X-ray tube and the subsequent interactions and energy deposition inside
the subject. The implemented setup of the GE eXplore 120 microCT, the derived
dosimetry, and the comparison to experimentally obtained data will be presented in
Section 3.6.
2.6 Methods of assessing the kinetic biodistribution
of radiopharmaceuticals
In nuclear dosimetry one is interested in the time integrated activity (cumulated
activity) of the radiopharmaceutical inside a particular source organ or tissue. It is
equal to the integration of the time-dependent activity A(t) (see 2.10) yielding the
total amount of nuclear disintegrations inside the source organ or tissue [75]. The
quantitatively accurate determination of the time activity curve (TAC) A(t) in all
activity bearing tissues is required for correct absorbed dose calculations. The TAC
is characterized by the uptake and the retention of the radiopharmaceutical and
includes the radioisotope specific physical half-life and the tissue specific biological
half-life describing the washout velocity of the radiopharmaceutical by biological
processes [76].The activity is quantified in serial measurements post administration
of the radiopharmaceutical by quantitative imaging (non-invasive), tissue sampling
(invasive) or excreta counting [75]. The temporal sampling frequency of the mea-
surement is of utter importance in order to accurately reconstruct the time-activity
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profile, as especially due to the administration via the blood stream the initial up-
take of the radiopharmaceutical can be a fast process and a low sampling frequency
could lead to a falsification of the TAC (aliasing). For subsequent absorbed dose
calculations it is vital that all activity that was administered to the studied subject
is accounted for in order to consider the total amount of energy deposited inside
matter. In the following sections, the methods used in the conducted experiments
to derive the TAC in various organs in a preclinical and / or clinical setup will be
explained.
2.6.1 Organ harvesting
The preclinical technique of tissue sampling or organ harvesting is a widely used
method of time-dependent activity quantification in small animals for dosimetry pur-
poses [41, 77–80]. The TAC is established by sacrificing several animals at different
time points post injection of the radiopharmaceutical. At each time point animals
are sacrificed, dissected, and their organs are harvested to subsequently quantify the
activity present in a specific organ using a gamma well counter. Usually three to five
animals are used per time point to provide a mean value at each point to account
for intraspecies differences. Animals are kept under anaesthesia from injection to
sacrificing by decapitation. For a detailed description of the organ harvesting meth-
ods the reader is referred to the respective publications (Appendix A, B and C) in
this manuscript. The method is labour intensive, requires an extensive amount of
animals per study and is slow regarding data acquisition. However, every organ /
tissue independent of size and function can be harvested.
2.6.2 Dynamic PET imaging
Another way of assessing the time-dependent distribution of the radiopharmaceuti-
cal post injection inside the body is dynamic PET imaging, which is used in clinical
[28, 81–83] as well as preclinical studies [84–88]. The subject is imaged for a longer
period of time (between 100 and 300 minutes, depending on tracer’s kinetics) di-
rectly after the administration of the radiopharmaceutical with the possibility of
dividing the total scanning duration into time frames of arbitrary length. This allows
for the reconstruction of the TAC of each region of interest within the scanners field
of view with a high temporal sampling frequency. If the subject exceeds the field
of view, multiple axial sections are acquired per frame to form a dynamic full-body
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image at the expense of temporal sampling frequency due to fewer frames. For ac-
curate organ delineation and/or the attenuation correction functional PET imaging
is often complemented by anatomical CT imaging for segmentation (or structural
magnetic resonance imaging (MRI) if available). For detailed information on the
scanners used, the time-framing of the dynamic acquisitions, segmentation of the
complementary and co-registered CT scan and other methodical details the reader
is referred to the publications (Appendix A to D). In a preclinical setup, dynamic mi-
croPET imaging has advantages over organ harvesting, since the number of animals
required can be drastically reduced (to around 5 per study compared to 30). The
full biodistribution inside each subject can be derived with a much higher temporal
resolution. However, imaging limitations such as the previously mentioned PVE need
to be addressed.
2.6.3 Hybrid imaging
Both previously explained methods of assessing the kinetic biodistribution (organ
harvesting and dynamic PET imaging) have advantages and disadvantages in preclin-
ical dosimetry, which will be addressed more detailed in chapter 4. Hybrid imaging,
which combines organ harvesting and imaging, aims to overcome the limitations
of both methods and it was first applied by Kesner et al. [41] towards dosimetry
derived from rat data. The small animals are scanned dynamically from injection
of the radiopharmaceutical to sacrificing and are dissected afterwards. The activity
remaining in organs is quantified using a gamma well counter, and the ratio between
the ex vivo measured activity and the in vivo measured activity of the last time point
of the dynamic PET scan is used to scale the TAC of the PET image. The method
reduces the number of animals to be sacrificed compared to the organ harvesting
method, while overcoming the imaging limitations of pure dynamic microPET imag-
ing. Whether the method can be applied in much smaller species such as mice needs
to be addressed.
2.7 Extrapolation from preclinical to clinical data
Before a first-in-human study can be conducted with any new radiopharmaceuti-
cal, it is, according to national regulations [40, 44], a prerequisite to derive the
human dosimetry preclinically to prevent any over-exposure of human subjects.
Consequently, the derived animal data has to be extrapolated to human data, since
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the data cannot be directly applied to the human case due to anatomical and/or
metabolic differences. One extrapolation method is the percentage kilogram per
gram method after Kirshner [89], which is widely used in literature [41, 88, 90–95].
It assumes proportionality based on the weight difference between organ and body
mass of the respective species allowing for the extrapolation of the activity level in
percentage of injected dose per gram of tissue from any species to another if organ











Although neglecting metabolic differences between species, the simple approach of
the percentage kilogram per gram method is the prevailing method for extrapolation
from animal data to human data. There are various methods for additional metabolic
scaling, since it is known that species with a greater body mass usually have a slower
metabolic rate, which are described here [19]. There are publications discussing the
effectiveness of the different extrapolation methods and their combinations [96],
but a conclusion, which method is superior, could not be reached [17, 19]. However,
as the simple method of Kirshner is widely applied in dosimetry literature, it was
used in all relevant publications in the frame of this work.
2.8 MIRD scheme for dosimetry in nuclear imaging
The estimation of internal radiation dosimetry of a radiopharmaceutical in diagnos-
tic nuclear medicine requires knowledge of the following physical or physiological
properties:
• The radiation decay scheme of the involved radionuclide (discussed in Section
2.3)
• The kinetic biodistribution of the radiopharmaceutical labelled with the spe-
cific radionuclide (discussed in Section 2.6) in a certain anatomy
• The radiation transport and energy deposition of the emitted particles in this
anatomy (discussed in Section 2.5)
The Medical Internal Radiation Dose (MIRD) scheme incorporates the above
mentioned physical entities and allows for calculation of the absorbed dose to any
anatomy as long as all three properties are known. It was developed by the MIRD
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committee, which is part of the American Society of Nuclear Medicine and periodi-
cally publishes dosimetry papers and guidelines in the Journal of Nuclear Medicine
with their first set of instructions being published in 1968 [97]. The MIRD scheme
provides a way to calculate the absorbed dose to a target region from a source region
containing a dynamic distribution of activity. Since the absorbed dose is additive by
nature, the contribution from each source region to a target region can be calculated
separately and summed up to obtain the total absorbed dose to a target region from
all contributing source regions [17, 76]. The main MIRD equation, describing the
time-dependent rate of the deliverance of the absorbed dose to a target region rT
from ionizing radiation emitted by a source region rS at time t after administration,
is
Ḋ(rT , t) =
∑
rS
A(rS, t)S(rT ← rS, t). (2.12)
Here A(rs, t) is referred to as the time-dependent activity in the source region rS
and S(rT ← rS, t) is commonly described as the radionuclide-specific S-factor men-
tioned in Section 2.5. It represents the mean absorbed dose rate received by the
target region rT from the source region rS at time t after administration per unit
activity as previously mentioned. There are two types of S-factors to be considered:
one is the case where target and source region are two spatially separated regions
(referred to as cross-radiation), and the case where target and source region are
the identical physical object (referred to as self-irradiation). In ordinary diagnostic
nuclear medicine dosimetry calculations the S-factor is precalculated for a specific
radionuclide including its decay scheme and a static set of target and source region.
However, in theory the volume of any region can vary over time with special phys-
iological cases being the bladder, the lung and the heart. Their volume fluctuates
constantly due to their physiological task inside the live organism, which will be
neglected throughout this manuscript and the static case is considered only. For
time-dependent considerations of the S-factor the reader is referred to [58]. As the
mean absorbed dose to the target region rT is the summation over all source organs
rS contributing radiation, the total absorbed dose can be written as a sum, already
neglecting the time dependency of the S-factor to consider fixed volumes for rT and
any rS only,
D(rT , TD) =
∑
rS
Ã(rS, TD)S(rT ← rS, t). (2.13)
The time-integrated activity Ã over dose-integration period TD in source region rS
is empirically determined by means of activity quantification as described in Section
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It is quite common to provide dosimetry results as absorbed dose coefficients d(rt, TD)
(although still referred to as absorbed dose in most literature publications), which
is the absorbed dose normalized per unit administered activity in Gy
Bq
. Therefore, the
time-integrated activity Ã is given as the fraction of total injected activity A0 having







The quantity is referred to as the time-integrated activity coefficient (formerly the
residence time). However, both terminologies are still used in various publications.
The S-factor represents the fraction of energy deposited in rT released from a single
radioactive decay inside rS and is normalized to the mass mrT . When not confined to
a fixed radionuclide, static volumes, masses and distances between them (rT and rS),
the S-factor is dependent on all mentioned parameters. However, in the following
chapters all S-factors are precalculated using fixed parameters representing a static
case for the radionuclide 18F. Therefore the S-factor can be defined based on the
previous description as






Here the summation occurs over all nuclear decay channels i having the energy Ei,
which is the released energy of a photon or kinetic energy in case of a β particle,
and the yield Y of the particular channel i. φ is the absorbed fraction of the energy
Ei of the decay channel i emitted in rS absorbed in rT and mrT is the fixed mass of
the target region. By substituting Ei and Yi one can rewrite the expression as






with 4i = EiYi being the mean energy emitted by each ith nuclear transition. To
further simplify one can express the specific absorbed fraction, which is the ratio of
the absorbed fraction and the target mass,
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Combining the expressions 2.17 and 2.18 and substituting the expressions in 2.13
the formula of the mean absorbed dose can be written as









If the absorbed dose coefficient d(rT , TD) normalized to the total injected activity A0
is used, which is more common in dosimetry publications, one can write











When using the MIRD scheme to calculate the mean absorbed dose received
by a target region in diagnostic nuclear medicine a few limitations hold true. The
activity within a source organ might vary dynamically but is assumed to have a spa-
tially homogeneous distribution inside the whole volume. Additionally, all regions,
whether target or source region, have a homogeneous mass distribution, i.e. the
density of the region is homogeneous as well. As earlier described in this chapter,
the geometry of source and target regions is assumed fixed over time when using
precalculated S-factors for a certain representative phantom, so no physiological
movement of organs during the presence of the radiopharmaceutical takes place.
Therefore, the absorbed doses calculated using the MIRD scheme (when assump-
tions apply) in combination with the previously described phantom and S-factors
(see Section 2.5.3) remain estimations for a hermaphroditic, age- and geometry
averaged static phantom.
2.9 Dosimetry in CT imaging
In this section, a brief overview of how the dose in CT imaging is calculated will
be provided. With the evolution from planar 2D radiography to rotational 3D CT,
new concepts for dose quantification were required. In CT imaging, as opposed to
radiography, the X-ray source rotates around the subject to acquire projections from
all angles for a specific axial length (depending on detector array, X-ray source and
type of CT) leading to a more homogeneous dose distribution with significant higher
exposure. Although the X-ray beam and therefore the exposure area is confined to
the axial length to be acquired by collimation of the beam, the axial dose profile is
not a rectangular function limited to the scan length. Due to scattering, energy is
deposited outside of the collimated area forming tales on each side of the respective
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axial dose profile. Additionally, depending on the type of CT scanner and imaging
protocol, several axial sections with overlapping dose distributions to obtain a full
body scan are acquired, further increasing the radiation burden to the subject. A
concept introduced by Shope et al. in 1981 [98], the computed tomography dose
index (CTDI), accounts for the scattered radiation outside of the collimated X-ray
beam by relating the total amount of dose deposited to the acquired axial image








Here, d represents the nominal slice thickness or the total axial length to be imaged
and D(z) denotes the function of dose along the axial direction z. The axial dose
profile D(z) is routinely measured for clinical CTs inside a standardized poly(methyl
methacrylate) (PMMA) phantom in different transaxial positions using an ionization
chamber [99, 100]. However, the radiation dose can be measured discretely using
thermoluminescent dosimetry chip (TLD) [101] or metal oxide semiconductor field-
effect transistor (MOSFET) sensors [102]. The standardized CTDI100, which is used
for characterizing the dose of a single axial image section including the dose profile







where N is the number of simultaneously acquired image slices during one full tube
rotation and T is the slice thickness in (mm). The CTDI depends on the CT system
and the protocol specific settings of tube voltage, tube current and exposure time per
projection. For comparison of the radiation burden between different CT systems
the normalized CTDI value is often used, which is normalized to the current-time





with i being the applied tube current and t the total exposure time over all projec-
tions of the specific protocol. If multiple axial image sections are acquired, the dose
increases due to overlapping dose profiles and each single dose profile contributes
to the dose deposition in the next acquired image section. The dose can then be
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Here, I refers to the central scan interval or image width, where the dose is quan-
tified, and DN,I(z) to the axial dose profile incorporating N adjacent single dose
profiles. There are several slightly different representations of the CTDI and MSAD
depending on the CT system used and the regulatory agency involved, which can
be found in the literature [56, 99]. However, the CTDI represents an averaged dose
over a volume inside a PMMA phantom or air (depending on which CTDI is used)
specific to a CT system and should not be regarded as a patient specific dose [103].
In the following Chapters the term CTDI will always refer to the CTDI100, which was
used exclusively.
C H A P T E R 3
Publications & studies
3.1 Preclinical radiation dosimetry for [18F]UCB-H
3.1.1 Overview
In this section the preclinical radiation dosimetry of a novel radiopharmaceutical
published in the European Journal of Nuclear Medicine and Molecular Imaging
Research is briefly discussed [80]. For detailed information on the performed exper-
iments and in-depth results the reader is referred to the Paper I in Appendix A. The
radiotracer 18F-UCB-H, newly developed by UCB Pharma (UCB Pharma Ltd., Slough,
Berkshire, UK) and the Cyclotron Research Centre of the University of Liège, was in-
vestigated in collaboration between UCB Pharma and the Cyclotron Research Centre
of the University of Liège. The compound shows a nanomolar affinity for the human
SV2A protein [104] which is believed to play a role in epilepsy as the antiepileptic
drug levetiracetam targets the same protein [105]. However, since the specific mech-
anism of levetiracetam is not fully understood, the new compound may provide a
deeper insight into epilepsy and other diseases of the central nervous system. As
required by research guidelines in the EU and the United States of America [40], we
derived the human radiation dosimetry of the radiopharmaceutical for the first time
from mice before any first-in-human use. Traditionally, the preclinical dosimetry is
obtained by ex vivo organ harvesting (see Section 2.6.1), but the method is time con-
suming, requires many animals to be sacrificed, and the data acquisition has to be
spread over several days for one tracer depending on staff and facilities available. An-
other promising approach is in vivo dynamic microPET imaging (see Section 2.6.2),
which might overcome several disadvantages of the traditional ex vivo organ harvest-
ing. The data acquisition is much faster, since the complete kinetic biodistribution
of the tracer over time can be derived from one animal in one microPET scanning
session. Consequently, fewer animals need to be sacrificed and less staff and fewer
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lab days are required per investigation. The study aimed at acquiring the preclinical
radiation dosimetry of 18F-UCB-H using both methodologies and to compare their
results. In this study we injected twenty-four male mice under isoflurane anaesthesia
with a bolus of the newly developed radiopharmaceutical 18F-UCB-H followed by
decapitation at 6 different time points for organ harvesting experiments (n=4 at 2, 5,
10, 30, 60 and 120 min). Following dissection of the animal the activities remaining
in organs were quantified with a gamma well counter. Dynamic microPET imaging
over 120 min including microCT imaging for segmentation was performed on five
separate mice. Two types of segmentation techniques were used; the laborious full-
organ segmentation and fast sphere segmentation, where spheres are placed in the
centre of each organ (see Figure 3.1). The obtained TACs, extrapolated to human
values as in Kirshner et al. [89] (see Section 2.7), were used for absorbed dose
calculations performed with the human dosimetry software OLINDA/EXM [70]. Dif-
ferent urinary excretion scenarios were modelled using the dynamic bladder module
implemented in the dosimetry software [106], including two voiding scenarios and
different fractions being excreted via the urinary pathways.
Figure 3.1: Representative PET/CT image including VOIs (full organ segmentation
and sphere segmentation); due to the limited axial field of view of the microPET the
brain could not be included in imaging analysis
The TACs over 120 min derived by organ harvesting and dynamic microPET
imaging are displayed in Figure 3.2. Biological clearance of the radiopharmaceutical
from organs was neglected after 120 min and only physical decay was assumed till
10h post injection.
The computed absorbed doses of major organs in humans and the resulting
effective dose based on the tissue weighting factors from ICRP publication 60 [22]
are shown in Figure 3.3. For a more detailed list of absorbed doses the reader is
referred to Paper I in Appendix A. A correlation of r=0.96 (p < 0.0001) was found
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Figure 3.2: TAC derived by (a) organ harvesting and (b) dynamic microPET imaging
(sphere segmentation); adopted from [80]
between datasets of absorbed doses (full datasets only shown in Paper I in Appendix
A) derived by organ harvesting and dynamic microPET imaging.
The effective dose derived by organ harvesting was 2.18E-02± 5.50E-04 mSv/MBq
and 2.15E-02 ± 2.88E-04 mSv/MBq derived by dynamic microPET imaging (single
sphere segmentation). The highest absorbed dose was received by the urinary blad-
der wall (1.54E-01 ± 5.00e-04 mGy/MBq derived by organ harvesting) followed by
the liver (5.84E-02 ± 7.35E-03 mGy/MBq derived by organ harvesting). The derived
urinary bladder wall absorbed dose was calculated using a theoretical model with a
fraction of 0.5 of all injected activity leaving via the urinary excretion system with
voiding every 4h. With the assumption of a smaller fraction of 0.3 the absorbed dose
would be decreased to 9.67E-02 ± 5.50E-04 mGy/MBq.
3.1.2 Discussion
The comparison of the labour intensive ex vivo organ harvesting and the fast dynamic
microPET imaging showed that despite the numerous advantages of microPET imag-
ing, the method does not provide accurate quantification in small animals. The
result agrees with findings by Constantinescu et al. [90], who also reported poor
correlation between microPET activities and activities in post-scan harvested organs.
Significant over-/underestimations were revealed in time-integrated activity coeffi-
cients (former residence times, see Section 2.8) of major organs in comparison to
organ harvesting with ratios of both values ranging from 2.3 (largest underestima-
tion in microPET; liver) to 0.53 (largest overestimation in microPET; lung) based
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Figure 3.3: Absorbed doses of main organs derived by organ harvesting (TD) and
dynamic imaging (imaging) with sphere segmentation; UBW = urinary bladder wall,
TB = total body and ED = effective dose in mSv/MBq based on tissue weighting
factors from ICRP 60
on full organ segmentation. The effect causing the differences in activity quantifica-
tion between organ harvesting and dynamic microPET imaging is the well known
imaging artifact PVE / spill over effect (see Section 2.1). It is especially present on
boundaries of structures having different activities and decreases with object size.
The main cause of the effect is the finite spatial resolution of microPET imaging,
which is limited by detector sizes and the physical nature of the positron emission.
We attempted to minimize the effect by decreasing the size of the volume of inter-
est (VOI) created in images used for extraction of the TAC from organs. Spheres
of 2 mm radius were positioned in the centre of organs to avoid PVEs on bound-
aries between structures, but only a slight improvement was observed and ratios of
time-integrated activity coefficients of organs in the range of 2.04 (largest under-
estimation in microPET; liver) to 0.64 (largest overestimation in microPET; lung)
remained. Although a correlation of above r=0.96 (p < 0.0001) was achieved be-
tween all dosimetry estimates and the resulting effective dose deviated by only 2%,
ratios of absorbed doses for some organs were in the range of 3.58 (brain) to 0.76
(lung). However, the brain was only derived by organ harvesting explaining the
large difference because only cross-radiation was taken into account in dosimetry es-
timates derived by microPET imaging (2nd largest overestimation was the liver with
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a ratio of 1.86). Projected maximum single injection doses according to research
regulations were 325 MBq in the USA and 459 MBq in the EU (both values based
on organ harvesting, bladder fraction of 0.5 and ICRP 60 values in case of EU limit).
We demonstrated, that 18F-UCB-H meets standard regulations regarding radiation
dosimetry for use in human clinical trials and its radiation burden is comparable
or less than the most widely used clinical tracer 18F-FDG with reported values be-
tween 2.1E-02 mSv/MBq and 2.9E-02 mSv/MBq [107]. Since preclinically derived
radiation dosimetry estimates are the basis for calculations of safe injection limits
for first-in-human use, it is of great importance to achieve accurate quantification to
prevent over-exposure of subjects in clinical studies. Therefore, ways of improving
dynamic microPET imaging for dosimetric purposes in mice, specifically the impact
of PVE, were sought. Kesner et al. [41] applied a method to improve quantification in
rats involving a cross-calibration between organ harvesting and dynamic microPET
imaging for radiation dosimetry. Since PVEs are object size dependent, success of
this method for dosimetry in mice was uncertain and it was applied to a study of
two different radiopharmaceuticals presented in the following Chapter.
3.2 Hybrid microPET imaging in mice for accelerated
dosimetry
In this Section the radiation dosimetry of 18F-FDOPA and 18F-FTYR as published
in Molecular Imaging and Biology is briefly summarized [108]. For in-depth infor-
mation the reader is referred to Paper II in Appendix B. 18F-FDOPA and 18F-FTYR
were selected for this study, since no radiation dosimetry estimates were available
in literature for 18F-FTYR and for 18F-FDOPA only clinical values were published.
The radiation dosimetry of both tracers was derived from mice by organ harvesting
and dynamic microPET imaging as was for 18F-UCB-H in Section 3.1. Additionally,
we applied a method we refer to as hybrid imaging for the first time in mice in
order to address the impaired quantification of pure microPET imaging revealed in
the preclinical study of 18F-UCB-H. TACs are cross-calibrated with activity measure-
ments from post scan dissected organs, which aims at combining the advantages of
microPET imaging of fast and efficient data acquisition involving far fewer animals
and the advantages of accurate quantification of organ harvesting. The preclinically
derived human radiation dosimetry of 18F-FDOPA was compared to the published
clinically derived values by Brown et al. [109] and the human radiation dosimetry
of 18F-FTYR was presented for the first time in literature. Additionally, the mouse
40 Chapter 3. Publications & studies
radiation dosimetry of both tracers was calculated using S-factors recently published
by Mauxion et al. [74]. However, since a separate manuscript investigating the an-
imal radiation dosimetry was prepared for all tracers used throughout this work,
the mouse dosimetry data is summarized and presented in Section 3.3. After bolus
injection of 18F-FDOPA, thirty anaesthetized mice in total were sacrificed by decap-
itation at 6 different time points (n=5 at 2, 5, 10, 30, 60 and 120 min) for organ
harvesting and four separate mice were scanned dynamically over 120 min with
microPET. Supplemental microCT images were acquired for image segmentation.
Co-registered 3D representations of microCT and averaged microPET images are
displayed in Figure 3.4. VOIs based on the co-registered microCT images were used
for data extraction from dynamic microPET images (full organ segmentation and
sphere segmentation). Every mouse undergoing dynamic microPET imaging was
dissected afterwards and the activity remaining in organs was quantified using the
same approach as in organ harvesting. A cross-calibration factor, the ratio between
the activity derived from the dissected organ and the activity at the last time point
in dynamic microPET in the same organ, was obtained and applied to scale TACs
derived from microPET imaging. For 18F-FTYR eighteen mice were sacrificed for
organ harvesting (n=3 at 2, 5, 10, 30, 60 and 120 min) and processed in the same
manner. However, mice used for the final time point (120 min) of organ harvest-
ing were scanned dynamically for 120 min instead of using separate subjects. The
obtained TACs were processed in the same way as for 18F-FDOPA. Time-integrated
activity coefficients were calculated from derived TACs for both tracers and used
for calculating human dosimetry estimates with OLINDA/EXM. All derived TACs ex-
trapolated to human data are displayed in Figure 3.5. Only data derived by sphere
segmentation is presented here.
Figure 3.4: 3D representation of co-registered microCT and averaged microPET
image of representative subjects with (a) 18F-FDOPA and (b) 18F-FTYR
The correlation between time-integrated activity coefficients derived by organ
harvesting and pure imaging was improved by the cross-calibration of hybrid imag-
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Figure 3.5: 18F-FDOPA TACs: (a) organ harvesting, (b) imaging, (c) hybrid imaging,
and 18F-FTYR: (d) organ harvesting, (e): imaging, (f) hybrid imaging [108]
ing from r=0.69 (p < 0.1995) to r=0.95 (p < 0.0149) for 18F-FDOPA and from
r=0.98 (p < 0.0034) to r=0.99 (p < 0.0001) for 18F-FTYR (data only shown in Pa-
per II in Appendix B). The highest time-integrated activity coefficient was obtained
for the urinary bladder wall (theoretical value, fraction of 0.5) and the liver for 18F-
FDOPA and the liver followed by the urinary bladder wall (theoretical value, fraction
of 0.2 due to evidence of less activity accumulation in the bladder) for 18F-FTYR.
Faster sphere segmentation resulted in time-integrated activity coefficients closer to
values derived by organ harvesting than values obtained using laborious manual full
organ segmentation. In Figure 3.6 the calculated absorbed doses of major organs
and the resulting effective dose of both tracers is displayed for all three methods.
The correlation between the sets of absorbed doses derived by organ harvesting and
pure imaging was marginally improved by hybrid imaging and correlation values
of above r=0.995 (p < 0.0001) were achieved. The effective dose (using the tissue
weighting factors from ICRP 60) of 18F-FDOPA was 1.97E-02 ± 1.00E-04 mSv/MBq
derived by organ harvesting (2.02E-02 ± 1.12E-04 mSv/MBq by imaging / 2.00E-02
± 7.07E-05 mSv/MBq by hybrid imaging). The highest absorbed dose was received
by the liver followed by the osteogenic cells (organ harvesting). The effective dose of
18F-FTYR was 1.64E-02 ± 2.50E-04 mSv/MBq obtained by organ harvesting (1.70E-
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02 ± 2.36E-04 mSv/MBq by imaging / 1.63E-02 ± 1.70E-04 mSv/MBq by hybrid
imaging). The liver received the highest radiation burden followed by the kidneys
(organ harvesting).
Figure 3.6: Absorbed doses of main organs derived by organ harvesting (TD) and
dynamic imaging (imaging) and hybrid imaging for (a) 18F-FDOPA and (b) 18F-
FTYR; UBW = urinary bladder wall, TB = total body and ED = effective dose in
mSv/MBq based on tissue weighting factors from ICRP 60
3.2.1 Discussion
Applying hybrid imaging towards dynamic microPET imaging for dosimetric pur-
poses has increased the accuracy of radiation dosimetry estimates for both radio-
pharmaceuticals. The fast small sphere segmentation produced more accurate results
making laborious full organ segmentation unnecessary as it is more prone to PVE.
Absolute errors in time-integrated activity coefficients and the resulting absorbed
doses were reduced by hybrid imaging for most organs in both tracers as can be
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seen in Figure 3.6. This is of special concern in radiation dosimetry as preclini-
cal estimates are used to calculate injection limits for first-in-human clinical trials
and underestimations could result in over-exposure of human subjects. Although
for some organs slight differences remained between organ harvesting and hybrid
imaging, they can be explained by methodological differences (such as the blood
removal from organs in organ harvesting) and remaining PVEs. In the microPET
attenuation scan (acquired at low resolution using a 57Co point source) PVEs on or-
gan boundaries cause additional overestimations in the reconstructed emission scan,
especially on boundaries with large density differences (i.e. on lung boundaries).
Using a modern combined PET/CT system might improve quantification accuracy.
Smaller remaining differences could be explained by only using the last time point
of microPET imaging for cross-calibration. PVE is a dynamic problem in imaging, as
it depends on the activity inside the region of interest as well as the activity in the
background [53]. Since conditions are changing constantly in the dynamic biodistri-
bution, the calibration factor might change dynamically as well. The comparison of
the preclinically derived radiation dosimetry of 18F-FDOPA in humans to the clini-
cally derived values by Brown et al. [109] showed that correlations of above r=0.99
(p < 0.0001) were achieved with all three methods. The total body absorbed dose
and the effective dose were estimated with an error of 10% and 2%, respectively.
However, ratios between the preclinically derived absorbed dose values and the clin-
ical values from Brown et al. for 18F-FDOPA from 0.61 (underestimation in kidney;
hybrid imaging) to 1.30 (overestimation in muscle; hybrid imaging) were found
for organ absorbed doses. Additionally, the critical organ was misinterpreted by our
preclinically derived values as the uterus was estimated to receive the highest dose,
whereas Brown et al. showed that the kidney is the critical organ. In conclusion, we
demonstrated that the new method hybrid imaging in mice yields comparable re-
sults to organ harvesting, while involving fewer resources, radiopharmaceuticals and
substantially fewer animals. The full biodistribution of each animal can be acquired
with a much higher time resolution with less intraspecies differences compared to
organ harvesting, where multiple animals are used for each derived time point. We
also showed that time-consuming whole-organ delineation is unnecessary and can
be replaced by the much faster sphere segmentation, which counteracts PVE on
organ boundaries further. We derived for the first time in literature the radiation
dosimetry of 18F-FTYR and determined the effective dose to be 1.64E-02 mSv/MBq
± 2.50E-04 mSv/MBq with the liver being the most exposed organ (based on organ
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harvesting). The revealed differences in human organ absorbed doses between pre-
clinically derived estimates and clinically derived estimates for 18F-FDOPA suggest
that preclinically derived radiation dosimetry estimates should nevertheless be used
with care when calculating injection doses for first-in-human studies.
3.3 Absorbed doses to mice for three [18F]-tracers
3.3.1 Overview
In this Section the animal radiation dosimetry of 18F-FDOPA, 18F-FTYR and 18F-
UCB-H (for details see Paper III in Appendix C) in mice is briefly summarized. The
manuscript was submitted for the Marie Cure Award at the EANM conference in
Lyon, France, and was considered as one of the best 5 of all submitted abstracts.
Since small animals are commonly used as translational models for human clinical
research, they often have to undergo longitudinal studies involving several con-
secutive microPET scans [15, 110]. The cumulative received absorbed dose of the
animals might be considerably large, which is often neglected in preclinical studies.
It might have a significant impact on the animal’s physiology and consequently could
compromise the outcome of the study. A single entrance absorbed dose of above 6 Gy
is considered lethal to a mouse [111]. The biological effects of low-level radiation,
however, will vary with type of radiation, dose delivered, delivery rate, type of tissue,
and animal strain [112]. Consequently, it is of great importance to be able to predict
the amount of radiation in various study setups. The aim of this investigation was
to quantify the radiation burden animals are exposed to by microPET imaging in a
typical preclinical setup and to project the data from single injections to longitudinal
studies, where animals have to undergo several consecutive scans. The experimen-
tally obtained biodistributions of the tracers were taken from the preclinical study
presented in Section 3.1 and the preclinical study presented in Section 3.2. The
TACs derived with several methods (organ harvesting, dynamic imaging and hybrid
imaging) were applied to the MOBY phantom [73] and using the S-factors recently
derived by Mauxion et al. [74] the mouse dosimetry was calculated for the first
time for the three 18F radiopharmaceuticals. A 3D representation of co-registered
images from microCT and averaged microPET images of all tracers for representative
subjects are displayed in Figure 3.7.
Absorbed doses of major organs in mice are shown in Figure 3.8 for all three
tracers. The total body absorbed dose was 14.04 ± 0.03 mGy/MBq derived by organ
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Figure 3.7: 3D representation of representative subject of averaged PET/CT image
for (a) 18F-FDOPA, (b) 18F-FTYR and (c) 18F-UCB-H
harvesting for 18F-FDOPA, 14.23 ± 0.05 mGy/MBq for 18F-FTYR and 14.38 ± 0.06
mGy/MBq for 18F-UCB-H. The average total body absorbed dose across all methods
and tracers was 14.19 ± 0.10 mGy/MBq. The largest absorbed dose was received
by the urinary bladder wall for 18F-FDOPA (value not included in Figure 3.8, 660.8
± 276.88 mGy/MBq), and the liver for 18F-FTYR (48.23 ± 6.27 mGy/MBq) and
18F-UCB-H (65.14 ± 8.47 mGy/MBq).
Figure 3.8: Absorbed doses in mice derived by organ harveting (TD), dynamic
imaging (Imaging) and hybrid imaging (Hybrid) from (a) 18F-FDOPA, (b) 18F-FTYR
and (c) 18F-UCB-H. TB = total body
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3.3.2 Discussion
Applying hybrid imaging led to an improvement of activity quantification in most
organs for 18F-FDOPA and 18F-FTYR (hybrid imaging not applied to 18F-UCB-H) in
mouse dosimetry analogous to the extrapolated human dosimetry. The calculation
of the mouse dosimetry has shown that the animals receive a significant amount of
radiation from a single microPET scan. When considering a standard injection of
10 MBq per animal per scan, absorbed organ doses can vary between 100 and 400
mGy with the urinary bladder wall for 18F-FDOPA receiving the highest amount of
radiation of above 6 Gy per single scan. However, the urinary bladder wall absorbed
dose was derived without voiding assuming a static organ volume and therefore
might be overestimated. The total body absorbed dose (effective dose cannot be
derived as there are no weighting factors for animal tissues) was calculated as ap-
proximately 140 mGy per scan per animal for all tracers, which is in agreement with
published data for other 18F-tracers in mice [37]. The organ receiving the highest
radiation for 18F-UCB-H and 18F-FTYR was the liver. Assuming five consecutive
scans in a longitudinal study with injections of 10 MBq each, the cumulative total
body absorbed dose from microPET amounts to 0.7 Gy. Single organ absorbed doses
might reach 3.25 Gy for the liver using 18F-UCB-H or 30 Gy for the bladder wall
using 18F-FDOPA. This significant exposure might alter the physiology and thus have
an impact on the results of the study or even introduce stochastic / deterministic
effects. In most longitudinal studies, subjects undergo for each microPET scan an
additional microCT scan, which further increases the radiation burden. Researchers
should always consider the amount of radiation delivered and keep it as low as pos-
sible by limiting the injected activity and the number of scans while still producing
the desired images. In order to be able to estimate the total received radiation in
a dual modality imaging setup, the dose inflicted on animals from microCT was
investigated and is presented in Section 3.5 and 3.6.
3.4 Radiation dosimetry for [18F]UCB-H: First-in-human
study
3.4.1 Overview
In this section the clinically derived human radiation dosimetry of 18F-UCB-H is
briefly discussed. For detailed information on the conducted experiments and in-
depth results the reader is referred to Paper IV in Appendix D. The investigated
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radiotracer is the same as in Section 3.1 and targets the human SV2A protein. Fol-
lowing the preclinical investigation of the radiation dosimetry, the safety of the
radiopharmaceutical for administration in humans has to be confirmed according
to national regulations by a first-in-human trial. The aim of the study was to de-
termine the biodistribution and the whole body radiation dosimetry of 18F-UCB-H
for the first time in 5 male subjects using dynamic PET imaging. Injection limits
according to European and American regulations in medical research, which keep
the radiation burden below recommended thresholds, were derived and presented.
Furthermore, since the same tracer was also investigated preclinically (see section
3.1), the radiation dosimetry results were compared to each other. Dynamic whole
body PET/CT imaging was performed on five healthy volunteers over approximately
110 minutes. TACs were derived from segmented organs on co-registered CT images
and the human radiation dosimetry was calculated using OLINDA/EXM [70]. The
same urinary excretion scenarios as in the preclinical study (Appendix A / [80])
were implemented with voiding every 2h or 4h and fractions of injected activity
leaving via urinary pathways of 0.3 to 0.5.
Figure 3.9: (a) Whole-body coronal image of representative subject at different
time points post administration of 18F-UCB-H and (b) 3D representation of PET/CT
image averaged over all frames
In Figure 3.9 a sequence of whole-body coronal images of a representative sub-
ject is displayed. High uptake could be observed in the brain, which is the tracer’s
main organ of interest, the liver, and the gallbladder. In Figure 3.10 the calculated
absorbed doses and the effective dose based on the tissue weighting factors from
ICRP publication 60 are presented along with their corresponding preclinically de-
rived values from Section 3.1. The effective dose amounted to 1.98E-02 ± 1.30E-04
mSv/MBq and the highest radiation was received by the urinary bladder wall (not
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included in Figure 3.10), followed by the gallbladder and the liver. However, the
urinary bladder wall value was derived using the software module of OLINDA/EXM
for urinary excretion in a rather conservative setup.
Figure 3.10: Preclinically and clinically derived absorbed dose estimates (both for
urinary excretion scenario of voiding every 4h and 0.5 of injected activity leaving
via urinary pathways), ED = Effective dose in [mSv/MBq]
3.4.2 Discussion
The biodistribution of 18F-UCB-H revealed a significant uptake of the tracer inside
the brain emphasizing its potential for the investigation of the role of SV2A in the
normal and pathological central nervous system. The effective dose based on tis-
sue weighting factors from ICRP publication 60 resulting from an administration
of 18F-UCB-H of 1.98E-02 ± 1.39E-04 mSv/MBq was determined to be less than
reported values in literature for the most widely used clinical tracer 18F-FDG [107].
The injection limits according to American and European regulatory agencies were
determined and showed, that single injections up to 321 MBq in the USA and 505
MBq in Europe result in equivalent doses (USA) and effective doses (EU) below lim-
its of the respective agency. When comparing clinically derived results to preclinical
results it becomes evident, that the effective dose and total body absorbed dose were
estimated preclinically within a 10% error window of the clinically derived values.
Despite the close estimations for total-body absorbed doses and a correlation value
r=0.969 (p < 0.0001) between the datasets, some significant differences with ratios
between clinical and preclinical values of 0.43 to 1.97 were found in single-organ
absorbed doses (i.e. 0.43 for preclinical overestimation of lung absorbed dose and
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1.97 for preclinical underestimation of gallbladder wall absorbed dose). They could
be related to methodological differences (anaesthetized in animals vs. awake in
humans) and interspecies differences in properties such as metabolic rate. Addition-
ally, the injected activity per kilogram body mass is 100-fold higher in mice than in
humans possibly resulting in higher blood activities increasing the absorbed dose in
highly perfused organs (such as brain, liver and lung). Since preclinical estimates
are only derived to project first injection doses to limit exposure of subjects in a
first-in-human trial, errors in single absorbed doses might cause an over-exposure of
the subject if the projections are not handled with care. However, most values were
overestimated in preclinical estimates.
3.5 X-ray dose quantification of the GE explore 120
micro-CT
3.5.1 Overview
In the following Section the manuscript published in the IEEE Transactions on Nu-
clear Science about the dosimetry and the performance evaluation of the microCT
GE eXplore 120 is discussed (for details the reader is referred to Appendix E /
[113]). All experiments and analysis related to the performance evaluation were
conducted by Dr. Mohamed Ali Bahri. However, since the focus of the manuscript
is on dosimetry, the performance evaluation is only partially summarized. Since
in most preclinical microPET studies a microCT scan is performed for anatomical
information, additional radiation is received by the animal with each scan. MicroCTs
are usually characterized by a very high spatial resolution of typically a few µm
to 100 µm depending on the machine, its intended application and protocol set-
tings. The high resolution and small detector sizes usually entail a high radiation
dose (high photon flux) in order to keep signal-to-noise ratios above acceptable
thresholds for image reconstruction. Therefore, in order to be able to predict to-
tal radiation received by animals in longitudinal studies involving microPET and
microCT, the dosimetry of the microCT GE eXplore 120 microCT was investigated
for the first time. The GE eXplore 120 microCT provides a set of pre-implemented
protocols for the end user to apply in different situations. In order to choose the
appropriate protocol for a specific study, the resulting image quality of each protocol
like contrast and resolution should be considered. Additionally, the resulting dose
to the animals should be known a priori in order to estimate the overall radiation
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burden received by the subjects, especially in dual modality and/or longitudinal
studies. Here we investigated the image quality and radiation burden of different
implemented protocols to provide help in choosing the appropriate protocol for
different studies and to clarify the dose inflicted on animals during microCT scans.
The dose measurements were conducted using a mobileMOSFET dose verification
system (BestMedical Canada, Canada) in four protocols that are regularly applied
in live animal scans. The properties of the protocols (P1 to P4) are summarized in
Table 3.1.
Table 3.1: Properties of investigated microCT protocols
A custom-built PMMA phantom with several inlets for sensors was used to obtain
dose profiles to calculate the CTDI100 and MSAD (see Section 2.9 / [99]). The
dose was also quantified in vivo in sacrificed rats of different size/weight to obtain
organ doses and to assess the impact of the surrounding tissue. single field of view
(sFOV) and multiple field of view (mFOV) scans were acquired and compared to
the CTDI100 and MSAD. Additionally, a scan with each protocol in each rat was
performed with the QRM bar pattern phantom [114] inserted into the abdominal
cavity to visually assess the in vivo image quality and its deterioration due to the
amount of surrounding tissue. The determined CTDI100 showed that the average
radiation inside the centre position of the PMMA phantom varied approximately
between 20 mGy (P1) and 56 mGy (P3). The MSAD was estimated by analytical
superposition of the acquired sFOV dose profiles according to machine properties
and amounted to approximately 28 mGy (P1) to 78 mGy (P3). Since the acquired
field of view (FOV) (55 mm) is smaller than the full width half maximum (FWHM)
(74.5 mm) of the dose profile, large tails at each side of the dose profile increase the
CTDI100 compared to the real measured in vivo point dose as can be seen in Figure
3.11.
When applying a factor accounting for the difference between the FOV and
the FWHM, the measurements agree. No significant impact of the animal’s weight
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Figure 3.11: (a) CTDI100 (single FOV measurement) (b) MSAD (multiple FOV mea-
surement) each vs. in vivo averaged dose point measurements (brain, chest, ab-
domen, anal cavity) in rats of different size [113]
or the location of the sensor (brain, chest, abdomen and anal cavity) on the dose
measurement was observed. However, when visually inspecting the in vivo scan of
the bar pattern phantom in Figure 3.12, a clear impact can be observed regarding
resolution and contrast.
Figure 3.12: In vivo bar pattern scan using (a) P2 in rat 272g, (b) P2 in rat 602g,
(c) P3 in rat 272g, (d) P3 in rat 602g, (e) P3 ex vivo in air and (f) technical sketch
of phantom [114]. All images from -500 to 2000 HU [113]
3.5.2 Discussion
We demonstrated by deriving the CTDI100 and the MSAD ex vivo using a phantom,
that the GE eXplore 120 microCT delivers a significant amount of radiation per
scan. Ex vivo measurements were confirmed by in vivo results obtained in sacrificed
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rats. Depending on the protocol additional doses of 28 mGy to 78 mGy are inflicted
on each animal per microCT scan when using mFOV acquisitions. Higher energy
protocols such as P3 were able to confirm the ex vivo measured resolution of 100 µm
independent of the rats weight, whereas low energy protocols could only achieve
150 µm in the smaller rat. The animal’s weight had a clear impact on the contrast
between the resolution plate and the filling material as can be seen in Figure 3.12c
and Figure 3.12d. The larger the amount of surrounding tissue the less contrast is
remaining between plate and filling material. In conclusion, a trade off between
resolution/contrast and the delivered dose must be made. If contrast/resolution is
of great importance, smaller animals seem more suitable for experiments. If the
highest resolution is not necessary, low energy protocols should be used for dose
reduction. Since the experimental setup only allows for dose point measurements,
Monte Carlo simulations were performed to investigate the spatial dose distribution
inside small animals further non-invasively. The results and their implications are
presented in the following Section.
3.6 Monte Carlo simulations of the dose from the GE
eXplore 120 microCT
3.6.1 Overview
In the following Section, the manuscript on Monte Carlo simulations (MCS) of the
GE Explore 120 microCT using GATE is summarized. For in-depth information on
the study the reader is referred to Paper VI in Appendix F. Small animal imaging
has gained significant importance in preclinical studies due to the increasing use
of small animals as translational models for clinical disease and treatment research
[13]. Most studies investigating the dose delivered by microCTs rely upon experi-
mental measurements in phantoms and sacrificed animals [101, 112, 113]. Organ
doses are derived using MOSFET sensors or TLD chips, but both have a large ge-
ometry and provide only dose point measures. MCS are a useful tool to investigate
the dose distribution within organs non-invasively [36, 115]. Bone doses, which
are expected to be higher than organ doses due to their high density, cannot be
derived experimentally since only surface entrance doses can be obtained. The aim
of this study was to establish a model of the GE eXplore 120 microCT in the MCS
package GATE [68] and to derive the dose delivered by the machine from several
protocols that are regularly applied to live animals. Simulated data was compared
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to experimentally derived results available in Appendix F and [113]. We modelled
the built-in X-ray source of the GE eXplore 120 microCT, the PX1483GS from Dunlee
(Subdivision of Philips Healthcare, Amsterdam, Netherlands), as a circular source of
the size of the focal spot (diameter of 0.3 mm) and simulated X-ray spectra at 70,
80 and 100 kVp tube voltage using an online tool provided by Siemens based on the
algorithm of Boone et al. [116]. The half-value layer (HVL) of the spectra, which
represents the thickness of a material in the beam path to reduce the intensity of
the radiation by half (in this case aluminium), was measured experimentally and
simulated in order to validate the spectra. CT images of the PMMA phantom used in
the experiments [113], a representative rat and mouse were implemented into the
model as phantoms and material compositions of PMMA, carbon fiber, soft tissue,
lung, air and bone were assigned to the respective regions of the three phantoms.
We derived the CTDI100 (from sFOV acquisitions) and the MSAD (mFOV acquisitions,
see Section 2.9 for definitions) using the PMMA phantom and organ doses in mice
and rats using the respective CT image phantom. Four protocols (P1 to P4) were in-
vestigated, which are displayed in Table 3.1. Only a fraction of the amount of emitted
photons per second from the X-ray tube was simulated to keep computation times in
an acceptable range. The ratio between the experimentally determined CTDI100 and
the CTDI100 in the simulated dose maps of the PMMA phantom was used to scale
the dose maps to exposures corresponding to the real amount of photons emitted
by the X-ray tube (similar to Taschereau et al. [36]). In Figure 3.13a the simulated
spectra at 70, 80 and 100 kVp are presented along with their corresponding HVL
determined by experiments and simulation in Figure 3.13b. A slight error increase
at higher tube voltages between simulated data and measured data was observed,
however, data agreed within 7%.
In Table 3.2 results from the simulations using the PMMA phantom for all inves-
tigated protocols are displayed. The largest dose was delivered by the protocol P3
followed by P2. Large standard deviations were observed for the transaxial average
of the CTDI100 for P1, P3 and P4 compared to P2.
In Figure 3.14 a comparison of experimentally derived dose profiles inside the
PMMA phantom and simulated dose profiles is displayed for sFOV acquisitions (Fig-
ure 3.14a) and mFOV acquisitions (Figure 3.14b). The CTDI100 derived from the
central position and all transaxial positions is compared in Figure 3.14c.
Simulation dose maps of the mouse and rat phantom showed large doses de-
posited in bone of 459.13 ± 96.37 mGy in mice and 298.69 ± 91.87 mGy in rats
from the high energy protocol P3. All soft tissue organs showed similar average
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Figure 3.13: (a) Simulated spectra at respective tube voltage and (b) the corre-
sponding HVL from simulation and experiments
Table 3.2: Scaling factor (ratio between simulated and experimental CTDI100), sim-
ulated CTDI100, and transaxial average of CTDI100 of all protocols and the simulated
MSAD of P1
radiation exposures of 159.42 ± 43.92 mGy in mice (P3) and 128.02 ± 36.67 mGy
in rats (P3). Mice received higher doses than rats due to their smaller mass with
an average total body dose of 188.70 ± 112.05 mGy from P3 (rat: 118.89 ± 71.09
mGy P3).
3.6.2 Discussion
We established a valid Monte Carlo simulation model of the GE eXplore 120 microCT.
The necessary X-ray spectra were simulated using a Siemens online tool. Their HVL
values simulated using our Monte Carlo model agreed within a 7% error window
with experimentally measured values. The error increase for higher tube voltages
could be related to characteristic emission peaks from the PX1483GS, whose anode
is made of tungsten and rhenium, while the spectra implemented in the simulations
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Figure 3.14: Dose profiles derived from the central position inside the PMMA phan-
tom for (a) sFOV acquisition, (b) mFOV acquisitions and (c) the corresponding
CTDI100 including the transaxial average; exp= experimentally derived and sim=
simulated
represented an anode fully made of tungsten. Characteristic emission peaks, which
become more apparent at higher tube voltages (see Figure 3.13a) are unique to the
respective material and might have caused a slight mismatch between experimen-
tally determined and simulated HVL values. Simulated CTDI100 and MSAD values
confirmed experimental results with the highest radiation delivered by P3 followed
by P2. Higher standard deviations in transaxial averages for P1, P3 and P4 compared
to P2 can be related to 192◦ gantry rotation increasing the radiation exposure on
one side of the phantom. The simulated mFOV acquisition dose profile compared to
the experimental dose profile shown in Figure 3.14b revealed dose deposition peaks
outside of the phantom boundaries in air, which are artifacts that might originate
from the sharp density drop on each side of the phantom. Those edge effects might
be related to scatter from inside the phantom. Further investigations need to be
performed. However, the calculation of the MSAD from the simulated mFOV dose
profile was not affected since only the central portion of the dose profile is taken
into account. The simulated organ doses revealed high dose depositions in small
animals that exceeded the estimations based on the MSAD from experimental values.
Especially bones receive large amounts of radiation with doses of 459.13 ± 96.37
mGy in mice and 298.69 ± 91.87 mGy in rats using P3. A higher radiation burden
in mice than in rats is a result of the lower mass / volume of the mouse, which is in
agreement with results presented by Boone et al. [117], who derived the total body
dose as a function of the diameter of the small animal present. The fact that a dose
increase of only approximately 50% from rat to mouse was observed, although the
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Figure 3.15: Organ doses derived from mFOV acquisitions in mice (3 sFOV, P1 to
P4) and rats (5 sFOV, P1 and P3), WB=whole body
volume of the rat is 10-fold greater, explains why no clear trend was observed for
experimental dose values in rats of different size (approximately 250g to 620g) in
Section 3.5. Researchers need to take the significant additional radiation exposure
from microCT into account especially when planning longitudinal dual-modality
studies combined with microPET. Since even low level radiations might alter phys-
iological processes [118, 119], the outcome of specific studies might be altered by
radiation induced effects.
C H A P T E R 4
Discussion
In this manuscript several studies were introduced aiming at the quantification of
the radiation burden inflicted on small animals in a preclinical environment or
on humans in clinical trials by PET and/or CT imaging. Methodological improve-
ments especially regarding faster and more ethical data acquisition in preclinical
radiation dosimetry of PET radiopharmaceuticals using mice were investigated and
presented. Comparisons were made between clinically and preclinically derived radi-
ation dosimetry estimates of the same radiopharmaceuticals. Furthermore, the dose
received by animals from microCT imaging in preclinical studies was investigated
both experimentally and through Monte Carlo simulations. In the introduction, sev-
eral specific aims (see Section 1.5) were defined and each was addressed with a
single study, summarized and discussed in Chapter 3 (see Appendix A to F for in-
depth information). The current chapter aims to combine the separate studies into
one comprehensive general discussion leading to the implications of the derived
results for the field of preclinical and clinical dosimetry.
4.1 Methods of preclinically derived human radiation
dosimetry
The human radiation dosimetry of 18F-UCB-H, 18F-FDOPA and 18F-FTYR was de-
rived for the first time preclinically from the biodistribution of the radiopharmaceuti-
cal in mice (see Sections 3.1 and 3.2). The biodistributions were obtained using the
traditional method of organ harvesting, dynamic microPET imaging, and the newly
applied method hybrid imaging (18F-FDOPA and 18F-FTYR only), which combines
imaging and organ harvesting.
In Table 4.1 a summary of advantages and disadvantages of all three methods is
provided. While organ harvesting features accurate quantification and the possibility
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Table 4.1: Advantages and disadvantages of activity quantification methods
to investigate all organs/tissues/fluids that can be extracted during a dissection, it
also requires a substantial amount of animals to be sacrificed (depending on number
of time-points and number of animals per time-point), which necessitates large ani-
mal housing facilities. The data acquisition is labour-intensive and has to be spread
across several days depending on the staff and facilities present. This also entails
the necessity of several tracer productions increasing the cost of the investigation.
Since only a few time-points are usually investigated, the time-resolution is low and
early blood peaks cannot be detected. Intraspecies variability is increased since every
sample of each time point is obtained using a different animal, which complicates
the derivation of statistics [41].
Dynamic microPET imaging features rapid and simplified data acquisition with a
high time resolution enabling the detection of early blood uptake peaks that might
contribute significantly to the radiation dosimetry. It involves very few animals, de-
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creasing the cost of tracer production and animal housing. The complete dynamic
biodistribution in each animal can be obtained for each microPET scan, reducing
intraspecies differences and facilitating the derivation of statistics. However, as has
been shown by using 18F-UCB-H ([80] / Appendix A), 18F-FDOPA and 18F-FTYR
([108] / Appendix B), and by other authors [90], microPET imaging in mice without
further corrections lacks the accurate quantification necessary for dosimetry applica-
tions. Significant differences were found in time-integrated activity coefficients, and
consequently, human absorbed dose estimates derived using organ harvesting and
dynamic microPET imaging. Ratios of time-integrated activity coefficients (organ
harvesting divided by microPET imaging full organ segmentation) of up to 0.53
(overestimation; lung) and 2.30 (underestimation; liver) were obtained in the pre-
clinical study of 18F-UCB-H, 0.23 (overestimation; lung) to 1.88 (underestimation;
kidney) using 18F-FDOPA and 0.30 (overestimation; lung) to 1.52 (underestima-
tion; liver) using 18F-FTYR. However, when excluding the lung, overestimations
were reduced to ratios of 0.73 for 18F-UCB-H, 0.63 for 18F-FDOPA and 0.9 for
18F-FTYR. The lung has a very high volume fluctuation due to movement during
respiration and the VOI in the microCT image represents only one specific inflation
state. Since neither microCT nor microPET images were gated to the respiration, the
co-registration is prone to misalignments as the volume of the lung shown in either
image is an average over the respective imaging time. Gating of both images to
the same time point might improve the quantification but would reduce the signal-
to-noise ratio significantly in microPET imaging as a high amount of coincidence
counts is neglected.
Additionally, PVEs arising from the attenuation correction using a 57Co point
source further impair the quantification in the lung (in case of stand alone microPET
like the Siemens Concorde Focus 120 microPET), which has been shown in the study
of 18F-FDOPA and 18F-FTYR (Appendix B). Since the resolution of the attenuation
scan is comparably low, PVEs occur on the boundary between lung and surrounding
tissue. As the attenuation correction of the emission scan is a multiplication of the
attenuation value and the detected coincidence signal, PVEs in the attenuation scan
lead to a misinterpretation of the signal in the emission scan. This effect should
be decreased when using newer dual modality microPET/microCT scanners, as the
resolution of the microCT is higher. These PVEs arise on every transition between
tissues of different density in the attenuation scan and between tissues of different
activities in the emission scan, which leads to the large over-/underestimations using
pure dynamic microPET imaging in most organs.
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We found that it was possible to counteract these effects by altering the seg-
mentation technique. By using small spheres that were placed in the centre of each
organ, PVEs on the boundaries of organs were avoided and the accuracy of quantifi-
cation was slightly improved in both studies. However, differences in values derived
by organ harvesting remained in time-integrated activity coefficients and conse-
quently human absorbed dose estimates. Total body absorbed doses and effective
doses agreed within a 10% error window, but far larger differences in single organ
absorbed doses remained (e.g. ratio of 2.05 between absorbed dose derived by or-
gan harvesting and imaging for the liver in 18F-UCB-H study; underestimation in
imaging). As has been stressed before, when using preclinically derived estimates to
calculate injection limits for first human trials, large differences in absorbed organ
doses might lead to significant over-exposures in subjects. The fact that the averaged
effective dose is not significantly different while such large differences in single or-
gan absorbed doses are present points out the weakness of using the effective dose
for the estimation of injection limits. This issue will be addressed in Section 4.2.1.
Another disadvantage of using microCT and microPET in mice for dosimetric
purposes was the low contrast in microCT images for segmentation. Automated seg-
mentation techniques are technically not feasible and most authors rely upon manual
full-organ segmentation [41, 88, 90, 120], which is subjective and time-consuming.
Using the sphere segmentation increased the segmentation speed significantly, but
the subjectivity of manual segmentation remains. Additionally, only major organs
can be segmented due to the low contrast, decreasing the accuracy of the radiation
dosimetry estimates. Recent developments in the field of preclinical MRI systems
might provide a solution for the segmentation issue, as MRI imaging (depending
on the sequence) provides a superior soft tissue contrast to CT imaging, possibly
allowing for user independent and fast automated segmentation.
Hybrid imaging, which was applied to microPET imaging in mice for the first
time, improved the quantification significantly as has been shown in the study of
18F-FDOPA and 18F-FTYR (Appendix B). The cross-calibration of microPET TACs
using activity measures of post-scan dissected organs decreased differences found in
derived time-integrated activity coefficients and consequently radiation dosimetry
estimates between organ harvesting and imaging. Ratios of time-integrated activity
coefficients between organ harvesting and hybrid imaging were improved to a range
from 0.39 to 1.32 for 18F-FDOPA (0.23 to 1.88 between organ harvesting and
imaging) and 0.94 to 1.12 for 18F-FTYR (0.30 to 1.52 between organ harvesting
and imaging). This is also reflected in the slight improvement of correlation values
4.2. Comparison of preclinically and clinically derived human dosimetry 61
between the derived datasets of dosimetry estimates (18F-FDOPA: r=0.997 pure
imaging / r=0.999 hybrid imaging; 18F-FTYR: r=0.985 pure imaging / r=0.996
hybrid imaging; all p < 0.0001). The combination of single-sphere segmentation and
the cross-calibration of hybrid imaging proved an appropriate method to counteract
the main disadvantage of microPET imaging, the impaired quantification.
Remaining differences can be explained by several points. The most obvious is
that both methods involve large uncertainties. As pointed out before, organ harvest-
ing lacks a high time resolution and incorporates many interspecies differences due
to the vast amount of animals involved per study. If experiments are not conducted
thoroughly, assumed time spans between injection and dissection are only approxi-
mated, as the blood circulation does not stop immediately after decapitation and the
blood content in extracted organs may vary across subjects. In hybrid imaging the
cross-calibration factor is derived using the last time point of the dynamic microPET
imaging acquisition and the activity in the post-scan dissected organ. Since the PVE
depends on several factors, some of which change dynamically in a dynamic system
(see Section 2.1), a calibration factor derived at the end of the acquisition may not
reflect the situation at the beginning, and could lead to remaining differences be-
tween TACs. There are other methods to correct for PVEs, such as the inversion of
the geometric transfer matrix [121], but it requires the point spread function of the
system, accurate anatomical information (ideally from MRI), and is computationally
expensive. Previously mentioned disadvantages like segmentation issues and vol-
ume fluctuations in organs due to non-gated scanning still apply to hybrid imaging
as well. However, the impact of PVEs were minimized by hybrid imaging reaching
a satisfactory level of activity quantification for dosimetric applications using mi-
croPET. From an economic, ethical and scientific point of view, organ harvesting has
become obsolete considering the similar results obtained using hybrid imaging and
the uncertainties involved in both methods. The technique requires only a fraction
of animals to be sacrificed and the data acquisition is faster and more efficient. A
dosimetric study can in theory be conducted in one day (by a small team of two
requiring only one tracer production, data analysis excluded).
4.2 Comparison of preclinically and clinically derived
human dosimetry
In Section 3.2 and Section 3.4 the preclinically derived dosimetry of 18F-FDOPA and
18F-UCB-H were compared to the existing clinically derived dosimetry of 18F-FDOPA
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[109] and to the herein conducted first-in-human study of 18F-UCB-H (Appendix
D). Although the effective dose and total body absorbed dose were estimated within
a 10% error window, significant differences were found in single-organ absorbed
doses (preclinical values derived by organ harvesting). For 18F-FDOPA the highest
difference was found for lungs and testes with ratios between absorbed doses of 1.63
and 1.55, respectively (both underestimated in preclinical data). In the comparison
of 18F-UCB-H the largest difference was found for the gallbladder wall and the lung
with ratios between absorbed doses of 1.97 and 0.43, respectively (underestimation
for galbladder wall and overestimation for lung in preclincal data). For 18F-FDOPA
the critical organ was misinterpreted in preclinical estimates possibly resulting in an
over-exposure in clinical trials. The variation in data can be traced back to method-
ological differences and interspecies dissimilarities. In preclinical studies animals
are anaesthetized (often using isoflurane or ketamine) and warmed, which might
have an impact on the distribution of the radiopharmaceutical. This has been shown
in mice for 18F-FDG by Fueger et al. [122]. They observed strong differences in the
uptake in skeletal muscle and especially in brown adipose tissue and myocardium,
depending on parameters such as fasting, type of anaesthesia, and temperature of
the animal. In clinical studies subjects are awake during the scan possibly resulting
in a slightly altered uptake scenario for some radiopharmaceuticals.
Another difference is the injected activity per body weight in comparison. As
stated in the manuscript of the clinical study of 18F-UCB-H (Appendix D), the in-
jected activity per kilogram body weight in mice is more than 100-fold the injected
activity in humans (285 MBq/kg vs. 2 MBq/kg). This might provide an explanation
for the deviation in large and highly perfused organs (i.e. liver), as the concen-
tration of the activity in the blood stream is higher entailing a larger amount of
radiation present in the organs. Extrapolation to human data is commonly based
in literature on the ratio of organ mass to body mass in both species (see Section
2.7). An assumption is made that metabolic rates are similar in both species and
only vary according to their weight differences [123]. But even monkeys used in pre-
clinical studies, which are assumed to possess a high physical similarity to humans,
were proven to poorly estimate radiation dosimetry in humans using radiopharma-
ceuticals labeled with 11C [123]. As pointed out in Section 2.7, there are methods
accounting for metabolic differences in species when extrapolating TACs, however,
none prevail but the method based on the ratio of organ mass to body mass in both
species. Sakata et al. [92] compared the clinically derived radiation dosimetry and
the preclinically obtained radiation dosimetry in mice (by organ harvesting) from
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five 11C and one 18F labelled tracer. Their radiation estimates, based on mice, also
showed only a rough similarity for effective doses (ratios from 0.86 to 1.88), but
especially significant differences for absorbed doses in single organs occurred and
the critical organ was misinterpreted for two out of six tracers. The results derived
within the study of 18F-UCB-H (Appendix A and D) and 18F-FDOPA (Appendix B)
further underline that animal data extrapolated to humans is notoriously unreli-
able due to intraspecies and methodological differences. Since injection limits for
first-in-human studies have to be based on preclinical estimates (the US follow FDA
regulations and some countries of the EU follow recommendations from the ICRP),
the safety of those regulations should be scrutinized.
Due to discrepancies between estimates based on preclinical data and results
obtained in humans, over-exposures of subjects in first-in-human studies may occur.
Therefore, it is recommended to use preclinical radiation dosimetry estimates with
caution and keep the injected activity in first-in-human studies as low as possible
while still obtaining images with sufficient signal-to-noise ratio for further investi-
gation. It might even be safer, if preclinical studies were omitted and replaced by
low activity first-in-human scans, as proposed by Zanotti et al. [39, 123], due to the
large uncertainty of preclinical estimates. They reviewed a large amount of clinical
dosimetry studies and concluded that the received effective dose across different 18F
and 11C tracers varied but was in a narrow range and is therefore predictable for
novel tracers. Low activity scans in humans, which are feasible due to the high sensi-
tivity of modern scanners, should be the first approach used to detect critical organs
and to estimate higher safe injection limits. This would remove the uncertainties
involved in preclinical estimates minimizing the risk of over-exposing subjects in
first-in-human studies. Another advantage would be, from an ethical point of view,
the avoidance of animal experiments.
4.2.1 Absorbed dose vs. effective dose
As already described in Section 1.4, the EU follows recommendations of the ICRP
limiting the effective dose per injection in clinical trials based on the expected health
benefit of the radiopharmaceutical [39, 40]. The FDA in the USA provides limits for
different organs based on the equivalent dose (which is equal to the absorbed dose
for PET imaging as the radiation weighting factor is unity) [39]. It is contentious
which quantity is more suitable for use in nuclear medicine. Several authors agree
that the broad use of the effective dose as commonly done nowadays in radiology
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and nuclear medicine is inappropriate [19, 30, 31]. The weighting factors reflecting
the radiosensitivity of tissues are averaged over population, age, and sex. The risk
of fatal cancer due to a uniform body exposure however, is a function of age and sex
and decreases with age. The effective dose can only be related to a reference person
and it should be used only for comparing the health detriment to a reference subject
for different types of exposures. The widespread misconception already pointed out
in Section 1.2 about the most recent tissue weighting factors from ICRP publication
103 and their erroneous use in literature creates additional uncertainty when basing
injection limits on the effective dose.
The absorbed dose (or equivalent dose in PET imaging) reflects only the de-
posited energy per unit mass and might be a better quantity to limit the injection of
the radiopharmaceutical. Risk assessment for individual patients in general should
always be based on absorbed organ dose estimates accounting for stature, gender,
and age. Especially when only a few radiosensitive organs receive a significant
absorbed dose, as was the case for most radiopharmaceuticals investigated, it is
more appropriate to use absorbed doses [30, 31]. Regarding preclinical radiation
dosimetry estimates, the effective dose was estimated correctly within ± 10%, but
absorbed doses of single organs showed much larger deviations. This might lead
to over-exposures when using effective doses to calculate injection limits. How-
ever, even the absorbed dose (or equivalent dose) should be used carefully as many
assumptions are made during the calculation of the quantity. The mathematical
hermaphroditic phantom developed by Cristy and Eckerman [71] and the respec-
tive S-factors [124] only approximate the anatomical geometry of each subject. The
distribution of the radiopharmaceutical inside each organ is assumed to be homo-
geneous and the organ itself has a uniform density. New computational phantoms
were developed by the ICRP and ICRU [23], which will improve the accuracy of the
radiation dosimetry once S-factors are published.
Martin [31] estimated the involved standard errors in absorbed dose calculations.
The uncertainty in the measurement of the administered dose was determined as ±
10%. For the measurement of the uptake, distribution, and retention of the tracer
it was ± 30% and the statistical error in the involved Monte Carlo simulations was
± 5%. These large standard deviations might explain the large inter-study differ-
ences for the same tracer that were found by Zanotti et al. [39]. This also further
questions the validity and safety of using preclinical estimates for the calculation
of first injection limits, when even clinically derived estimates vary for the same
tracer, since preclinical estimates involve even more assumptions and uncertainties.
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A standardized investigation protocol, as suggested by Eberlein et al. [24] and pro-
vided for clinical studies by Lassmann et al. [125], regarding image acquisition and
absorbed dose calculations might reduce methodological differences and possibly
provide safer radiation dosimetry estimates for the calculation of injection limits.
4.3 Exposure considerations in preclinical longitudi-
nal studies
While the great majority of publications dealing with radiation dosimetry focus on
human dosimetry for first-in-human studies and safe application of radiopharmaceu-
ticals in a clinical environment, relatively few publications focus on the radiation
received by animals in preclinical studies. Bearing in mind the ever increasing use
of small animals as translational models for clinical research, however, the radia-
tion dosimetry should be taken into account. This is especially important when
conducting longitudinal studies with several consecutive microPET/microCT scans,
which possibly introduce radiation levels that could compromise the outcome of the
study. Due to the 100-fold amount of activity per bodyweight injected in mice for
microPET studies compared to human studies, the absorbed doses from microPET
are significantly higher than from regular PET imaging in humans, as was shown
in Chapter 3.5. MicroCT imaging requires a high photon flux compared to clinical
systems to achieve the very fine resolution while still maintaining an appropriate
signal-to-noise ratio. It therefore delivers an additional considerable amount of ra-
diation as was shown experimentally and using Monte Carlo simulations in Section
3.5 and 3.6.
A lethal level of radiation for mice is considered to be a single total body entrance
dose of 6 Gy [111]. While it is unlikely that such an excessive amount of radiation
is received during a dual modality scan especially as a single entrance dose, studies
have shown that far lower radiations might have an impact on the animal’s neurology
or physiology [16, 118, 119]. The biological effects of low-level radiation, however,
will vary with type of radiation, dose delivered, delivery rate, strain of mice, and
type of tissue [112]. The herein derived radiation dosimetry in mice for 18F-UCB-H,
18F-FDOPA and 18F-FTYR revealed total body absorbed doses of approximately 14
mGy/MBq, which is in accordance with data published by other authors for other 18F
tracers [37]. Critical organs received far higher absorbed doses than other organs,
with the urinary bladder wall for 18F-FDOPA being exposed to the excessive absorbed
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dose of 660 mGy/MBq (liver with 65 mGy/MBq for 18F-UCB-H and liver with 49
mGy/MBq for 18F-FTYR).
In longitudinal microPET studies, which are commonly conducted in preclinical
oncology studies to investigate tumour growth or inhibition by pharmaceuticals,
up to five or six consecutive microPET/microCT scans [15, 126, 127] can be per-
formed over several weeks. Most of the studies do not address the radiation burden
inflicted on the animals or the possible impact on tumour growth. We created six
theoretical scenarios of microPET/microCT imaging studies in mice (see Table 4.2)
to project cumulative doses received in longitudinal dual modality imaging studies.
We assumed 7 MBq injected activity per microPET scan, since this was the common
amount of injected activity for mice in our conducted experiments. Each microCT
protocol (P1 to P4) was implemented in a different 5 consecutive dual modality scan
scenario (S1 to S4). Two rather excessive scenarios involving 10 consecutive scans
were created to estimate the strong accumulation of absorbed doses, especially in
local organs. The microCT protocols P1 and P3 were used, since P1 produces the
lowest exposure and P3 provides the highest soft tissue contrast while resulting in
the highest radiation burden.
Table 4.2: Dual-modality imaging scenarios (for details on P1 to P4 see Table 3.1)
We used the absorbed doses in mice from the three radiopharmaceuticals pre-
sented in Section 3.3 and the microCT doses simulated using MCSs in Section 2.5
(for details see Appendix C and F). Single-modality doses per scan and the cumula-
tive dose from both modalities for the respective longitudinal setup are displayed in
Table 4.3.
Depending on the chosen microCT protocol and the radiopharmaceutical in-
volved, cumulative total body doses of up to 1.4 Gy can be inflicted on mice in a 5
scan dual-modality longitudinal study. Cumulative organ or bone doses can reach
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Table 4.3: Cumulative doses from longitudinal dual-modality imaging scenarios;
dose refers to absorbed dose
far higher levels with the liver being exposed to 2.7 Gy in S4 and bones to 2.5 Gy
in S2. In the rather conservative scenarios S5 and S6 involving 10 consecutive dual
modality scans cumulative total body doses of up to 3.3 Gy are reached with single
organ doses of 6.9 Gy received by the liver. The cumulative exposure of several con-
secutive scans is probably sublethal in mice, since a single entrance dose of 6 Gy is
considered lethal [111], but the radiation may be large enough to induce stochastic
or deterministic effects in animals. The radiation could possibly alter physiological
parameters [119, 128] and therefore have an impact on the outcome of a study if
the respective parameter is involved. Cumulative doses in rats from dual-modality
studies are expected to be lower, since it was shown that the microCT dose is a
function of the volume of the animal. However, microPET absorbed doses in rats
might reach an equivalent or higher level than in mice due to the high injected dose
per kilogram (average of 385 MBq/kg in [104] or 400 Mbq/kg in [41]).
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4.4 Future directions
National regulations requiring preclinical radiation dosimetry in small animals as
a prerequisite for first-in-human studies should be reconsidered due to the large
uncertainties involved in preclinical dosimetry. Modern PET scanners feature a high
sensitivity, which makes low-activity human scans a viable option for detecting criti-
cally exposed organs. This may be an ethical and scientifically accurate alternative
to preclinical animal testing. However, if preclinical radiation dosimetry in small ani-
mals has to be performed, the ethical and efficient method of hybrid imaging should
be applied. Partial volume corrections in dynamic small animal imaging should be
further investigated and the benefits of combining microPET and small animal MRI
imaging should be explored. Replacing CT with MRI in small animal imaging would
additionally mean a decrease of the radiation exposure. Researchers in preclinical
imaging should be aware of the large radiation burden inflicted on animals and
should consider its impact on their respective study. We derived microPET absorbed
doses of three 18F radiopharmaceuticals in mice and microCT doses in mice and
rats. At the time this manuscript was prepared, rat models for internal dose calcu-
lations were available, but no absorbed doses for any radiopharmaceutical in rats
were published to our knowledge. Since the injected activity per kilogram in rats in
several studies is even larger than in mice, a significant radiation burden can be ex-
pected. Absorbed doses for several radiopharmaceuticals in rats should therefore be
calculated and published to provide researchers with the possibility of assessing the
dose inflicted on animals in their specific study setup. The same holds true for every
new microCT machine available to researchers. The radiation dosimetry should be
assessed in a similar way as proposed in this manuscript and published to provide
every user with the information. Monte Carlo simulations proved to be a valuable
tool for the non-invasive investigation of the microCT dose. Future improvements
could be detailed computational phantoms and incorporating the exact amount of
photons generated by the source.
C H A P T E R 5
Conclusions
• By acquiring the biodistribution of three 18F-tracers using traditional organ
harvesting and dynamic microPET imaging we demonstrated that without
appropriate corrections and precautions sole dynamic microPET imaging lacks
the accurate quantification necessary for preclinical radiation dosimetry in
mice.
• The method of hybrid imaging, which we applied to dynamic microPET imag-
ing of mice for the first time, increased the accuracy of quantification and
provided similar results to organ harvesting, while being more efficient from
an ethical, economical, and scientific point of view.
• It was shown by comparing data of three 18F-tracers that full organ segmenta-
tion for dosimetry is unnecessarily laborious and prone to errors due to PVE
and the misinterpretation of boundaries. Simple sphere segmentation inside
each organ produced more accurate results.
• We presented for the first time in literature the preclinically derived human
radiation dosimetry of 18F-UCB-H, 18F-FDOPA and 18F-FTYR with effective
doses based on tissue weighting factors from ICRP publication 60 of 2.18E-
02 ± 5.5E-04 mSv/MBq, 1.97E-02 ± 1.00E-04 mSv/MBq and 1.64E-02 ±
2.50E-04 mSv/MBq, respectively.
• By conducting the first-in-human clinical dosimetry study of 18F-UCB-H we
determined the effective dose to be 1.98E-02 ± 1.39E-04 mSv/MBq with the
critical organs being the urinary bladder wall, the gallbladder, and the liver.
We showed that the radiation burden of the tracer is similar or lower than that
of widely used clinical tracers such as 18F-FDG and provided safe injection
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doses according to research guidelines in the EU (single injection of 505 MBq)
and USA (single injection of 321 MBq).
• We compared preclinically derived data and clinically derived data of 18F-UCB-
H and 18F-FDOPA and showed that preclinically derived estimates roughly pre-
dicted total-body absorbed doses and the effective dose, but poorly predicted
single-organ absorbed doses. In case of 18F-FDOPA the critical organ was mis-
interpreted in preclinical dose estimates. They should be used with care when
estimating first injection limits for first-in-human studies.
• We calculated and presented for the first time the mouse radiation dosimetry
of 18F-UCB-H, 18F-FDOPA and 18F-FTYR and demonstrated that mice receive
highly significant amounts of radiation from microPET scanning. Total body
absorbed doses of 14 mGy/MBq were calculated for all three tracers with
critical organ exposures of 65 mGy/MBq for 18F-UCB-H (liver), 660 mGy/MBq
for 18F-FDOPA (urinary bladder wall), and 48 mGy/MBq for 18F-FTYR (liver).
• The radiation dosimetry of the GE eXplore 120 microCT was experimentally
derived in a PMMA phantom and presented. The single-field-of-view radiation
ranged from 20.15 to 56.79 mGy (CTDI100) and the multiple-field-of-view from
27.98 to 77.45 mGy (MSAD), depending on the chosen protocol. In vivo results
acquired in sacrificed rats confirmed ex vivo phantom measurements.
• A Monte Carlo simulation model of the GE eXplore 120 microCT was estab-
lished for the first time, validated, and used to further investigate the radiation
dose non-invasively in mice and rats. It was shown that the skeleton receives
far higher doses (average maximum of 459 mGy in mice using P3) than pre-
dicted by the CTDI100 and MSAD.
• By deriving the radiation dosimetry from microPET and microCT we demon-
strated that mice are exposed to significant amounts of radiation in dual
modality studies. In longitudinal studies cumulative doses (of up to 3.3 Gy
for total body and 6.9 Gy for single organs) could potentially induce stochas-
tic/deterministic effects and alter the outcome of the investigation.
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Abstract
Background: [18F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A,
the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation
dosimetry of [18F]UCB-H in a preclinical trial and to determine the maximum injectable dose according to
guidelines for human biomedical research. The radiation dosimetry was derived by organ harvesting and dynamic
micro positron emission tomography (PET) imaging in mice, and the results of both methods were compared.
Methods: Twenty-four male C57BL-6 mice were injected with 6.96 ± 0.81 MBq of [18F]UCB-H, and the
biodistribution was determined by organ harvesting at 2, 5, 10, 30, 60, and 120 min (n = 4 for each time point).
Dynamic microPET imaging was performed on five male C57BL-6 mice after the injection of 9.19 ± 3.40 MBq of
[18F]UCB-H. A theoretical dynamic bladder model was applied to simulate urinary excretion. Human radiation dose
estimates were derived from animal data using the International Commission on Radiological Protection 103 tissue
weighting factors.
Results: Based on organ harvesting, the urinary bladder wall, liver and brain received the highest radiation dose
with a resulting effective dose of 1.88E-02 mSv/MBq. Based on dynamic imaging an effective dose of 1.86E-02 mSv/
MBq was calculated, with the urinary bladder wall and liver (brain was not in the imaging field of view) receiving
the highest radiation.
Conclusions: This first preclinical dosimetry study of [18F]UCB-H showed that the tracer meets the standard criteria
for radiation exposure in clinical studies. The dose-limiting organ based on US Food and Drug Administration (FDA)
and European guidelines was the urinary bladder wall for FDA and the effective dose for Europe with a maximum
injectable single dose of approximately 325 MBq was calculated. Although microPET imaging showed significant
deviations from organ harvesting, the Pearson’s correlation coefficient between radiation dosimetry derived by
either method was 0.9666.
Keywords: Dosimetry, Preclinical microPET, Organ harvesting, SV2
Background
Epilepsy is a chronic neurological disorder characterized
by seizures and abnormal electroencephalographic activ-
ity. It affects people of all ages with more than 50 mil-
lion cases worldwide. In contrast to other antiepileptic
drugs, levetiracetam (Keppra®, UCB Pharma Ltd., Slough,
Berkshire, UK) has a unique mechanism of action,
binding to the neuronal synaptic vesicle protein 2A
(SV2A) in the brain [1]. SV2 proteins are critical to
proper nervous system function, and they have been
demonstrated to be involved in vesicle trafficking. How-
ever, the specific role of SV2A in epilepsy remains
unclear. The newly developed fluorine-18 radiolabelled
positron emission tomography (PET) imaging agent
[18F]UCB-H shows a nanomolar affinity for the human
SV2A protein and will be of great value in studying the
function of SV2A in diseases of the central nervous sys-
tem [2].
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A prerequisite to the use of a novel radiotracer in
human clinical trials and good clinical practice is a pre-
clinical dosimetry study in animals. This enables the pre-
diction of dose limits in humans that will keep radiation
doses below harmful limits while still producing diag-
nostically beneficial images. Radiation estimates for
humans derived from small animals are traditionally
obtained by ex vivo tissue distribution (TD) studies,
where organs are harvested post-injection at several time
points to establish the biodistribution. However, dynamic
imaging approaches in small animals using microPET
are a promising alternative, because the complete bio-
distribution of the radiopharmaceutical can be obtained
within a single in vivo scan with a much higher time
resolution. The aims of this study were to predict the ra-
diation dose given to humans based on the distribution
of [18F]UCB-H in mice and to determine the maximum
injectable dose according to radiation guidelines in bio-
medical research. Additionally, the TD and microPET




[18F]UCB-H was obtained in a four-step radiosynthesis.
Briefly, this consisted of nucleophilic labeling of a pyri-
dine precursor, reductive amination of the labeled prod-
uct, and internal cyclisation. Specific activity was higher
than 500 MBq/μg at the end of synthesis.
Animals
Male C57BL-6 mice were initially obtained at 5 weeks of
age from Charles River Laboratories (Brussels, Belgium)
and subsequently bred at the Animal Facility of the
GIGA-University of Liège (BE-LA 2610359). The ani-
mals were housed under standard 12h:12h light/dark
conditions with food and water available ad libitum. All
experimental procedures and protocols used in this inves-
tigation were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of
Liège.
Tissue distribution
The data acquisition and analysis were conducted in ac-
cordance with MIRD pamphlet no. 16 [3]. For the TD of
[18F]UCB-H, 24 male C57BL-6 mice (23.96 ± 1.31 g
[20.6 to 26.1 g]) were injected with an iv bolus of 6.96 ±
0.81 MBq [5.18 to 8.06 MBq] [18F]UCB-H via the tail vein
under isoflurane anesthesia. Anesthesia was maintained
until sacrificed by decapitation after 2, 5, 10, 30, 60, and
120 min (n = 4 for each time point). Blood samples were
obtained (0.5 to 1 ml), and the following organs were
harvested by dissection: the brain, bone (femur), liver (par-
tial), kidney, heart, spleen, intestine (partial), pancreas,
adrenals, testes, skin (partial), muscle (partial/thigh),
stomach, lung, and bladder. All organs were weighed
(NewClassic ML, Mettler Toledo, Switzerland), and the
activity was quantified using a gamma well counter (Cobra
II Auto-Gamma, Perkin-Elmer, Waltham, MA, USA),
resulting in the average activity per gram of tissue in mice.
The gamma well counter was calibrated measuring a
known quantity of 18F activity (quantified using a cali-
brated gamma spectrometer: high purity 30% germanium
GR3020 from Canberra Industries, Meriden, CT, USA),
thereby obtaining a calibration factor between real and
measured activity. The measurement uncertainty was
evaluated to be ±5%.
Dynamic microPET imaging
Dynamic microPET imaging was performed on five male
C57BL-6 mice with an average weight of 29.72 ± 6.70 g
[24.2 to 40.8 g]. 9.19 ± 3.40 MBq [3.84 to 14.20 MBq]
[18F]UCB-H was administered via the tail vein as bolus.
All procedures were performed under isoflurane
anesthesia. Co-registered micro-computed tomography
(CT) images were acquired with an eXplore 120 microCT
(Gamma Medica, USA/GE Healthcare, Sevenoaks, Kent,
UK) [4] to obtain anatomical information for segmenta-
tion. An iodine-based contrast agent (1:10 dilution of
iobitridol-XENETIX300, Guerbet, Roissy, France) was ad-
ministered in the peritoneal cavity prior to microCT to
aid full organ segmentation. All microCT images were
reconstructed using Feldkamp’s filtered backprojection
algorithm [5] with a cutoff at the Nyquist frequency and
an isotropic voxel size of 100 μm. The same MINERVE
animal cell bed (Equipement Veterinaire Minerve,
Esternay, France) was used in both imaging modalities
to provide anesthesia, physiological control, monitoring
of respiration, and simplified co-registration of the im-
ages. Dynamic microPET scans over 120 min were ac-
quired using a Siemens Concorde Focus 120 microPET
(Siemens, Munich, Germany) [6] and followed by trans-
mission measurement with 57Co point source. In order
to obtain dynamic imaging data for as many organs as
possible, the field of view of the scanner was positioned
on the chest and lower body disregarding the brain.
The list-mode data were histogrammed into three-
dimensional (3D) sinograms by Fourier rebinning [7]
and reconstructed by filtered backprojection with a
ramp filter cutoff at the Nyquist frequency. Corrections
for randoms, dead time, and attenuation were applied
but not scatter correction, since it was shown by Bahri
et al. [8] that no benefit for quantification is gained by
applying scatter correction for the Focus-F120. No
partial volume correction was performed on the acquired
data. A set of 3D images was reconstructed in a 256 ×
256 × 95 matrix with a pixel size of 0.4 × 0.4 × 0.8 mm.
The dynamic time framing was as follows: 6 × 5 s, 6 ×
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10 s, 3 × 20 s, 5 × 30 s, 5 × 60 s, 8 × 150 s, 6 × 300 s, and
6 × 600 s, and all data were decay corrected to the begin-
ning of each individual frame.
MicroCT and microPET images were co-registered
using a landmark-based approach. Volumes of interest
(VOIs) were drawn manually by a single observer on the
microCT images using PMOD (Version 3.306, PMOD
Technologies, Zurich, Switzerland). This allowed the de-
lineation of the following organs: the heart, lung, liver,
kidneys, and testes (referred to as ‘dynamic whole’). The
average organ activity per volume was obtained from the
co-registered microPET images. Additionally, VOIs in
the shape of spheres with a radius of 2 mm were placed
in the center of the same organs to limit the impact of
partial volume effects on the quantification and used for
dosimetry (referred to as ‘dynamic single’). For the heart,
one VOI was positioned over the myocardium and parts
of the chambers; for the liver, two VOIs were placed in
the center of the organ; for lungs, kidneys, and testes,
one VOI was placed in the center of each organ (i.e., left
and right wing for lungs, left and right organ for kidneys
and testes). MicroPET calibration for conversion of
counts/pixel in Bq/ml was performed as recommended
by the manufacturer. Accuracy of the technique has
been reported to be better than 2% [8].
Dosimetry analysis
When using animal data to predict human dosimetry, an
interspecies extrapolation is necessary to account for dif-
ferences between animal and human. A commonly used
method in preclinical imaging is that of Kirshner et al.
[9], which is based on a linear scaling of the percent up-
take in the animal by the ratio of the organ weights and


















The organ uptake in percentage of injected dose multi-
plied by the body weight in kilograms is assumed to be
constant across species, allowing for the calculation of
equivalent organ activities in humans from animal data.
Since the organ-to-body weight ratio is necessary to ex-
trapolate to humans and to create consistent time-
activity curves from the obtained average organ activity
per volume or gram of tissue, a ‘standard mouse’ was
created using six C57BL-6 mice. This ‘standard mouse’
allowed both organ density and the ratio of organ weight
to body weight to be calculated and a species average as-
sumed. The mice were weighed and then dissected to
determine the organ weight and density by microCT for
volume quantification. The mean total body weight was
32.28 ± 3.98 g [28.6 to 39.8 g]. The following organs
were harvested: the brain, liver, kidney, heart, spleen,
testes, and lung. The organ volume was obtained from
the microCT images by a threshold-based segmentation
approach. All weights were finally scaled to a bodyweight
of 35 g. Only data from organs where the ratio of organ
weight to bodyweight was known were used for dosimetry.
Average organ activity per mass or volume was normal-
ized for injected dose and multiplied by organ weights or
organ volumes, respectively. Activity levels were linearly
interpolated, and only physical decay was assumed after the
last time point up to 10 h post-injection. Thus, a
homogenous activity distribution within each organ was
assumed, and biological clearance after 2 h post-injection
was neglected, assuming the activity was ‘trapped’ within
the source organ. The time-activity curves (TACs) were
then extrapolated from animal values to human values
using Equation 1. Human organ weights and body weight
were taken from the standard 70-kg adult male hermaphro-
ditic phantom implemented in the human dosimetry
software OLINDA/EXM (version 1.1) [10] and animal
organ weights from the standard mouse as described above.
In addition, TACs that were calculated based only on
animal organs (i.e., no extrapolation to human values) were
used to calculate additional dose estimates to provide an
estimation window for the human dosimetry (referred to as
‘NE’ for no extrapolation). Urine excretion data were
modeled using the implemented dynamic voiding bladder
module [11] in OLINDA/EXM. A voiding interval of 4 h
was assumed, and fractions of 0.5 to 0.3 of total injected
activity leaving the body via the urinary excretion system
with a biological half-life of 3 h were defined and separately
implemented. The same scenarios were implemented using
a voiding interval of 2 h to provide data for the impact of a
possible pre-scan hydration of the subject to decrease the
bladder dose. The residence time for each organ, which is
equal to the number of disintegrations within the source
organ, was calculated by trapezoidal numerical integration
of the TACs in MATLAB (version 7.12.0) as proposed in
literature [3,12]. Activity from other organs that could not
be extrapolated due to the unknown weight-to-body weight
ratio was assigned together with all unaccounted for activity
to the remainder, which is assumed to be homogenously
distributed throughout the remaining body. OLINDA/
EXM was used to calculate absorbed doses. The effective
doses in the standard 70-kg male human based on the
recent tissue weighting factors published in International
Commission on Radiological Protection (ICRP) 103 [13]
were calculated using Excel (version 2010, Microsoft,
Albuquerque, NM, USA) and are presented in the ‘Results’
section. For comparison purposes with other tracers and
previous works, the effective doses using old tissue
weighting factors from ICRP 60 [14] were also calculated
using OLINDA/EXM and were provided as additional files.
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Since the TACs of the TD are derived from several time
points in different animals, each individual time point has
its own standard deviation (SD). Therefore, the SD of
residence times derived from the TD was calculated as
follows. Two additional animal TACs were constructed
using mean ± 1 SD of each individual time point of the
activity measurement. These two TACs were then extrapo-
lated to human values as previously described, and the
mean residence time corresponding to each TAC was
computed [15-17]. This provided a residence time window
which is expressed as a coefficient of variation in percent
(%CV) from the mean value. The residence time window
was used to calculate a minimum and maximum dose for
the TD, resulting more in a best and worst case scenario as
opposed to a real SD. The mean of best and worst case
scenario was used as the error for the measured absorbed
dose and reported as %CV of the mean value. For the
statistics of the microPET imaging, every scan was treated
separately, and mean and standard deviation expressed as
%CV were regularly calculated across scans. Correlations
between datasets were calculated by the Pearson product–
moment correlation coefficient in MATLAB.
Results
Figures 1 and 2 illustrate the human biodistribution of [18F]
UCB-H derived from animal TD and from microPET
imaging based on sphere segmentation (dynamic single),
respectively. In both datasets, the highest initial activity
uptake was obtained within the liver with 29% and 18%,
respectively. However, brain data could not be derived from
PET data, as the brain was outside the scanner’s field of
view. Furthermore, the spleen could not be accurately
delineated in CT images in the absence of additional
contrast agents. TACs from whole organ segmentation
(dynamic whole) were provided as Additional file 1 (whole
TACs) and Additional file 2 (zoom in).
The mean residence times obtained by the TD and
dynamic microPET imaging with both segmentation
methods are presented in Table 1. The highest level of
disintegrations per organ occurred within the liver with
4.45E-01 h (TD), 1.93E-01 (dynamic whole), and 2.18E-01 h
(dynamic single). Bladder values are theoretical values
derived using the dynamic bladder module described above.
A cross section of all anatomical planes of the merged
PET/CT image is illustrated in Figure 3. High uptake in
liver, kidneys, bladder, and spinal cord can be observed.
The animal-derived dose estimations from the TD
method (Table 2) predicted that the highest absorbed dose
is received by the urinary bladder wall (modeled theoretical
value) with 1.54E-01 ± 5.00E-04 mGy/MBq, followed by
the liver with 5.84E-02 ± 7.35E-03 mGy/MBq and the brain
with 3.08E-02 ± 5.15E-03 mGy/MBq. The effective dose
Figure 1 Mean human TACs derived by TD in mice (A: total, B: zoom in).
Figure 2 Mean human TACs derived by microPET imaging in mice (dynamic single) (A: total, B: zoom in).
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was 1.88E-02 ± 5.11E-04 mSv/MBq. The highest dose
estimate, based on microPET imaging (dynamic single),
was received by the urinary bladder wall with 1.56E-01 ±
0.00E-00 mGy/MBq, followed by the liver with 3.14E-02 ±
1.97E-03 mGy/MBq (brain was not imaged). The effective
dose was 1.84E-02 ± 3.51E-04 mSv/MBq. Mean dose
estimates based on whole organ segmentation are provided
as Additional file 3 and effective doses for all three methods
obtained using old weighting factors form ICRP 60 as
Additional file 4.
In Table 3, the variation of the urinary bladder wall
absorbed dose when using fractions of 0.3 to 0.5 as
previously described is shown as well as its impact on the
effective dose for both methods. When reducing the
voiding interval to 2 h, the absorbed dose decreases to
9.21E-02 mGy/MBq (TD) for a bladder fraction of 0.5 and
to 5.94E-02 mGy/MBq (TD) for a bladder fraction of 0.3.
Discussion
The tissue distribution of [18F]UCB-H was obtained by
traditional organ harvesting at several time points in mice
as well as by dynamic microPET imaging to compare the
results of both methods. Dynamic microPET imaging is
an interesting alternative to organ harvesting. Organ
harvesting requires many animals and can be labor
intensive. In dynamic microPET imaging, the complete
biodistribution can be obtained within a single scan.
Furthermore, it allows sampling of the activity distribution
with a much higher time resolution, thus catching early
blood uptake peaks in organs that are well perfused. Such
peaks could substantially contribute to organ radiation.
However, when comparing the residence times obtained
with all three techniques (Table 1), dynamic imaging (dy-
namic whole) alone significantly over- or underestimated
the activity within organs. This effect could be explained by
known imaging limitations in very small volumes such as
partial volume effect or spill over from nearby organs. Low
activity organs (i.e., the heart and lung) were overestimated
by 36 to 89% in the microPET images presumably due to
spill over from neighboring high activity organs (i.e., the
liver). All other organs were underestimated in microPET
images by 43 to 50%, which could be related to partial
volume effect. Deriving TACs from small sphere VOIs in
the center of organs (dynamic single) should have reduced
the impact of partial volume effect and slightly improved
quantification. However, underestimations of 49 to 53 %
and overestimations of 33 to 55% remained. A further
improvement in quantification might have been achieved
Table 1 Human residence times (h) (bladder fraction 0.5) derived by TD and dynamic imaging based on whole organ
segmentation and single spheres
Organ TD %CV Dynamic whole %CV Dynamic single %CV
Bladder (theoretical) 3.08E-01 - 3.08E-01 0.0 3.08E-01 0.0
Brain 1.74E-01 18.1 - - - -
Heart wall 1.79E-02 10.1 2.45E-02 11.6 2.39E-02 12.3
Kidneys 3.57E-02 10.5 1.67E-02 9.1 1.90E-02 13.2
Liver 4.45E-01 13.8 1.93E-01 6.7 2.18E-01 6.6
Lung 5.96E-02 9.8 1.13E-01 11.8 9.30E-02 14.8
Spleen 9.04E-03 13.6 - - - -
Testes 2.11E-03 12.7 1.04E-03 12.1 1.12E-03 12.8
Remaining body 1.58E + 00 6.7 1.98E + 00 1.4 1.97E + 00 1.2
Figure 3 Transverse (A), sagittal (B), and coronal (C) planes of merged average PET/CT image of a representative subject. PET image
was averaged across all frames and smoothed using a Gaussian kernel of 1 × 1 × 2 mm in PMOD. The color scale was set to the range 80 to 800
kBq/cc in all planes (Brain outside FOV).
Bretin et al. EJNMMI Research 2013, 3:35 Page 5 of 8
http://www.ejnmmires.com/content/3/1/35
76 Appendix A. Paper I
by applying partial volume correction based on the inver-
sion of geometric transfer matrix [18], but it requires the
point spread function of the system and accurate anatom-
ical information (ideally from MRI). Another, simpler ap-
proach to overcome these limitations that could be useful
is a combined method where animals are sacrificed after
dynamic imaging, and the activity of the harvested organs
is quantified with a gamma well counter to cross-calibrate
organ activity measured with microPET. Kesner et al.
applied this approach to dosimetry in rats [15]. An investi-
gation of this approach in mice, where size dependent ef-
fects are more eminent than in rats, will be part of future
studies. Furthermore, movement artifacts arising due to
rapid respiration and heart motion could be avoided by
gated scanning [19]. However, it should be noted that
gating decreases signal to noise ratios and leads to longer
and fewer frames. An iodine-based contrast agent was
used to aid organ delineation in the microCT scans.
Although of great use in organ delineation, this contrast
agent is most likely cleared via the same pathways as the
tracer and might thus have altered uptake in liver and
kidneys. The effect of IP contrast agent on residence times
in the TD method will be considered in future studies.
Table 3 Influence of bladder fraction on urinary bladder
wall dose (UBW) and effective dose (ED)
Dose TD Dynamic single
Bladder fraction 0.3 UBW 9.67E-02 9.85E-02
ED 1.66E-02 1.63E-02
Bladder fraction 0.4 UBW 1.26E-01 1.28E-01
ED 1.77E-02 1.74E-02
Bladder fraction 0.5 UBW 1.54E-01 1.56E-01
ED 1.88E-02 1.84E-02
Variation of UBW absorbed dose in mGy/MBq and ED for ICRP 103 weighting
factors (mSv/MBq) for different bladder fractions and a voiding interval of 4 h.
Table 2 Human absorbed dose (mGy/MBq) and effective dose (mSv/MBq)
Target Organ TD %CV TD NE Dynamic single %CV Dynamic single NE
Adrenals 1.43E-02 1.7 1.65E-02 1.36E-02 1.0 1.44E-02
Brain 3.08E-02 16.7 2.05E-02 8.61E-03 1.1 8.27E-03
Breasts 7.71E-03 2.9 7.18E-03 8.88E-03 0.7 8.36E-03
Gallbladder wall 1.86E-02 4.3 2.26E-02 1.56E-02 1.7 1.75E-02
LLI wall 1.36E-02 4.0 1.28E-02 1.55E-02 0.8 1.52E-02
Small intestine 1.24E-02 3.2 1.22E-02 1.37E-02 0.5 1.37E-02
Stomach wall 1.11E-02 2.3 1.11E-02 1.20E-02 0.4 1.20E-02
ULI wall 1.25E-02 2.4 1.27E-02 1.34E-02 0.6 1.36E-02
Heart wall 1.76E-02 6.5 1.77E-02 2.09E-02 9.2 1.26E-02
Kidneys 2.96E-02 8.4 7.07E-02 1.87E-02 9.1 4.06E-02
Liver 5.84E-02 12.6 8.40E-02 3.14E-02 6.3 4.32E-02
Lungs 1.64E-02 6.7 1.11E-02 2.17E-02 12.0 1.23E-02
Muscle 9.82E-03 3.1 9.42E-03 1.10E-02 0.4 1.08E-02
Ovaries 1.38E-02 4.0 1.30E-02 1.57E-02 0.7 1.54E-02
Pancreas 1.40E-02 0.7 1.55E-02 1.37E-02 0.7 1.43E-02
Red marrow 9.71E-03 2.0 9.41E-03 1.04E-02 0.4 1.03E-02
Osteogenic cells 1.39E-02 3.6 1.26E-02 1.57E-02 0.8 1.53E-02
Skin 7.22E-03 3.7 6.73E-03 8.17E-03 0.7 8.00E-03
Spleen 1.52E-02 7.9 1.50E-02 1.15E-02 0.5 1.16E-02
Testes 1.58E-02 6.6 1.13E-01 1.25E-02 5.1 6.41E-02
Thymus 9.26E-03 3.5 8.39E-03 1.09E-02 0.8 1.01E-02
Thyroid 8.86E-03 4.1 7.62E-03 1.01E-02 0.9 9.63E-03
Urinary bladder wall 1.54E-01 0.3 1.54E-01 1.56E-01 0.0 1.56E-01
Uterus 1.90E-02 2.9 1.82E-02 2.09E-02 0.5 2.06E-02
Total body 1.19E-02 0.0 1.21E-02 1.18E-02 0.4 1.19E-02
Effective dose (mSv/MBq) 1.88E-02 2.7 2.72E-02 1.84E-02 1.9 2.19E-02
Human absorbed dose (mGy/MBq) and effective dose for ICRP 103 weighting factors (mSv/MBq) derived by animal tissue distribution (TD) and dynamic imaging
based on single sphere segmentation (both bladder fraction 0.5) for the standard 70-kg male phantom including no extrapolation (NE) estimation based on pure
animal data.
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The correlation between the extrapolated dose estimates
derived by TD and dynamic single was r = 0.9666
(p < 0.0001) and r = 0.9603 (p < 0.0001) between TD and
dynamic whole. The largest absolute differences in
absorbed dose were found in brain, liver, and kidneys,
which were underestimated in dynamic imaging by 72%
(expressed as percentage of absorbed dose derived by
organ harvesting), 46% and 37%, respectively. Since the
brain data in dynamic imaging were derived from the
remainder, the large deviation in absorbed dose for brain
is a logical consequence of the methodology, as opposed
to liver and kidneys, which were clearly derived by both
methods. However, the effective dose deviated by only
approximately 2%.
In comparison to the effective dose for 18F-FDG using
the 70-kg adult male phantom, [18F]UCB-H remained
below the reported effective dose for FDG of 2.1E-02 to
2.9E-02 mSv/MBq [20] with values (based on ICRP 103)
of 1.88E-02 mSv/MBq (TD) and 1.84E-02 mSv/MBq
(dynamic single). Based on the old tissue weighting factors
from ICRP 60, the effective dose was 2.18E-02 mSv/MBq
(TD) and 2.15E-02 mSv/MBq (dynamic single). These
values are also well below the limits given by the ICRP
[21]. When assuming a smaller bladder fraction of 0.3,
the effective dose based on TD is decreased to an aver-
age of 1.66E-02 mSv/MBq (dynamic single 1.63E-02
mSv/MBq, both ICRP 103) for the standard 70-kg male.
Assuming a shorter voiding interval (pre-scan hydration
of the subject) of 2 h, the effective dose further
decreases to 1.65E-02 mSv/MBq (TD and ICRP 103;
1.61E-02 mSv/MBq for dynamic single) for a bladder
fraction of 0.5 and 1.53E-02 mSv/MBq (TD and ICRP
103; 1.49E-02 mSv/MBq for dynamic single) for a
bladder fraction of 0.3.
The dose limits described by the US Food and Drug
Administration (expressed in equivalent dose, equal to
absorbed dose in this case, radiation weighting factor equal
to 1) state that 30 mSv per scan should not be exceeded, or
an annual dose of 50 mSv for whole body, blood forming
organs, lens of the eye and gonads. The limits for all other
organs are 50 mSv (single scan) and 150 mSv (annual) [22].
Therefore, for research in the USA, the maximum single
injected dose of [18F]UCB-H allowed (assuming a bladder
fraction of 0.5 and ICRP 103 factors) is 325 MBq, while the
maximum annual dose is 974 MBq, with the urinary
bladder being the critical organ for both (values derived
from TD; dynamic imaging yields very similar values of 321
and 962 MBq). When decreasing the bladder fraction to
0.3, the critical organ remains the urinary bladder, but the
single and annual doses increase to 517 MBq for single
injection and 1,551 MBq for annual injection (508 MBq/
1,523 MBq dynamic imaging). European regulations
propose that the effective dose should not exceed 10 mSv
per scan [21]. Based on this more stringent criterion, the
maximum injectable dose per scan derived by organ
harvesting would be 532 MBq per subject (543 MBq
dynamic single). If the bladder fraction is only 0.3, the
maximum injectable dose is 601 MBq (614 MBq dynamic
single). However, the presently derived injection limits
represent a worst case scenario due to assumptions made,
such as physical decay only after the last measured time
point or the relatively high fraction of injected activity
cleared via urinary pathways. First human clinical trials are
indispensable for confirming injection limits.
In displacement studies, subjects are injected at least
twice in a short time interval in order to detect the baseline
state and the activation state, or displacement [23]. There-
fore, a limit of 300 MBq per scan will keep radiation
exposure below harmful limits with an annual limit of three
injections for practice in the USA. However, based on the
high amount of activity reaching the brain [2], the injection
of 200 MBq per scan ought to be sufficient to provide
diagnostically useful images with [18F]UCB-H.
Conclusions
In this study, it was shown that the novel SV2A radiotracer
[18F]UCB-H meets the standard regulations regarding
radiation dose for use in human clinical trials. A maximum
single injectable dose of approximately 325 MBq per scan
was estimated based on the classical organ harvesting
technique. Dynamic imaging results by microPET showed
significant deviations from organ harvesting results for
single-organ absorbed doses, indicating that accurate
quantification in such small volumes as mice organs is lim-
ited. However, the effective dose derived by microPET devi-
ated by only 2% from the classical organ harvesting result.
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by whole organ segmentation (zoom in).
Additional file 3: Mean doses (dynamic whole). Mean absorbed
doses in mGy/MBq including effective dose in mSv/MBq (ICRP 103) from
whole organ segmentation.
Additional file 4: Effective doses (ICRP 60). Mean effective doses from
old tissue weighting factors from ICRP 60.
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Introduction
According to most governmental research guidelines forthe use of newly developed radiopharmaceuticals in
humans, the biodistribution and the radiation dosimetry must
be determined preclinically in advance of any clinical
application in order to eliminate the chance of excess
radiation exposure. Ex vivo measurement of the
biodistribution over time using harvested organs has long
been considered the gold-standard technique. Organs are
harvested from small to mid-size animals such as mice or
dogs at several time points post administration of theCorrespondence to: A. Plenevaux; e-mail: Alain.Plenevaux@ulg.ac.be
Abstract
Purpose: Dynamic microPET imaging has advantages over traditional organ harvesting, but is
prone to quantification errors in small volumes. Hybrid imaging, wheremicroPET activities are cross-
calibrated using post scan harvested organs, can improve quantification. Organ harvesting,
dynamic imaging and hybrid imaging were applied to determine the human and mouse radiation
dosimetry of 6-[18 F]fluoro-L-DOPA and 2-[18 F]fluoro-L-tyrosine and compared.
Procedures: Two-hour dynamic microPET imaging was performed with both tracers in four
separate mice for 18 F-FDOPA and three mice for 18 F-FTYR. Organ harvesting was performed
at 2, 5, 10, 30, 60 and 120 min post tracer injection with n=5 at each time point for 18 F-FDOPA
and n=3 at each time point for 18 F-FTYR. Human radiation dosimetry projected from animal
data was calculated for the three different approaches for each tracer using OLINDA/EXM. S-
factors for the MOBY phantom were used to calculate the animal dosimetry.
Results: Correlations between dose estimates based on organ harvesting and imaging was
improved from r=0.997 to r=0.999 for 18 F-FDOPA and from r=0.985 to r=0.996 (pG0.0001 for
all) for 18 F-FTYR by using hybrid imaging.
Conclusion: Hybrid imaging yields comparable results to traditional organ harvesting while
partially overcoming the limitations of pure imaging. It is an advantageous technique in terms of
number of animals needed and labour involved.
Key words: 18 F-FDOPA, 18 F-FTYR, MicroPET, Dosimetry, Quantification
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radiopharmaceutical and the behaviour of the tracer extrap-
olated to human data [1–3]. However, organ harvesting is
labour intensive and many animals are required to establish
the biodistribution. Additionally, due to the low time
resolution, early blood peaks in organs cannot be detected.
In primates or larger animals dynamic PET is increasingly
common in radiation dosimetry due to its high time
resolution and time efficient procedure [4–6]. However,
animal husbandry for larger species is complex and costly.
The development of microPET imaging allows determina-
tion of the complete in vivo biodistribution in small rodents,
which are easier to handle and widely used in other
preclinical applications. However, microPET is prone to
partial volume effects (PVE) in small volumes with
subsequent quantification errors [7] and hence dosimetry
errors, which in the worst case could lead to overexposure of
subjects in the clinic. A simple method of correcting for
PVE is scaling of the extracted time–activity curve (TAC).
This scaling is based on the ratio between measured activity
from PET and the post scan harvested organ activity
(measured with a gamma well counter). This method,
sometimes referred to as hybrid imaging, was applied in
rats by Kesner et al. [8] with a resultant improvement in the
correlation between dose estimates derived by organ
harvesting, imaging and hybrid imaging. PVE and spill-over
are size dependent and thus more prevalent in smaller
animals (an average mouse weighs approximately ten times
less than an average rat). Thus, the hybrid approach may be
of even more value in mice. The aim of this study was to
apply the hybrid technique in mice and to compare the
absorbed dose values obtained after extrapolation to humans
with this technique to those obtained using the widely
accepted organ harvesting. The compounds used in this
study were 6-[18F]fluoro-L-DOPA (18 F-FDOPA) and
2-[18F]fluoro-L-tyrosine (18 F-FTYR). The radiation dosi-
metry of 18 F-FDOPA in humans (with carbidopa pretreat-
ment) was derived by Brown et al. [9] and will be compared
to the results derived in this study. To the best of our
knowledge, the radiation dosimetry of 18 F-FTYR is not
available in literature and will be presented for the first time.
Additionally, we present the dosimetry in mice calculated
using the MOBY phantom [10] and S-factors derived using
Monte Carlo Simulations (GATE) [11].
Materials and Methods
Animals
Male C57BL/6 mice were obtained from Charles River Laborato-
ries (Brussels, Belgium) and subsequently bred at the Animal
Facility of the GIGA-University of Liege (BE-LA 2610359). All
animals were housed under standard 12 h:12 h light/dark conditions
with food and water available ad libitum. All protocols and
experimental procedures used in this investigation were reviewed
and approved by the Institutional Animal Care and Use Committee
of the University of Liege.
Radiochemistry
6-[18F]fluoro-L-DOPA was synthesized as described by Libert et al.
[12]. 2-[18F]fluoro-L-Tyrosine was prepared using a similar
me thodo logy bu t wi t h 2 - fo rmyl -5 -me thoxy -N ,N ,N -
trimethylbenzenaminium trifluoromethanesulfonate as the starting
chemical. The tracers were obtained at the NCA level and therefore
with the highest specific activity ever achieved for these tracers
(540 GBq/μmol).
Study Protocol
All data acquisition and analysis was performed in accordance to
MIRD pamphlet no. 16 [13]. Anesthesia was induced with 4.5 %
isoflurane (in oxygen) and maintained after tail vein tracer injection
by inhalation of 1–2 % isoflurane. After sacrifice by decapitation
brain, liver, kidney, heart, spleen, testes and lung were harvested.
The tissues were weighed (NewClassic ML, Mettler Toledo,
Switzerland) and activities were quantified by radioassay using a
gamma well counter (Cobra II Auto-Gamma; Perkin-Elmer, USA)
resulting in the average activity per g of tissue at each time point.
For 18 F-FDOPA, organ harvesting was performed in 30 mice
(average weight 23.51±1.75 g) after an average i.v. bolus of 8.47±
1.45 MBq. Five mice per time point were sacrificed by decapitation
after 2, 5, 10, 30, 60, and 120 min. Dynamic PET images were
acquired for 120 min after i.v. bolus injection of 7.66±1.62 MBq
18 F-FDOPA via the tail vein in four separate mice (average
bodyweight 22.10±1.21 g). Organs were harvested post scan and
activity per gram of tissue was determined as described above.
For 18 F-FTYR, dynamic imaging and organ harvesting were
performed in the same experiment. 18 mice (average weight 27.63
±1.97 g) received 8.08±1.21 MBq and were sacrificed by
decapitation after 2, 5, 10, 30, 60 and 120 min, with n=3 at each
time point. The three mice to be sacrificed at 120 min post injection
were also scanned dynamically from injection to sacrifice.
Dynamic microPET images were acquired using a Siemens
Concorde Focus 120 microPET (Siemens, Germany) [14] and
followed by transmission measurement using the rotating 57Co
point source of the scanner. The list-mode data were histogrammed
into 3D sinograms using Fourier rebinning [15] and reconstructed
using filtered backprojection (FBP) with a ramp filter cutoff at the
Nyquist frequency. Corrections for randoms, dead-time and
attenuation were applied but not for scatter, since it was shown
that there is no significant improvement by applying the scatter
correction for the Focus 120 microPET [16]. A set of 3D images
were reconstructed in a 256×256×95 matrix with a pixel size of
0.4×0.4×0.8 mm. The dynamic time framing consisted of the
following frames: 6×5, 6×10, 3×20, 5×30, 5×60, 8×150, 6×300,
6×600 s, and all data were decay corrected to the beginning of each
individual frame. Micro-CT images were also acquired with an
eXplore 120 micro-CT (Gamma Medica, USA/GE Healthcare, UK)
to obtain anatomical information for segmentation. All CT images
were reconstructed using Feldkamp's FBP algorithm [17] with a
cut-off at the Nyquist frequency and an isotropic voxel size of
100 μm. In both imaging modalities, the MINERVE animal cell
bed (Bioscan, USA) was used which provided anesthesia, physio-
logical control and monitoring of respiration. Micro-CT and
microPET images were manually co-registered using the commer-
cially available research software PMOD (Version 3.306, PMOD
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Technologies, Switzerland). The frame-averaged microPET image
was matched by rigid transformations to the microCT image, as for
both tracers skull and spine showed significant uptake, which was
sufficient for registration to microCT images. Two types of volume
of interest (VOI) were drawn by a single observer (F.B.) on the
micro-CT images. Full organ segmentation was performed (brain,
heart, liver, lung and kidneys) and spheres of 2-mm radius were
placed in organs (two VOIs in liver, kidneys and lung, single VOIs
otherwise) to decrease the impact of PVE and average activity per
volume were derived. Results based on both segmentation
techniques were compared. MicroPET calibration for conversion
of counts/pixel to Bq/ml was performed as recommended by the
manufacturer. The accuracy of this calibration has been reported to
be better than 2 % in our laboratory [16].
CT images displayed in the Results section were filtered with an
isotropic 3D Gaussian kernel of 0.2×0.2×0.2 mm3 and the PET
image with a 3D Gaussian kernel of 1×1×2 mm3. The PET image
was averaged over all dynamic frames and scaled from 0 to
1,200 kBq/ml.
For each tracer three different TAC were derived: organ
harvesting only (will be referred to as organ harvesting), dynamic
PET imaging only (imaging) and hybrid dynamic PET imaging
(hybrid imaging), where the activity measured with PET was scaled
by a factor derived from the ratio between PET activity at the end
of the image acquisition and the quantified post scan activity from
harvested organs of the same animal.
Organ weights and volumes were taken from a standard
C57BL/6 mouse of 35 g created from five male mice, whose
organs were weighed and the volume quantified using microCT.
Organ activities per gram or volume from organ harvesting or
microPET images were then normalized for injected activity and
organ weight or volume of the standard mouse, respectively. For
hybrid dynamic PET imaging, the TAC was then scaled as
described above. All TACs were interpolated with piecewise cubic
Hermite interpolation between time points and then extrapolated to
human values as described by Kirshner et al. [18]. The method is
based on the ratio of organ weight to body weight using animal
organ weights from the standard mouse created and human organ
weights from the standard 70 kg standard hermaphroditic male
phantom [19] implemented in OLINDA/EXM (Version 1.1) [20].
In all TACs, physical decay only was assumed after 120 min
neglecting any biological clearance from the organs. All numbers
of disintegrations in an organ (cumulated activity) were calculated
as area under the curve, which is mathematically equal to the
residence time, using trapezoidal numerical integration in Matlab.
Urinary excretion was theoretically modeled using the urinary
bladder module [21] implemented in OLINDA/EXM for human
dose estimates. For 18 F-FDOPA,a fraction of 0.5 of the injected
activity was assumed to be cleared via the urinary pathway with a
biological half-life of 3 h and voiding was assumed to occur every 4 h.
For 18 F-FTYR the same scenario was used, but with a fraction of only
0.2 due to evidence of much reduced accumulation of activity in the
bladder. The absorbed doses in major human organs and the effective
dose based on the old tissue weighting factors from ICRP 60 [22] were
calculated with OLINDA/EXM using the three different TACs for
each tracer. Effective doses based on the more recent tissue weighting
factors from ICRP 103 [23] were calculated using the absorbed doses
from OLINDA/EXM in Microsoft Excel.
Since the TACs derived by organ harvesting consist of
numerous time points in different animals, every individual time
point has its own standard deviation (SD). Hence, the SD of
residence times derived by organ harvesting could not be calculated
directly and was calculated as follows. Two additional animal
TACs were calculated using the mean±1SD of each individual time
point of the activity measurement, which were then extrapolated to
human values and the residence times corresponding to each TAC
was computed [24]. This residence time window was expressed as
a coefficient of variation in percent (%CV) from the mean value.
These residence times (mean±1SD) were used to calculate a
minimum and maximum absorbed dose for organ harvesting
resulting in a best and worst case scenario rather than a real SD.
The mean of best and worst case scenario was used as the error for
the absorbed dose expressed as %CV of the mean absorbed dose
value obtained using the mean TAC. For the statistics of imaging
and hybrid imaging every scan was treated separately and
mean±1SD expressed as %CV were calculated across scans as
usual. Correlations between datasets were calculated using Pearson
product–moment correlation coefficient in MATLAB.
Mouse Dosimetry
S-factors were derived for the MOBY phantom [10] using GATE
v6.1 [25]. The method used to generate the MOBY dataset and S-
factors has been previously described [11]. The biodistribution data
acquired for both tracers was processed in the same way as for the
human dosimetry but without final extrapolation. Also, organ
weights and volumes were not taken from our created standard
mouse but from the MOBY phantom, as S-factors are geometry
dependent. No bladder model was used, but the bladder activity
acquired from the dynamic microPET scans using a 2-mm-radius
spherical VOI on the coregistered microCT image was assigned to
the bladder of the MOBY phantom. The absorbed doses for organs
with derived S-factors and the total body absorbed dose were
calculated. SDs for organ harvesting were derived as described
above.
Results
The biodistribution for both 18 F-FDOPA and 18 F-FTYR
was acquired using organ harvesting, imaging and hybrid
imaging. Results based on sphere segmentation are de-
scribed below, whole organ segmentation data are provided
as electronic supplemental material 1 (ESM 1). A represen-
tative co-registered PET/CT image for each tracer is
illustrated in Fig. 1.
Mean human TACs, normalized for injected activity and
organ weight/size, for both radiopharmaceuticals were
calculated for all three techniques and are displayed in
Fig. 2.
Residence times based on the TACs for organ harvesting,
imaging and hybrid imaging were calculated and are
displayed in Table 1 for 18 F-FDOPA and in Table 2 for
18 F-FTYR. Pearson's product–moment correlation coeffi-
cient r and the significance value p for imaging and hybrid
imaging to organ harvesting were calculated for the set of
residence times obtained with all three approaches (i.e.,
brain, heart, kidney, liver, lung). Correlation between
datasets for 18 F-FDOPA was improved from r=0.6875
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(p=0.1995) for imaging to r=0.9460 (p=0.0149) for hybrid
imaging. The highest number of disintegrations per organ
occurred in the urinary bladder followed by the liver for all
three methods.
For 18 F-FTYR the correlation was improved from
r=0.9801 (p=0.0034) to r=0.9999 (pG0.0001). The largest
residence time derived for 18 F-FTYR was in the liver,
followed by the bladder.
When assuming the organ harvesting residence time to be
the reference value, a recovery coefficient defined as the
ratio between residence times derived by organ harvesting
and imaging can be calculated. These recovery coefficients
Fig. 1 18 F-FDOPA PET/CT image: a transversal, b sagittal, c coronal image plane, and 18 F-FTYR PET/CT image: d
transversal, e sagittal, f coronal image plane.
Fig. 2 18 F-FDOPA TACs: a organ harvesting, b imaging, c hybrid imaging, and 18 F-FTYR TACs: d organ harvesting, e
imaging, f hybrid imaging.
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are shown in Table 3. Applying hybrid imaging improved
quantification for most organs, except for brain and heart
using 18 F-FDOPA and for heart using 18 F-FTYR.
Large overestimations occurred for the lung with imaging
for both tracers. Human dose estimates projected from
animal data derived by organ harvesting, imaging and
hybrid imaging are displayed in Table 4 (18 F-FDOPA)
and Table 5 (18 F-FTYR). The Correlation for 18 F-
FDOPA was marginally improved from r=0.9974
(pG0.0001) between organ harvesting and imaging to
r=0.9988 (pG0.0001) between organ harvesting and
hybrid imaging. The organ receiving the highest
absorbed dose was the urinary bladder wall for all three
datasets. The second highest absorbed dose received for
all three methods was in the uterus.
For 18 F-FTYR, the correlation was increased from
r=0.9852 (pG0.0001) to r=0.9962 (pG0.0001). The highest
absorbed dose was received by the urinary bladder wall,
followed by the liver, for all three methods.
Mouse absorbed dose estimates for both tracers calculat-
ed from organ harvesting, imaging and hybrid imaging are
displayed in Tables 6 and 7. For 18 F-FDOPA the organ
receiving the highest absorbed dose was the kidney for
organ harvesting and the bladder for imaging and hybrid
imaging. For 18 F-FTYR the critical organ was the liver for
all three methods.
Discussion
The biodistribution and radiation dosimetry (human and
mouse) of 6-[18 F]fluoro-L-DOPA and 2-[18 F]fluoro-L-
tyrosine were obtained using not only the well-established
gold-standard technique of organ harvesting, but also using a
conventional imaging technique and sophisticated hybrid
imaging technique. Differences between (human) residence
times derived by organ harvesting and conventional imaging
were found for both radiopharmaceuticals (Table 3), most
likely resulting from deficiencies in quantification in
microPET. Constantinescu et al. also reported a poor
correlation between post scan harvested organ activities
and final microPET measurements [26].
For 18 F-FDOPA, the brain, heart and lung were
overestimated in conventional imaging, whereas kidney
and liver were underestimated with pure imaging. The brain
overestimation is a result of high tracer uptake in the skull
compared to the brain tissue itself, causing a spill over into
the brain VOI. The heart uptake from imaging combines
counts from blood and myocardium. This highlights a
limitation of microPET for this purpose, compared to ex
vivo harvesting, where blood is mostly removed from organs
before activity quantification. Thus, despite PVE the heart
activity is slightly overestimated in imaging. The substantial
overestimation of activity in the lung is a combination of
Table 1. Human residence times and %CV for 18 F-FDOPA obtained with organ harvesting, imaging and hybrid imaging
18 F-FDOPA TD %CV Imaging %CV Hybrid Imaging %CV
Braina 1.38E−02 20.5 1.54E−02 28.0 1.17E−02 26.6
Hearta 3.41E−03 15.6 3.49E−03 8.6 3.56E−03 13.7
Kidneya 2.19E−02 31.8 1.32E−02 17.2 1.66E−02 9.5
Livera 8.86E−02 27.4 5.33E−02 7.1 7.77E−02 15.9
Lunga 1.25E−02 13.1 4.72E−02 15.5 3.22E−02 20.9
Spleen 2.12E−03 16.6
Testes 2.90E−04 41.8
Bladder 3.08E−01 0.0 3.08E−01 0.0 3.08E−01 0.0
Remainder 2.18E+00 1.7 2.19E+00 0.5 2.18E+00 0.3
Pearson's r – – 0.6875 0.9460
Significance (p) – – 0.1995 0.0149
aExperimentally derived by all three methods and used for calculation of correlation
Table 2. Human residence times and %CV for 18 F-FTYR obtained by organ harvesting, imaging and hybrid imaging
18 F-FTYR TD %CV Imaging %CV Hybrid Imaging %CV
Braina 3.86E−02 22.2 3.81E−02 15.7 3.83E−02 22.6
Hearta 8.78E−03 9.1 9.21E−03 3.0 7.86E−03 9.4
Kidneya 2.24E−02 8.7 1.87E−02 13.5 2.38E−02 8.4
Livera 3.05E−01 18.1 2.60E−01 13.6 2.92E−01 16.8
Lunga 3.42E−02 8.8 7.80E−02 7.9 3.19E−02 11.1
Spleen 1.06E−02 13.3 – – – –
Testes 9.51E−04 12.8 – – – –
Bladder 1.23E−01 0.0 1.23E−01 0.0 1.23E−01 0.0
Remainder 2.08E+00 3.6 2.14E+00 8.0 2.19E+00 7.0
Pearson's r – – 0.9801 – 0.9999 –
Significance (p) – – 0.0034 – G0.0001 –
aExperimentally derived by all three methods and used for calculation of correlation
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spill over from the high activity organs (liver and heart) in
its vicinity and limitations in attenuation correction resulting
from PVE and the lack of resolution in the attenuation map.
Fig. 3 displays a representative microCT image and
corresponding co-registered PET attenuation map obtained
with the rotating 57CO point source. Overestimation of the
attenuation value is especially apparent on the boundaries of
the microCT VOI. Using a combination of the low
resolution attenuation map for attenuation correction and
high resolution microCT images for segmentation in the
lung leads to an overestimation of average activity.
However, using the microCT VOI to manipulate the
attenuation map proved impossible due to proprietary file
format issues (PMOD and Siemens file formats). The
manufacturer's software (ASIpro) (Siemens Medical Solu-
tions USA, Inc.) could be used for lung segmentation based
on the attenuation map and to improve attenuation correc-
tion, but the accuracy of segmentation proved very low due
to poor contrast and resolution in the attenuation map. As
such, the resulting difference in lung residence times was
negligible. The use of a combined PET/CT system would
overcome this limitation.
For 18 F-FDOPA, hybrid imaging appeared to increase
the accuracy for almost every organ by partially compensat-
ing for the errors described above. However, the lung was
still overestimated by a factor of 2.57 and the kidney was
underestimated by a factor of 0.76 (Table 3). The agreement
between brain and heart residence times for the quantifica-
tion methods was slightly decreased for 18 F-FDOPA
(compared to 18 F-FTYR). For 18 F-FTYR, using hybrid
imaging slightly decreased the accuracy of quantification in
the heart as described above, but the agreement between
organ harvesting and imaging was increased or equal for
every other organ after cross calibration. On the whole,
hybrid imaging tends to slightly underestimate organ activity
in comparison to organ harvesting, with the largest under-
estimation in the kidney for 18 F-FDOPA. Improved
residence time correlations for 18 F-FTYR compared to
18 F-FDOPA might be an effect of using the same animals
for organ harvesting at 120 min and dynamic scanning, due
Table 3. Ratios between human residence times derived by organ
harvesting and imaging techniques
18 F-FDOPA 18 F-FTYR
Organ Imaging Hybrid imaging Imaging Hybrid imaging
Brain 1.11 0.85 0.99 0.99
Heart 1.02 1.04 1.05 0.89
Kidney 0.60 0.76 0.83 1.06
Liver 0.60 0.88 0.85 0.96
Lung 3.77 2.57 2.28 0.93











Adrenals 1.27E−02 1.25E−02 1.27E−02 2.0 0.0 0.9
Braina 4.69E−03 4.96E−03 4.34E−03 9.1 14.2 12.1
Breasts 8.86E−03 9.03E−03 8.96E−03 1.0 0.4 0.3
Gallbladder wall 1.39E−02 1.32E−02 1.37E−02 2.5 0.3 1.6
LLI wall 1.68E−02 1.69E−02 1.68E−02 1.2 0.3 0.3
Small intestine 1.46E−02 1.46E−02 1.46E−02 1.0 0.3 0.0
Stomach wall 1.24E−02 1.24E−02 1.24E−02 0.4 0.0 0.0
ULI wall 1.40E−02 1.39E−02 1.40E−02 0.4 0.3 0.3
Heart Walla 8.63E−03 8.87E−03 8.85E−03 4.1 1.3 3.1
Kidneysa 1.99E−02 1.45E−02 1.67E−02 21.9 9.7 5.9
Livera 1.56E−02 1.14E−02 1.43E−02 18.6 4.0 10.5
Lungsa 7.81E−03 1.35E−02 1.11E−02 4.2 9.0 9.9
Muscle 1.16E−02 1.16E−02 1.16E−02 0.9 0.4 0.0
Ovaries 1.69E−02 1.69E−02 1.69E−02 1.2 0.4 0.0
Pancreas 1.33E−02 1.32E−02 1.33E−02 0.8 0.4 0.6
Red marrow 1.08E−02 1.08E−02 1.08E−02 0.9 0.0 0.0
Osteogenic cells 1.69E−02 1.70E−02 1.69E−02 1.2 0.3 0.3
Skin 8.74E−03 8.77E−03 8.75E−03 1.2 0.3 0.2
Spleen 8.59E−03 1.20E−02 1.20E−02 5.0 0.0 0.0
Testes 9.56E−03 1.34E−02 1.33E−02 4.3 0.4 0.0
Thymus 1.09E−02 1.11E−02 1.10E−02 0.9 0.4 0.8
Thyroid 1.09E−02 1.10E−02 1.09E−02 1.8 0.4 0.4
Urinary bladder wall 1.57E−01 1.57E−01 1.57E−01 0.3 0.0 0.0
Uterus 2.22E−02 2.22E−02 2.22E−02 0.9 0.3 0.2
Total body 1.17E−02 1.17E−02 1.17E−02 0.0 0.0 0.0
Effective dose ICRP 60 (mSv/MBq) 1.97E−02 2.02E−02 2.00E−02 0.5 0.5 0.7
Effective dose ICRP 103 (mSv/MBq) 1.60E−02 1.68E−02 1.67E−02 1.0 0.9 0.7
Pearson's r 0.9974 0.9988
Significance (p) G0.0001 G0.0001
aExperimentally derived by all three methods
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Adrenals 1.48E−02 1.45E−02 1.48E−02 2.4 1.4 1.6
Braina 8.74E−03 8.67E−03 8.70E−03 15.6 10.9 15.9
Breasts 9.14E−03 9.36E−03 9.17E−03 1.4 0.8 1.2
Gallbladder wall 1.79E−02 1.71E−02 1.77E−02 4.7 3.1 4.3
LLI wall 1.39E−02 1.40E−02 1.40E−02 2.9 1.9 2.2
Small intestine 1.39E−02 1.38E−02 1.39E−02 1.8 1.4 1.2
Stomach wall 1.29E−02 1.28E−02 1.29E−02 0.8 0.7 1.0
ULI wall 1.39E−02 1.37E−02 1.39E−02 0.7 0.7 0.9
Heart walla 1.29E−02 1.33E−02 1.23E−02 4.7 1.5 3.9
Kidneysa 2.16E−02 1.91E−02 2.23E−02 6.7 8.6 4.8
Livera 4.20E−02 3.67E−02 4.04E−02 15.7 11.7 14.6
Lungsa 1.24E−02 1.96E−02 1.20E−02 5.2 5.8 5.3
Muscle 1.11E−02 1.11E−02 1.11E−02 1.8 1.3 1.5
Ovaries 1.43E−02 1.44E−02 1.44E−02 2.4 1.8 2.1
Pancreas 1.51E−02 1.47E−02 1.49E−02 1.3 0.8 0.8
Red marrow 1.07E−02 1.07E−02 1.07E−02 0.9 0.9 0.9
Osteogenic cells 1.65E−02 1.67E−02 1.66E−02 2.1 1.6 1.9
Skin 8.50E−03 8.55E−03 8.57E−03 2.1 1.5 1.7
Spleen 1.74E−02 1.21E−02 1.22E−02 8.0 0.8 1.5
Testes 1.05E−02 1.13E−02 1.13E−02 3.3 2.3 2.5
Thymus 1.11E−02 1.14E−02 1.11E−02 1.8 1.1 1.3
Thyroid 1.07E−02 1.08E−02 1.08E−02 2.8 1.6 2.2
Urinary bladder wall 6.94E−02 6.96E−02 6.96E−02 0.5 0.4 0.4
Uterus 1.64E−02 1.64E−02 1.65E−02 2.1 1.4 1.9
Total body 1.21E−02 1.21E−02 1.21E−02 0.4 0.0 0.4
Effective dose ICRP 60 (mSv/MBq) 1.64E−02 1.70E−02 1.63E−02 1.5 1.4 1.0
Effective dose ICRP 103 (mSv/MBq) 1.43E−02 1.50E−02 1.42E−02 2.2 1.9 1.5
Pearson's r 0.9852 0.9962
Significance (p) G0.0001 G0.0001
aExperimentally derived by all three methods
Table 6. Mouse dose (mGy/MBq) estimates and %CV for 18 F-FDOPA using organ harvesting, imaging and hybrid imaging
Target organ Organ harvesting Imaging Hybrid imaging %CV organ harvesting %CV imaging %CV hybrid imaging
Skin 6.41 5.79 5.68 2.8 5.4 6.9
Heart total 4.74 3.94 4.21 7.1 5.6 3.6
Heart tissue 4.49 3.77 3.97 4.7 5.7 3.6
Heart blood 4.84 4.00 4.30 7.9 5.5 3.7
Body 17.64 16.28 15.95 2.9 4.4 6.1
Liver 15.70 11.08 14.50 23.6 7.4 15.3
Gallbladder 6.35 4.66 5.85 20.2 6.6 12.8
Total lung 7.40 6.72 6.05 7.9 7.8 9.3
Right lung 7.55 6.85 6.20 7.6 7.5 8.9
Left lung 7.34 6.69 5.99 8.0 8.0 9.5
Stomach total 2.73 2.33 2.44 4.7 4.8 3.0
Stomach wall 5.99 5.04 5.25 3.7 5.7 3.8
Stomach content 2.18 1.88 1.97 5.1 4.4 2.7
Pancreas 3.60 3.04 3.17 7.4 5.5 3.3
Total kidney 23.61 17.13 17.84 26.9 16.9 9.3
Right kidney 23.32 16.96 17.58 26.9 16.9 9.4
Left kidney 24.10 17.45 18.23 26.9 16.9 9.3
Spleen 6.27 2.94 2.92 8.2 5.2 5.5
Small intestine total 3.38 3.28 3.28 0.2 1.3 1.5
Small intestine wall 4.37 4.13 4.13 0.5 2.5 2.8
Small intestine content 2.09 2.15 2.16 0.5 1.5 1.6
Large intestine total 4.08 4.13 4.09 1.1 0.2 0.8
Large intestine wall 5.69 5.55 5.48 1.3 1.6 2.5
Large intestine content 2.40 2.65 2.64 0.5 3.8 3.4
Bladder 4.89 660.79 660.70 2.9 41.9 41.9
Vas deferens 8.84 33.19 33.01 2.7 30.8 30.6
Testes 6.67 5.14 5.05 9.4 2.3 1.3
Bones 6.35 5.71 5.60 2.1 5.8 7.0
Brain 4.13 4.66 3.52 12.8 25.1 21.5
Thyroid 6.47 5.73 5.61 2.9 6.5 8.2
Bone marrow 4.15 3.78 3.69 1.7 5.8 6.7
Total body 14.03 14.12 14.14 0.2 0.3 0.4
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to a reduction in cross-population differences. The remaining
differences between organ harvesting and hybrid imaging for
both tracers are most likely a consequence of cross-
calibrating activities based only on final microPET measure-
ments. PVE in dynamic microPET imaging is a dynamic
problem, since it depends on the activity within the region
Table 7. Mouse dose (mGy/MBq) estimates and %CV for 18 F-FTYR using organ harvesting, imaging and hybrid imaging
Target organ Organ harvesting Imaging Hybrid imaging %CV organ harvesting %CV imaging %CV hybrid imaging
Skin 5.16 5.25 5.13 6.3 5.6 7.1
Heart total 7.71 7.43 7.78 9.6 8.7 11.1
Heart tissue 6.54 6.37 6.59 7.8 7.0 9.3
Heart blood 8.14 7.81 8.21 10.1 9.3 11.6
Body 13.95 14.22 13.87 6.9 6.1 7.8
Liver 48.23 46.26 49.28 17.3 15.9 20.2
Gallbladder 17.67 16.98 18.03 16.4 15.0 19.3
Total lung 14.33 11.07 13.74 8.2 7.9 9.3
Right lung 14.39 11.22 13.82 8.1 7.8 9.1
Left lung 14.39 11.05 13.78 8.2 8.0 9.4
Stomach total 3.82 3.60 3.70 7.1 6.2 8.0
Stomach wall 8.17 7.66 7.84 6.5 5.5 7.4
Stomach content 3.09 2.92 3.00 7.3 6.5 8.2
Pancreas 4.71 4.45 4.57 6.6 6.5 5.9
Total kidney 23.90 23.79 25.02 7.8 14.3 8.0
Right kidney 22.89 22.78 23.94 7.3 14.2 8.9
Left kidney 25.04 24.94 26.25 8.2 14.3 7.4
Spleen 17.65 3.02 3.01 10.6 1.4 3.2
Small intestine total 3.25 3.27 3.27 1.0 0.8 1.1
Small intestine wall 4.13 4.16 4.14 1.4 1.2 1.6
Small intestine content 2.10 2.11 2.12 0.3 0.4 0.3
Large intestine total 3.50 3.56 3.51 4.0 3.3 4.9
Large intestine wall 4.79 4.87 4.79 4.7 3.9 5.7
Large intestine content 2.17 2.20 2.18 2.6 2.0 3.2
Bladder 3.84 37.20 37.10 7.1 22.6 22.5
Vas deferens 7.05 8.16 7.97 6.9 5.8 6.3
Testes 9.80 3.82 3.72 5.0 6.6 8.4
Bones 5.50 5.56 5.47 4.0 3.7 4.6
Brain 8.80 9.67 8.73 18.7 16.3 23.8
Thyroid 5.19 5.28 5.16 6.5 5.8 7.3
Bone marrow 3.72 3.77 3.70 2.8 2.5 3.5
Total body 14.23 14.22 14.24 0.4 0.3 0.4
Fig. 3 Co-registered image of microCT and attenuation map of representative subject with lung VOI (from microCT): a
microCT, b attenuation map, c overlay of both (transversal, sagittal and coronal image for each).
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and the warmth of the background, which changes over time
[27]. When comparing major organ absorbed dose estimates
for 18 F-FDOPA, hybrid imaging offers increased accuracy
compared to conventional imaging (Fig. 4a), with the
exception of the absorbed dose in the brain. No general
trend for statistical variance (SD) of the dose estimates could
be observed and it is not largely increased for imaging. As
can be seen in Fig. 4b, hybrid imaging failed to increase
accuracy of absorbed dose estimates for 18 F-FTYR in only
the heart wall in comparison to imaging only and no trend
regarding increase or decrease of statistical variance of dose
estimates could be observed. Bland–Altman plots are
another bio-statistical technique to examine the agreement
between two methods measuring the same quantity [28]. For
both tracers, the Bland–Altman plots (Fig. 5) show clearly
that the difference between dose estimates as well as the SD
of the difference was reduced by applying hybrid imaging
compared to imaging.
For human dose estimates with both tracers, a
correlation coefficient 90.9950 with pG0.0001 between
organ harvesting and hybrid imaging was achieved.
Considering this high degree of correlation, hybrid
dynamic microPET imaging requires far fewer animals
compared to the traditional organ harvesting approach.
Furthermore, organ harvesting is time-consuming and,
depending on the amount of people available for the
study, has to be spread over 2 or 3 days, whereas three
dynamic microPET scans can easily be executed by a
single person in 1 day (data analysis excluded). This in
turn decreases the amount of radiopharmaceutical re-
quired, making dynamic microPET imaging for radiation
dosimetry a more ethical, efficient and cheaper (assuming
the equipment to perform microPET imaging is available)
way to obtain equivalent results. Using techniques such
as parallel scanning of multiple animals in larger bore
PET scanners, preclinical dosimetry studies could be
performed within a single 2-h dynamic scan [29].
However, due to low in vivo contrast in microCT, used
to obtain anatomical information for segmentation, fewer
organs can be derived from microPET than with organ
harvesting and obtaining blood activities is inaccurate (or
impossible) due to PVE in small volumes (such as heart
chambers and vessels) with microPET. Magnetic reso-
nance imaging may offer a useful alternative for
improved segmentation.
When comparing whole organ- and sphere-based
segmentation (see supplemental data ESM 1), it becomes
clear that whole organ segmentation is redundant, since
similar or better results were achieved using hybrid
imaging based on sphere segmentation. Particularly when
using low contrast microCT imaging for anatomical
reference, sphere-based segmentation is far less time-
Fig. 4 Human dose comparison 18 F-FDOPA (a) and human dose comparison 18 F-FTYR (b).
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consuming and much less prone to failures in automated organ
segmentation due to insufficient soft tissue contrast. However,
manual co-registration was applied in this study. Using
landmark based co-registration as applied by Warnock et al.
[30] might have improved whole organ segmentation as
accuracy of registration might be higher.
Fig. 5 Bland–Altman plots of derived dosimetry values for 18 F-FDOPA: a organ harvesting vs. imaging, b organ harvesting vs.
hybrid imaging and 18 F-FTYR, c organ harvesting vs. imaging, d organ harvesting vs. hybrid imaging; broken green lines
represent confidence interval (mean difference±1.96* SD) or 95 % limits of agreement.
Table 8. Comparison of mean 18 F-FDOPA dose estimates with literature
Target organ Organ harvesting Imaging Hybrid imaging Comparison from Brown
et al. [mGy/MBq]
Adrenals 1.27E−02 1.25E−02 1.27E−02 1.50E−02
Brain 4.69E−03 4.96E−03 4.34E−03
Breasts 8.86E−03 9.03E−03 8.96E−03
Gallbladder wall 1.39E−02 1.32E−02 1.37E−02
LLI wall 1.68E−02 1.69E−02 1.68E−02 1.60E−02
Small intestine 1.46E−02 1.46E−02 1.46E−02 1.41E−02
Stomach wall 1.24E−02 1.24E−02 1.24E−02 1.21E−02
ULI wall 1.40E−02 1.39E−02 1.40E−02 1.40E−02
Heart wall 8.63E−03 8.87E−03 8.85E−03
Kidneys 1.99E−02 1.45E−02 1.67E−02 2.74E−02
Liver 1.56E−02 1.14E−02 1.43E−02 1.54E−02
Lungs 7.81E−03 1.35E−02 1.11E−02 1.27E−02
Muscle 1.16E−02 1.16E−02 1.16E−02 8.90E−03
Ovaries 1.69E−02 1.69E−02 1.69E−02 1.41E−02
Pancreas 1.33E−02 1.32E−02 1.33E−02 1.97E−02
Red marrow 1.08E−02 1.08E−02 1.08E−02 1.05E−02
Osteogenic cells 1.69E−02 1.70E−02 1.69E−02
Skin 8.74E−03 8.77E−03 8.75E−03 8.50E−03
Spleen 8.59E−03 1.20E−02 1.20E−02 1.17E−02
Testes 9.56E−03 1.34E−02 1.33E−02 1.48E−02
Thymus 1.09E−02 1.11E−02 1.10E−02
Thyroid 1.09E−02 1.10E−02 1.09E−02 1.03E−02
Urinary bladder wall 1.57E−01 1.57E−01 1.57E−01 1.50E−01
Uterus 2.22E−02 2.22E−02 2.22E−02 1.86E−02
Total body 1.17E−02 1.17E−02 1.17E−02 1.05E−02
Effective dose ICRP 60 (mSv/MBq) 1.97E−02 2.02E−02 2.00E−02 1.99E−02
Pearson's r 0.9951 0.9929 0.9946
Significance (p) G0.0001 G0.0001 G0.0001
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Table 8 compares the human radiation dosimetry for
18 F-FDOPA extrapolated from mice to that from human
PET scans from Brown et al. [9]. Subjects in their study
were pretreated with carbidopa to inhibit peripheral
aromatic L-amino acid decarboxylase (AAAD). This
allows more 18 F-FDOPA to cross the blood brain barrier
in order to increase brain uptake. However, this also
slightly alters the biodistribution of 18 F-FDOPA. Never-
theless, most of the absorbed dose estimates derived
within this study (extrapolated from animals to humans)
are in accordance with the radiation dosimetry derived by
Brown et al. and a correlation coefficient 90.99 with
pG0.001 for all three methods was achieved. In the
present study, dosimetry for the urinary bladder wall was
based on a theoretical model implemented in OLINDA/
EXM, assuming that a fraction of 0.5 of the injected
activity was cleared via the urinary pathway. The resulting
projected absorbed dose estimate for the urinary bladder
wall of 1.57E−02 mGy/MBq closely matched the
absorbed dose provided by Brown et al. of 1.50E−
02 mGy/MBq. The calculated effective dose deviated by
only 1–2 % from that reported in the literature.
To our knowledge, the human dosimetry for 18 F-FTYR
was not available in the literature and was derived from
preclinical data for the first time in this study. In comparison
to 18 F-FDOPA, most of the major organs receive a higher
absorbed dose, most likely due to reduced excretion (far less
accumulation of activity within the bladder). However, due
to the high absorbed dose for the urinary bladder wall, the
resulting effective dose is higher for 18 F-FDOPA than for
18 F-FTYR.
A similar pattern was seen in the mouse dosimetry for
18 F-FDOPA and 18 F-FTYR. While for 18 F-FTYR all
major organs receive higher absorbed doses, for 18 F-
FDOPA the absorbed dose to the bladder is approximately
15 times higher, indicating more rapid excretion and
explaining the lack of activity in the remaining organs.
For 18 F-FDOPA the calculated absorbed dose for the
urinary bladder wall in mice is comparable to the
absorbed dose of 543 mGy/MBq to the urinary bladder
wall for FDG, as derived by Taschereau and
Chatziioannou [31] using a combination of in vivo
biodistribution and Monte Carlo Simulations on a
voxelized mouse phantom. However, the average activity
per cc was applied to a small static bladder volume,
which might overestimate the resulting activity inside the
bladder. When calculating the absorbed doses for the in
average injected activity of approximately 10 MBq,
organ absorbed doses and total body absorbed dose
range from 100 to 400 mGy. The bladder wall absorbed
dose for 18 F-FDOPA in the contrary is above 6 Gy for
a single scan.
Conclusion
In this study the human radiation dosimetry for both 18 F-
FDOPA and 18 F-FTYR was derived from mice using
traditional organ harvesting, dynamic microPET imaging
and hybrid dynamic imaging (where microPET activities are
cross-calibrated with post scan harvested organs to improve
quantification). Correlations between organ harvesting and
imaging were improved by using hybrid imaging to above
r=0.9950 (pG0.0001). In particular, the error in single organ
absorbed doses was reduced, which is of great importance
when using preclinical dosimetry data to estimate safe doses
for human subjects in clinical trials. Hybrid imaging yields
comparable results to traditional organ harvesting with
similar statistical variation, yet tends to underestimate single
organ absorbed doses slightly compared to organ harvesting.
Hybrid imaging also involves fewer resources, radiophar-
maceuticals and substantially fewer animals. Additionally, it
was shown that the combination of hybrid imaging and
segmentation based on spherical VOIs placed in organs
leads to more accurate results than laborious organ delinea-
tion. The preclinically derived radiation dosimetry for 18 F-
FDOPA showed a correlation to literature (human) values of
above 0.99 (pG0.0001) for all three methods. The effective
dose for 18 F-FTYR (not yet available in the literature), was
1.43E − 02 mSv/MBq for organ harvest ing and
1.42E−02 mSv/MBq for hybrid imaging (based on ICRP
103 tissue weighting factors). Mouse dosimetry showed that
the radiation received after an injection of 10 MBq is non-
negligible and can reach up to 140 mGy for the total body
absorbed dose and several Gy for critical organs.
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Paper III
Absorbed doses to mice for three [18F]-tracers
calculated from experimental data and Monte Carlo
simulations
Bretin F., Mauxion T., Bahri MA., Luxen A., Plenevaux A.,







Abstract- In preclinical microPET imaging, small rodents often 
have to undergo longitudinal studies involving multiple scans 
combined with microCT imaging to gather anatomical 
information. The radiation exposure of the animals needs to be 
addressed since the impact of the radiation might compromise 
the validity of the results. The aim of the study was to use 
experimentally obtained kinetic data of three [18F]-tracers and S-
values derived by Monte Carlo simulations to calculate absorbed 
doses in mice and estimate radiation exposure in longitudinal 
studies. 
The bio-distribution of 6-[18F]fluoro-L-DOPA, 2-[18F]fluoro-L-
Tyrosine and [18F]UCB-H was obtained using organ harvesting 
(OH) at multiple time points, dynamic microPET imaging (DI) 
and hybrid imaging (HI), where organs are harvested post scan 
to improve quantification of microPET. Monte Carlo simulations 
were carried out using GATE v6.1 and the MOBY phantom to 
determine S-values of multiple source and target organs. Time 
activity curves were derived from experimental data and 
residence times for multiple source organs were calculated and 
used for absorbed dose calculations.  
The average total body absorbed dose for all three [18F]-
tracers and all methods was almost identical with  
14.19 ± 0.10 mGy/MBq. The critical organs for 6-[18F]fluoro-L-
DOPA were the kidneys with 23.61 ± 6.34 mGy/MBq for OH and 
the bladder wall for DI and HM with 660.79 ± 276.57 mGy/MBq 
and 660.70 ± 276.51 mGy/MBq, respectively. The high derived 
bladder wall absorbed dose is similar to values provided in 
literature for bladder wall from [18F]FDG in mice. For  
2-[18F]fluoro-L-Tyrosine the highest dose was absorbed by the 
liver for all three methods with 48.23 ± 8.32 mGy/MBq derived 
by OH (DI: 46.26 ± 7.35 mGy/MBq; HM: 49.28 ± 9.97 
mGy/MBq). For [18F]UCB-H the critical  organs were the liver 
for OH with 65.14 ± 8.47 mGy/MBq and the bladder wall for DI 
with 57.63 ± 28.36 mGy/MBq.  
The calculated absorbed doses derived from the three 
experimental methods showed good agreement, and correlations 
between OH and DI were improved by using HI. When assuming 
multiple injected activities of 10 MBq plus additional radiation 
from microCT, an accumulated total body absorbed dose of more 
than 1 Gy and much higher absorbed doses for single organs can 
be reached possibly introducing stochastic effects. The lethal 
absorbed dose for a mouse is considered 6 Gy, however, studies 
have shown that far lower absorbed doses can alter the 
physiology and compromise results. 
 
Index Terms—18F-FDOPA, 18F-FTYR, 18F-UCB-H, 





N preclinical microPET imaging, small rodents are 
frequently used as translational models for clinical research, 
where they have to undergo longitudinal studies involving 
multiple scans often combined with microCT imaging for 
anatomical referencing [1-3]. The radiation exposure of 
animals from each modality needs to be addressed, since 
multiple studies have shown that even low level exposure 
might impact on physiological or neurological processes and 
therefore might compromise the validity of results depending 
on the type of study [4-7]. A single entrance dose of above 6 
Gy is considered lethal to a mouse [8]. However, a study 
conducted by Detombe et al. found no radiation induced 
effects on pulmonary or myocardial tissue for a cumulative 
entrance dose of 5.04 Gy from microCT over six weeks [9]. In 
general, the biological effects of low-level radiation will vary 
with the type of radiation, dose delivered, delivery rate, and 
type of tissue among others [10]. Most studies consider x-ray 
radiation only regarding biological damage and, especially 
since the type of radiation, amount and delivery rate differ for 
microPET, more research needs to be conducted regarding 
biological damage. In order to quantify the radiation dose 
from PET imaging, the dynamic biodistribution of the 
radiopharmaceutical needs to be obtained. Ex vivo 
measurement of the kinetic data using harvested organs has 
long been considered the gold-standard technique. Organs are 
harvested at several time points post administration of the 
radiopharmaceutical and (for human dosimetry studies) the 
behaviour of the tracer extrapolated to human data [11-13]. 
However, organ harvesting is labour intensive and many 
animals are required to establish the biodistribution. Due to 
the low time resolution, early blood peaks in organs cannot be 
detected. Dynamic microPET imaging is a promising 
technique due to its high time resolution and time efficient 
procedure. Yet, microPET is prone to partial volume effects 
(PVE) in small volumes with subsequent quantification errors 
[14] and hence dosimetry errors. A simple method of 
correcting for PVE is scaling of the extracted time-activity-
curve (TAC). This scaling is based on the ratio between 
measured activity from PET and the post scan harvested organ 
activity (measured with a gamma well counter). This method, 
sometimes referred to as hybrid imaging, was applied in rats 
by Kesner et al. [15] with a resultant improvement in the 
correlation between dose estimates (animal data extrapolated 
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to human data) derived by organ harvesting, imaging and 
hybrid imaging. PVE and spill-over are size dependent [16] 
and thus more prevalent in smaller animals (an average mouse 
weighs approximately ten times less than an average rat). 
Therefore, the hybrid approach may be of even more value in 
mice. The aim of this study was to use the experimentally 
obtained kinetic data of all three methods (organ harvesting, 
imaging and hybrid imaging) and to calculate the dosimetry in 
mice using the MOBY phantom [17] and S-factors derived 
using Monte Carlo Simulations (GATE) [18]. The compounds 
used in this study were the well-established 6-[
18
F]fluoro-L-
dopa (18F-FDOPA) and 2-[
18
F]fluoro-L-tyrosine (18F-
FTYR), plus the newly developed [
18
F]UCB-H (18F-UCB-H). 
The dosimetry results derived by organ harvesting, imaging 
and hybrid imaging were compared with respect to 
improvement of quantification of dynamic microPET imaging 
and to correlation between dosimetry datasets. 
II. MATERIALS & METHODS 
A. Animals 
Male C57BL/6 mice were obtained from Charles River 
Laboratories (Brussels, Belgium) and subsequently bred at the 
Animal Facility of the GIGA-University of Liege (BE-LA 
2610359). All animals were housed under standard 12h:12h 
light:dark conditions with food and water available ad libitum. 
All protocols and experimental procedures used in this 
investigation were reviewed and approved by the Institutional 





F]fluoro-L-Dopa was synthesized as described by 
Libert et al. [19]. 2-[
18
F]fluoro-L-Tyrosine was prepared using 
a similar methodology but with 2-formyl-5-methoxy-N,N,N-
trimethylbenzenaminium trifluoromethanesulfonate as the 
starting chemical. The tracers were obtained at the NCA level 
and therefore with the highest specific activity ever achieved 
for these tracers (> 540 GBq/µmol). [
18
F]UCB-H was obtained 
in a four-step radiosynthesis. Briefly, this consisted of 
nucleophilic labeling of a pyridine precursor, reductive 
amination of the labeled product, and internal cyclisation. 
Specific activity was higher than 500 MBq/µg at the end of 
synthesis [20]. 
 
C. Study protocol 
All data acquisition and analysis was performed in 
accordance to MIRD pamphlet no. 16 [21]. Anaesthesia was 
induced with 4.5% isoflurane (in oxygen) and maintained after 
tail vein tracer injection by inhalation of 1-2% isoflurane. 
After sacrifice by decapitation organs were harvested, 
weighed (NewClassic ML, Mettler Toledo, Switzerland) and 
activities were quantified by radioassay using a gamma well 
counter (Cobra II Auto-Gamma, Perkin-Elmer, USA) resulting 
in the average activity per g of tissue at each time point. 
For 18F-FDOPA, organ harvesting was performed in 30 
mice (average weight 23.51 ± 1.75 g) after an average iv bolus 
of 8.47 ± 1.45 MBq. Five mice per time point were sacrificed 
by decapitation after 2, 5, 10, 30, 60, and 120 minutes 
(dissection of: brain, kidney, liver, lung, spleen and testes). 
Dynamic PET images were acquired for 120 minutes after iv 
bolus injection of 7.66 ± 1.62 MBq 18F-FDOPA via the tail 
vein in four separate mice (average bodyweight 
 22.10 ± 1.21 g). Organs were harvested post scan and activity 
per gram of tissue was determined as described above.  
For 18F-FTYR, dynamic imaging and organ harvesting 
were performed in the same experiment. 18 mice (average 
weight 27.63 ± 1.97 g) received 8.08 ± 1.21 MBq and were 
sacrificed by decapitation after 2, 5, 10, 30, 60 and  
120 minutes, with n=3 at each time point (dissection of: brain, 
kidney, liver, lung, spleen and testes). The three mice to be 
sacrificed at 120 minutes post injection were also scanned 
dynamically from injection to sacrifice.  
For organ harvesting of 18F-UCB-H, 24 mice (average 
weight 23.96 ± 1.31 g) were injected with an iv bolus of  
6.96 ± 0.81 MBq via the tail vein and were sacrificed by 
decapitation after 2,  5, 10, 30, 60 and 120 minutes with n=4 at 
each time point (dissection of: blood, bone, brain, kidney, 
liver, lung, pancreas, spleen and testes). Dynamic PET images 
were acquired on 5 mice (average weight 29.72 ± 6.70 g). An 
average of 9.19 ± 3.40 MBq 18F-UCB-H was administered 
via the tail vein as bolus. Additionally, an iodine-based 
contrast agent (1:10 dilution of iobitridol-XENETIX300, 
Guerbet, Roissy, France) was administered in the peritoneal 
cavity prior to microCT to aid full organ segmentation. No 
post scan harvesting was performed for 18F-UCB-H, hence, 
no hybrid imaging data is available for 18F-UCB-H. 
Dynamic microPET images were acquired using a Siemens 
Concorde Focus 120 microPET (Siemens, Germany) [22] and 
followed by transmission measurement using the rotating 
57Co point source of the scanner. The list-mode data were 
histogrammed into 3D sinograms using Fourier rebinning [23] 
and reconstructed using Filtered backprojection (FBP) with a 
ramp filter cutoff at the Nyquist frequency. Corrections for 
randoms, dead-time and attenuation were applied but not for 
scatter, since it was shown that there is no significant 
improvement by applying the scatter correction for the Focus 
120 microPET [24]. A set of 3D images were reconstructed in 
a 256 x 256 x 95 matrix with a pixel size of  
0.4 x 0.4 x 0.8 mm. The dynamic time framing consisted of 
the following frames: 6x5s, 6x10s, 3x20s, 5x30s, 5x60s, 
8x150s, 6x300s, 6x600s and all data were decay corrected to 
the beginning of each individual frame. Micro-CT images 
were acquired with an eXplore 120 micro-CT (Gamma 
Medica, USA / GE Healthcare, UK) to obtain anatomical 
information for segmentation. All CT images were 
reconstructed using Feldkamp’s Filtered backprojection 
algorithm [25] with a cut-off at the Nyquist frequency and an 
isotropic voxel size of 100 µm. In both imaging modalities the 
MINERVE animal cell bed (Bioscan, USA) was used which 
provided anaesthesia, physiological control and monitoring of 
respiration. Micro-CT and microPET images were co-
registered using a landmark based approach. Volumes of 





micro-CT images using the commercially available research 
software PMOD (Version 3.306, PMOD Technologies, 
Switzerland). Spheres of 2 mm radius were placed in organs 
with sufficient contrast (two VOIs in liver, kidneys and lung, 
single VOIs otherwise) to decrease the impact of PVE and 
average activity per volume was derived. MicroPET 
calibration for conversion of counts/pixel to Bq/ml was 
performed as recommended by the manufacturer. The 
accuracy of this calibration has been reported to be better than 
2% in our laboratory [24].  
For 18F-FDOPA and 18F-FTYR, three different TAC were 
derived: organ harvesting only (will be referred to as organ 
harvesting), dynamic PET imaging only (imaging) and hybrid 
dynamic PET imaging (hybrid imaging), where the activity 
measured with PET was scaled by a factor derived from the 
ratio between PET activity at the end of the image acquisition 
and the quantified post scan activity from harvested organs of 
the same animal. For 18F-UCB-H organ harvesting and 
imaging data only is provided.  
Organ activities per gram or volume were normalized for 
injected activity and organ weight or volume, respectively. 
Organ weights and volumes were taken from the MOBY 
phantom [17]. For hybrid dynamic PET imaging, the TAC was 
then scaled as described above. All TACs were interpolated 
with piecewise cubic Hermite interpolation between time 
points. In all TACs, physical decay only was assumed after 
120 min neglecting any biological clearance from the organs. 
All numbers of disintegrations in an organ (cumulated 
activity) were calculated as area under the curve, which is 
mathematically equal to the residence time, using trapezoidal 
numerical integration in Matlab.  
Since the TACs derived by organ harvesting consist of 
numerous time points in different animals, every individual 
time point has its own standard deviation (SD). Hence, the SD 
of residence times derived by organ harvesting could not be 
calculated directly and was calculated as follows. Two 
additional animal TACs were calculated using the mean ± 
1SD of each individual time point of the activity measurement 
and the residence times corresponding to each TAC was 
computed [20]. This residence time window was expressed as 
a coefficient of variation in percent (%CV) from the mean 
value. These residence times (mean ± 1SD) were used to 
calculate a minimum and maximum absorbed dose for organ 
harvesting resulting in a best and worst case scenario rather 
than a real SD. The mean of best and worst case scenario was 
used as the error for the absorbed dose expressed as %CV of 
the mean absorbed dose value obtained using the mean TAC. 
For the statistics of imaging and hybrid imaging every scan 
was treated separately and mean ± 1SD expressed as %CV 
were calculated across scans as usual. Correlations between 
datasets were calculated using Pearson product-moment 
correlation coefficient in MATLAB. 
 
D. Monte Carlo Simulations 
S-factors were derived for the MOBY phantom [17] using 
GATE v6.1 [26]. The method used to generate the MOBY 
dataset and S-factors has been previously described [18]. The 
absorbed doses for organs with derived S-factors and the total 
body absorbed dose were calculated. Self-radiation could only 
be accounted for in organs, where the pharmacokinetic data 
was experimentally determined. Absorbed doses for residual 
organs were calculated on the basis of cross-radiation from 
source organs and the remainder only.  
III. RESULTS 
The biodistribution for both 18F-FDOPA and 18F-FTYR 
was acquired using organ harvesting, imaging and hybrid 
imaging, whereas the biodistribution of 18F-UCB-H was 
acquired using organ harvesting and imaging only. A 
representative co-registered PET/CT image for each tracer is 
illustrated in Figure 1. Each CT image was filtered with an 
isotropic 3D Gaussian kernel of 0.3 x 0.3 x 0.3 mm
3
 and the 
PET image with a 3D Gaussian kernel of 1 x 1 x 2 mm
3
. The 
PET image was averaged over all dynamic frames and scaled 
from 0 to 1200 kBq/cc. 
 
Mean TACs, normalized for injected activity and organ 
weight/size, for all radiopharmaceuticals were calculated for 
all techniques and are displayed in Figure 2.   
 
Fig. 1.  Co-registered image of microCT and frame-averaged microPET 
of representative subjects for (a-c) 18F-FDOPA, (d-f) 18F-FTYR and (g-
h) 18F-UCB-H with transverse, sagittal and coronal plane each. 





Residence times based on the TACs for organ harvesting, 
imaging and hybrid imaging were calculated and are displayed 
in Table 1 for 18F-FDOPA, Table 2 for 18F-FTYR and Table 
3 for 18F-UCB-H. Pearson’s product-moment correlation 
coefficient r and the significance value p for imaging and 
hybrid imaging to organ harvesting were calculated for the set 













Liver* 2.12E-01 27.6 1.43E-01 7.1 1.98E-01 15.9 
Lung* 7.86E-03 13.0 7.90E-03 15.5 5.66E-03 20.9 
Kidney* 5.47E-02 31.1 3.81E-02 17.2 3.99E-02 9.5 
Spleen 2.66E-03 16.5 - - - - 
Bladder - - 3.61E-01 36.5 3.61E-01 36.5 
Testes 3.16E-03 41.3 - - - - 
Brain* 1.03E-02 20.5 1.29E-02 28.0 8.70E-03 26.6 
Remainder 2.34E+00 3.4 2.07E+00 5.7 2.02E+00 7.5 
Pearson's r - - 0.9996 - 0.9985 - 
Significance 
p 
- - 0.0004 - 0.0015 - 
* Values used for correlation (derived by all methods) 
 
Fig. 2.  Mean TACs of (a) 18F-FDOPA Organ harvesting, (b) 18F-FDOPA Imaging, (c) 18F-FDOPA Hybrid Imaging, (d) 18F-FTYR Organ harvesting, (e) 








Mouse absorbed dose estimates for 18F-FDOPA and  
18F-FTYR were calculated from organ harvesting, imaging 
and hybrid imaging and are displayed in Tables 4 and 5. For 
18F-UCB-H absorbed dose estimates were only derived by 
organ harvesting and imaging (Table 6). 
 
 
For 18F-FDOPA the highest derived absorbed dose from 
organ harvesting was the kidney with 23.6 ± 6.34 mGy/MBq 
followed by the remaining body with 17.64 ± 0.52 mGy/Mbq. 
For imaging and hybrid imaging the highest absorbed dose 
estimate was for the bladder with 660.79 ± 276.57 (imaging) 
and 660.70 ± 276.51 (hybrid imaging) mGy/MBq followed by 
the vas deferens with 33.19 ± 10.24 (imaging) and  
33.01 ± 10.11 mGy/MBq (hybrid imaging). The total body 
absorbed dose was 14.03 ± 0.03 (organ harvesting),  
14.12 ± 0.04 (imaging) and 14.14 ± 0.06 mGy/MBq (hybrid 
imaging). The correlation between dose estimates (after 
exclusion of values derived by one method only) was 
TABLE II 









Liver* 2.12E-01 27.6 1.43E-01 7.1 1.98E-01 15.9 
Lung* 7.86E-03 13.0 7.90E-03 15.5 5.66E-03 20.9 
Kidney* 5.47E-02 31.1 3.81E-02 17.2 3.99E-02 9.5 
Spleen 2.66E-03 16.5 - - - - 
Bladder - - 3.61E-01 36.5 3.61E-01 36.5 
Testes 3.16E-03 41.3 - - - - 
Brain* 1.03E-02 20.5 1.29E-02 28.0 8.70E-03 26.6 
Remainder 2.34E+00 3.4 2.07E+00 5.7 2.02E+00 7.5 
Pearson's r - - 0.9996 - 0.9985 - 
Significance 
p 
- - 0.0004 - 0.0015 - 
* Values used for correlation (derived by all methods) 
TABLE III 
RESIDENCE TIMES 18F-UCB-H IN h 
18F-UCB-H Organ harvesting %CV Imaging %CV 
Heart blood 1.27E-02 9.6 - - 
Liver* 9.95E-01 13.5 5.56E-01 6.6 
Lung* 3.44E-02 9.3 1.48E-02 14.7 
Pancreas 4.30E-02 16.9 - - 
Kidney* 8.26E-02 10.5 5.22E-02 13.3 
Spleen 1.06E-02 13.6 - - 
Bladder - - 2.94E-02 47.5 
Testes* 2.13E-02 12.7 1.32E-02 12.8 
Bones 7.71E-02 23.6 - - 
Brain 1.22E-01 18.6 - - 
Remainder 1.23E+00 16.2 1.97E+00 1.7 
Pearson's r - - 0.9999 - 
Significance p - - 0.0001 0 
* Values used for correlation (derived by all methods) 
TABLE IV 









Skin 6.41 2.8 5.79 5.4 5.68 6.9 
Heart total 4.74 7.1 3.94 5.6 4.21 3.6 
Body 17.64 2.9 16.28 4.4 15.95 6.1 
Liver 15.7 23.6 11.08 7.4 14.5 15.3 
Gallbladder 6.35 20.2 4.66 6.6 5.85 12.8 
Total lung 7.4 7.9 6.72 7.8 6.05 9.3 
Stomach total 2.73 4.7 2.33 4.8 2.44 3 
Stomach wall 5.99 3.7 5.04 5.7 5.25 3.8 
Stomach content 2.18 5.1 1.88 4.4 1.97 2.7 
Pancreas 3.6 7.4 3.04 5.5 3.17 3.3 
Total kidney 23.61 26.9 17.13 16.9 17.84 9.3 
Spleen* 6.27 8.2 2.94 5.2 2.92 5.5 
Small intestine total 3.38 0.2 3.28 1.3 3.28 1.5 
Small intestine wall 4.37 0.5 4.13 2.5 4.13 2.8 
Small intestine 
content 
2.09 0.5 2.15 1.5 2.16 1.6 
Large intestine total 4.08 1.1 4.13 0.2 4.09 0.8 
Large intestine wall 5.69 1.3 5.55 1.6 5.48 2.5 
Large intestine 
content 
2.4 0.5 2.65 3.8 2.64 3.4 
Bladder* 4.89 2.9 660.8 41.9 660.7 41.9 
Vas deferens* 8.84 2.7 33.19 30.8 33.01 30.6 
Testes* 6.67 9.4 5.14 2.3 5.05 1.3 
Bones 6.35 2.1 5.71 5.8 5.6 7 
Brain 4.13 12.8 4.66 25.1 3.52 21.5 
Thyroid 6.47 2.9 5.73 6.5 5.61 8.2 
Bone marrow 4.15 1.7 3.78 5.8 3.69 6.7 
Total body 14.03 0.2 14.12 0.3 14.14 0.4 
Pearson's r - - 9.82E-01 - 9.88E-01 - 
Significance p - - 2.45E-20 - 9.59E-23 - 
* Values excluded from correlation, derived by one technique only 




increased from 0.9820 (p < 0.0001) to 0.9883 (p < 0.0001) by 
applying hybrid imaging. 
 
For 18F-FTYR the highest absorbed dose derived by organ 
harvesting was for the liver with 48.23 ± 8.32 mGy/MBq, 
followed by the kidney with 23.90 ± 1.85 mGy/MBq. For 
imaging and hybrid imaging the liver was the critical organ as 
well, with 46.26 ± 7.35 mGy/MBq for imaging and  
49.28 ± 9.97 mGy/MBq for hybrid imaging. The second 
highest radiation was received by the bladder with  
37.20 ± 8.40 (imaging) and 37.10 ± 8.33 mGy/MBq (hybrid 
imaging). The total body absorbed dose was  
14.23 ± 0.05 mGy/MBq derived by organ harvesting 
(Imaging: 14.22 ± 0.05 mGy/MBq / Hybrid imaging  
14.24 ± 0.06 mGy/MBq). The correlation between data sets 
was improved from 0.9943 for imaging to 0.9992 for hybrid 
imaging (both p < 0.0001). 
 
 
For 18F-UCB-H the highest radiation was received by the 
liver with 65.14 ± 8.47 mGy/MBq derived by organ harvesting 
and the bladder with 57.63 ± 28.36 mGy/MBq derived by 
imaging. The second largest absorbed dose for organ 
TABLE V 









Skin 5.16 10.8 5.25 5.6 5.13 7.1 
Heart total 7.71 8.7 7.43 8.7 7.78 11.1 
Body 13.95 12 14.22 6.1 13.87 7.8 
Liver 48.23 13 46.26 15.9 49.28 20.2 
Gallbladder 17.67 12.5 16.98 15 18.03 19.3 
Total lung 14.33 8.5 11.07 7.9 13.74 9.3 
Stomach total 3.82 6.9 3.6 6.2 3.7 8 
Stomach wall 8.17 6.5 7.66 5.5 7.84 7.4 
Stomach content 3.09 7.1 2.92 6.5 3 8.2 
Pancreas 4.71 14 4.45 6.5 4.57 5.9 
Total kidney 23.9 9.6 23.79 14.3 25.02 8 
Spleen* 17.65 10.7 3.02 1.4 3.01 3.2 
Small intestine total 3.25 1.8 3.27 0.8 3.27 1.1 
Small intestine wall 4.13 2.4 4.16 1.2 4.14 1.6 
Small intestine 
content 
2.1 0.2 2.11 0.4 2.12 0.3 
Large intestine total 3.5 5.6 3.56 3.3 3.51 4.9 
Large intestine wall 4.79 6.6 4.87 3.9 4.79 5.7 
Large intestine 
content 
2.17 3.5 2.2 2 2.18 3.2 
Bladder* 3.84 12.7 37.2 22.6 37.1 22.5 
Vas deferens* 7.05 11.3 8.16 5.8 7.97 6.3 
Testes* 9.8 8.1 3.82 6.6 3.72 8.4 
Bones 5.5 8.4 5.56 3.7 5.47 4.6 
Brain 8.8 17.9 9.67 16.3 8.73 23.8 
Thyroid 5.19 9.5 5.28 5.8 5.16 7.3 
Bone marrow 3.72 8.2 3.77 2.5 3.7 3.5 
Total body 14.23 0.4 14.22 0.3 14.24 0.4 
Pearson's r - - 9.94E-01 - 9.99E-01 - 
Significance p - - 9.44E-28 - 1.45E-39 - 
* Values excluded from correlation, derived by one technique only 
TABLE VI 
MOUSE ABSORBED DOSES FOR 18F-UCB-H IN 
mGy/MBq 
18F-UCB-H Organ harvesting %CV Imaging %CV 
Skin 4 10.8 5.58 1.5 
Heart total 14.88 8.7 6.67 3.6 
Heart tissue 8.99 7.2 5.83 3 
Heart blood 16.98 9 6.98 3.7 
Body 10.56 12 15.25 1.6 
Liver 65.14 13 37.27 6.9 
Gallbladder 23.52 12.5 13.85 6.5 
Total lung 20.68 8.5 11.25 8.4 
Stomach total 4.6 6.9 3.33 2.5 
Stomach wall 9.72 6.5 7.14 2.4 
Stomach content 3.73 7.1 2.69 2.6 
Pancreas 19.49 14 4.17 2.4 
Total kidney 34.84 9.6 22.98 12.4 
Spleen* 15.23 10.7 3.09 0.8 
Small intestine total 3.09 1.8 3.32 0.2 
Small intestine wall 3.87 2.4 4.23 0.4 
Small intestine 
content 
2.07 0.2 2.12 0.2 
Large intestine total 3.1 5.6 3.73 1.2 
Large intestine wall 4.14 6.6 5.13 1.2 
Large intestine 
content 
2 3.5 2.28 1.1 
Bladder* 2.87 12.7 57.63 49.2 
Vas deferens* 5.49 11.3 9.89 11.6 
Testes* 15.42 8.1 12 9.2 
Bones 9.37 8.4 5.66 1 
Brain 33.63 17.9 1.25 1.1 
Thyroid 4.21 9.5 5.58 1.5 
Bone marrow 6.18 8.2 3.66 1 
Total body 14.38 0.4 14.17 0.1 
Pearson's r - - 9.56E-01 - 
Significance p - - 2.94E-14 - 





harvesting was the kidney with 34.84 ± 3.34 mGy/MBq and 
the liver with 37.27 ± 2.59 mGy/MBq for imaging. The total 
body absorbed dose was 14.38 ± 0.06 mGy/MBq for organ 
harvesting and 14.17 ± 0.01 mGy/MBq for imaging. The 
correlation between dose estimates derived by organ 
harvesting and imaging was 0.9558 (p < 0.0001). 
IV. DISCUSSION 





F]fluoro-L-Tyrosine were obtained 
using not only the well-established gold-standard technique of 
organ harvesting, but also using a conventional imaging 
technique and the hybrid imaging technique using a cross-
calibration between in vivo activities and post scan harvested 
ex vivo activities. For [
18
F]UCB-H organ harvesting and 
conventional imaging data was acquired only. Differences 
between residence times derived by organ harvesting and 
conventional imaging were found for all radiopharmaceuticals, 
most likely resulting from deficiencies in quantification in 
microPET due to PVE. Constantinescu et al. also reported a 
poor correlation between post scan harvested organ activities 
and final microPET measurements [27]. When assuming the 
organ harvesting residence time to be the reference value, a 
recovery coefficient defined as the ratio between residence 
times derived by organ harvesting and imaging can be 




For 18F-FDOPA the hybrid imaging technique improved 
accuracy of dynamic microPET imaging for the brain, kidney 
and liver, but slightly decreased it for the lung. For 18F-
FTYR, except for the kidney, all derived residence times were 
improved by applying the hybrid imaging method. Since no 
post scan harvesting was conducted for 18F-UCB-H, no 
recovery coefficients for hybrid imaging are available. 
Additionally, the brain was not in the field of view of the 
microPET, so no imaging recovery coefficient could be 
derived for the brain for 18F-UCB-H. All correlation values r 
(shown in Table I – III) between residence times were above 
0.99 (with at least p < 0.0015), but were based on four values 
only. Improved residence time correlations for 18F-FTYR 
compared to 18F-FDOPA might be an effect of using the same 
animals for organ harvesting at 120 minutes and dynamic 
scanning due to a reduction in cross-population differences. 
The remaining differences between organ harvesting and 
hybrid imaging for both tracers are most likely a consequence 
of cross-calibrating activities based only on final microPET 
measurements. PVE in dynamic microPET imaging is a 
dynamic problem, since it depends on the activity within the 
region and the warmth of the background, which changes over 
time [16]. In other words, early blood peaks, which change 
conditions between regions, cannot be compensated for using 
this technique.  
When comparing dose estimates derived by the different 
methods for all three tracers, a high correlation for all 
estimates (Pearson’s r > 0.95 with p < 0.0001 for imaging; 
Pearson’s r > 0.98 with p < 0.0001 for hybrid imaging) can be 
observed. However, since with organ harvesting some 
residence times could be derived that could not be derived 
with imaging and vice versa, some dose estimates had to be 
excluded from the data sets for the computation of the 
correlation. As the activity accumulation in those organs was 
significant, the resulting doses were substantially different 
(highly reducing correlation between datasets) since self-
radiation including cross-radiation from other organs was 
much higher than cross-radiation only. This highlights a 
limitation of both techniques. Organ harvesting lacks the 
possibility of quantifying activity of organ contents (i.e. 
bladder content, stomach content, gallbladder content, blood 
inside heart chambers), but has the advantage of allowing for 
the dissection of any organ. However, the technique requires 
many animals (here at least 18 per tracer) and is time-
consuming as well as labour-intensive. Dynamic microPET 
imaging on the other hand, which requires far fewer animals, 
allows for the quantification of organ contents (which can be 
very significant as can be seen for bladder absorbed dose of 
18F-FDOPA), but lacks, due to PVE in such small volumes, 
the accuracy in quantification necessary for dosimetry. The 
hybrid imaging approach applied here could partially 
overcome PVE and improved dose estimates derived by 
imaging. However, due to low in vivo contrast in microCT 
used to obtain anatomical information for segmentation, fewer 
organs can be derived from microPET than with organ 
harvesting. Magnetic resonance imaging (MRI) may offer a 
useful alternative for improved segmentation. Considering the 
high degree of correlation achieved and the drawbacks of both 
techniques, dynamic microPET imaging (with appropriate 
corrections) is a more ethical and efficient way to obtain 
equivalent results. 
The dosimetry of all three tracers (and all three methods) 
estimates an average total body dose of approximately 14 
mGy/MBq. However, single organ absorbed doses can be 
much higher depending on the tracer. Especially organs which 
are part of the urinary excretion pathways (i.e. bladder, kidney 
and liver) can receive excessive radiation with the urinary 
bladder wall for 18F-FDOPA being the highest absorbed dose 
with approx. 660 mGy/MBq (derived by imaging), which is 
comparable to the urinary bladder wall absorbed dose derived 
by Tascherau et al. of 543 mGy/MBq from 18F-FDG using a 
combination of in vivo biodistribution and Monte Carlo 
Simulations on a voxelized mouse phantom [28].  
TABLE VII 
RECOVERY COEFFICIENTS BETWEEN ORGAN 
HARVESTING AND IMAGING TECHNIQUES 










Brain 0.80 1.19 0.90 1.01 - - 
Kidney 1.43 1.37 1.00 0.95 1.58 - 
Liver 1.48 1.07 1.04 0.98 1.79 - 
Lung 0.99 1.39 1.62 1.09 2.33 - 
 




For 18F-TYR and 18F-UCB-H the liver was the critical organ 
with 45 – 50 mGy/MBq and 65 mGy/MBq, respectively.  
The 3D representation shown in Fig. 3 also highlights the 
significant uptake in the critical organs for each tracer in 
comparison to other organs. When considering an average 
injection of 10 MBq per scan as routinely done in our institute, 
single organ absorbed doses can vary between approximately 
0.5 Gy up to 6.6 Gy for a single microPET scan, without 
taking the additional radiation from microCT scanning into 
account. Delivered doses from microCT highly depend on the 
machine used and the protocol settings, but can range from 
several mGy only up to 0.5 Gy per scan [10] further increasing 
the radiation burden per scan. However, the lethal single 
entrance total body absorbed dose of 6 Gy [8] will not be 
exceeded, but organs in the urinary excretion pathways might 
receive radiations in a range of 1 to 6 Gy. The cumulative 
organ absorbed doses when assuming longitudinal studies 
involving several microPET/microCT scans can be much 
higher depending on the investigated tracer, the injected 
activity, the number of scans per subject and the used 
microCT. Nevertheless, investigators should try to keep the 
radiation burden on animals low by keeping the injected 
activity as low as possible and using low energy microCT 
protocols while still obtaining images containing the necessary 
detail for their study. The use of small animal MRI for 
anatomical imaging would be beneficial as it would lower the 
cumulative radiation further. Additionally, using the lowest 
possible radiation dose reduces the risk of adversely impacting 
study results. 
V. CONCLUSIONS 
In this study the mouse radiation dosimetry of 18F-FDOPA, 
18F-FTYR and 18F-UCB-H was derived using traditional 
organ harvesting (all tracers), dynamic microPET imaging (all 
tracers) and hybrid imaging (18F-FDOPA and 18F-FTYR 
only), where microPET activities are cross-calibrated with 
post scan harvested organs to improve quantification. 
Differences in cumulative activity, which can be related to 
PVE, between organ harvesting and imaging were reduced by 
using hybrid imaging for most organs and the correlation 
between dosimetry datasets was improved. Especially, the 
error in single organ absorbed doses was reduced, which is of 
great importance in dosimetry to avoid significant over-
exposure of subjects. Hybrid imaging yields comparable 
results to traditional organ harvesting, yet involves 
substantially fewer animals, less labour and is more time-
efficient.  
The presented radiation dosimetry of the three 18F-tracers 
has shown that mice receive a non-negligible amount of 
radiation with total body absorbed doses of 14 mGy/MBq and 
single organ absorbed doses ranging from a few mGy/MBq to 
up to 65 mGy/MBq. Especially urinary bladder wall are 
critical with an absorbed dose from 18F-FDOPA of 660 
mGy/MBq. Assuming single injections of 10 MBq per scan in 
a longitudinal study setup including additional radiation from 
microCT scans for anatomical referencing, cumulative total 
body doses of above 1 - 2  Gy and cumulative single organ 
absorbed doses between 5 – 10 Gy have to be expected, 
possibly introducing stochastic effects (depending on number 
of scans, microCT machine and protocol). Although the 
amount of radiation will not exceed single entrance lethal 
limits for mice, studies have shown that far lower doses can 
alter the physiology. Therefore, keeping the radiation burden 
on animals as low as possible while still producing the 
necessary imaging detail should be of concern for any study 
involving microPET/microCT scans. 
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Abstract- [18F]UCB-H is a novel radiotracer with a high affinity 
for SV2A, a protein expressed in synaptic vesicles. SV2A is the 
binding site of levetiracetam, a “first in class” antiepileptic drug 
with a distinct but still poorly understood mechanism of action. 
The objective of this study was to determine biodistribution and 
radiation dosimetry in a human clinical trial after injection of 
[18F]UCB-H and to establish injection limits according to 
biomedical research guidelines. Additionally, the clinical 
radiation dosimetry results were compared to estimations in 
previously published preclinical data. Dynamic whole body 
PET/CT imaging was performed over approximately 110 minutes 
on five healthy male volunteers after injection of 144.5 ± 7.1 MBq 
(range, 139.1 – 156.5 MBq) of [18F]UCB-H. Major organs were 
delineated on CT images and time-activity curves were obtained 
from co-registered dynamic PET emission scans. Time-integrated 
activity coefficients were calculated as area under the curve using 
trapezoidal numerical integration. A theoretical dynamic bladder 
model was applied to simulate excretion data and radiation 
dosimetry was calculated using OLINDA/EXM. The effective 
dose to the OLINDA/EXM 70 kg standard male was 1.98E-02 ± 
1.30E-04 mSv/MBq, with urinary bladder wall, gallbladder wall 
and the liver receiving the highest absorbed dose. The brain, the 
tracer’s main organ of interest, received an absorbed dose of 
1.89E-02 ± 2.66E-03 mGy/MBq. This first human dosimetry 
study of [18F]UCB-H indicated that the tracer shows similar 
radiation burdens to widely used common clinical tracers. Single 
injections of at maximum 321 MBq for USA practice and 505 
MBq for European practice keep radiation exposure below 
recommended limits. Recently published preclinical dosimetry 
data extrapolated from mice provided satisfactory prediction of 
total body and effective dose, but showed significant differences 
in organ absorbed doses compared to human data. 
  
Index Terms — Radiotracer, Human dosimetry, Brain, PET, 
SV2A, Translational 
I. INTRODUCTION 
he newly developed radiopharmaceutical [18F]UCB-H 
shows a nanomolar affinity for the human neuronal 
synaptic vesicle glycoprotein 2A (SV2A) in the brain. SV2A 
is critical to proper nervous system function and has been 
demonstrated to be involved in vesicle trafficking. 
Levetiracetam, which is a marketed antiepileptic drug, binds 
 
 
to the SV2A protein [1]. However, the specific mechanism of 
action of this “first in class” drug to treat epilepsy is not yet 
fully understood [2]. Since [18F]UCB-H targets the SV2A 
protein in the brain [3], it is a promising candidate for 
investigating the role of SV2A in central nervous system 
diseases and to provide a deeper insight into the mechanism of 
action of levetiracetam. 
The intended purpose of this study was to determine in a 
first clinical trial the whole body distribution of radiation dose 
following intravenous (iv) injection of [18F]UCB-H in humans 
and to provide injection limits according to American and 
European biomedical research guidelines. Additionally, the 
results of the clinical trial are discussed in relation to the 
previously reported preclinical radiation dose estimates 
derived by ex vitro measuring the radioactivity in dissected 
organs of mice [4]. 
II. MATERIALS & METHODS 
A. Subjects and Study design 
Five healthy males volunteered to participate in this study. 
Mean subject characteristics are shown in Table 1. Suitability 
of subjects for participation in this clinical trial was 
determined by interview, vital signs and physical examination, 
clinical blood laboratory tests, 12-lead electrocardiogram and 
urine drug screening.  
 
Subjects were males over the age of 65 or over the age of 18 
if vasectomised, with a body mass index of 18 to 30 kg/m2, a 
height of ≤ 190 cm and vital signs and clinical blood 
laboratory tests not deviating from any reference ranges. 
Subjects were excluded if they had previously participated in a 
study of an investigational medication (or a medical device) 
within the last 3 months; if they had received any prescription 
Biodistribution and radiation dosimetry for 
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  Age (y) Weight (kg) Height (cm) BMI (kg/m
2
) 
Mean 49.5 86.0 180.1 26.4 
SD 9.8 15.1 9.4 3.4 
Min 42 69 167 22 
Max 66 102 190 30 
 




or over the counter medication within 14 days prior to the 
study, or had a history of drug abuse within the last 6 months; 
if they had any medical or psychiatric condition that could 
compromise the study, or if they had undergone medical 
imaging involving the application of ionizing radiation in the 
last 12 months or had such imaging planned in the next 12 
months; if they had taken part in any previous research or 
medical protocol involving radiation (ICRP category IIb: no 
more than 10 mSv in addition to the natural background 
radiation in the previous 3 years including the dose from the 
study [5]); ); if they had a family history of cancer (one or 
more first degree relatives diagnosed before the age of 55 
years) or history or presence of any neurological diagnosis. 
Subjects were furthermore excluded if any medical or surgical 
condition might alter the metabolism or lead to any risk in 
regard to the administration of the drug; or if they showed 
abnormality in 12-lead ECG. The participants were paid to 
take part in the study, which was approved by the University 
Hospital Ethic Committee of Liège (Belgium). Subjects 
provided written informed consent prior to participation. The 
clinical registration number (EudraCT number) of the study 
was 2011-003413-42. A single dose microdosing study over a 
period of 14 days was performed prior to the clinical study in 
Wistar Han rats using the cold [19F]UCB-H compound. A dose 
of 0.2 mg/kg was administered as bolus (which is 
approximately 1000-fold the dose that was administered in 
humans). No test item treatment-related findings were noted 
during the study. Therefore, the dose level of 0.2 mg/kg was 
considered as a “No Observed Effect Level” (NOEL). 
 
B. PET imaging 
Data acquisition and analysis were conducted in accordance 
with MIRD pamphlet no. 16 [6]. Whole body dynamic 
PET/CT from head to mid-thigh was performed using a 
Philips GEMINI TF PET/CT (Philips, Amsterdam, 
Netherlands) [7]. An average of 144.5 ± 7.1 MBq [range, 
139.1 - 156.5 MBq] of [18F]UCB-H tracer was injected as iv 
bolus. Activity remaining in the injection syringe and the 
attached catheter was quantified and taken into account. The 
mean and standard deviation of the administered mass of 
[18F]UCB-H and the specific activity was 0.35 ± 0.18 µg 
[range, 0.16 – 0.70 µg] and 1022.4 ± 456.6 MBq/µg [range, 
410 – 1654 MBq/µg], respectively. The time framing of the 
dynamic PET scan consisted of six frames with the following 
duration: 15 s, 30 s, 60 s, 120 s, and twice 180 s. Depending 
on the height of the subject 11 to 12 bed positions were 
acquired within each frame, resulting in a total acquisition 
time of approximately 110 min. All bed positions were decay 
corrected to the starting time of the individual frame (0.1 min, 
5 min, 12 min, 26 min, 66 min, 101 min), which varied 
slightly from subject to subject due to different amounts of 
bed positions acquired per frame. The first two subjects were 
scanned starting at mid-thigh, which was changed to head first 
for the last three subjects to be able to obtain the peak of the 
uptake for the upper organs. Prior to the PET scan a whole 
body spiral CT scan was acquired with 60 – 100 mAs 
(depending on the subject’s weight) for organ segmentation 
and attenuation correction. All CT images were reconstructed 
using Feldkamp’s Filtered Backprojection [8] with a cut-off at 
the Nyquist frequency. All PET images were reconstructed 
using the iterative list mode time-of-flight algorithm [9] and 
corrections for attenuation, dead-time, random events and 
scatter were applied. The PET scanner is periodically checked 
for calibration accuracy as part of quality control according to 
Belgian rules and has the EARL accreditation [10]. 
   
 
C. Dosimetry analysis 
Full organ segmentation was performed by a single 
observer (FB) on CT images for clearly visible organs (i.e. 
brain, gallbladder, heart, kidneys, lung, spleen, liver and 
testes) using PMOD (Version 3.306, PMOD Technologies, 
Zurich, Switzerland). CT-based volumes of interest (VOI) 
were used on co-registered PET images to obtain average 
organ activity per volume in kBq/cc for each frame. Although 
the bladder was visible in the CT, the volume increase of the 
organ due to filling with urine throughout the PET emission 
scan created a misalignment between the location and size of 
the VOI in CT and PET emission scan. Average activity per 
volume was applied to organ volumes of the standard 70 kg 
hermaphroditic phantom [11] implemented in OLINDA/EXM 
(Version 1.1) [12] and normalized for injected activity. Heart 
wall and heart blood pool could not be separated in the images 
due to insufficient contrast and were summarized as heart 
wall. Time-activity curves (TAC) were linearly interpolated 
between time points (0.1 min, 5 min, 12 min, 26 min, 66 min, 
101 min) and physical decay only was assumed after the last 
time point up to 10 h post injection. Biological clearance of 
activity from organs after 2h was neglected assuming the 
activity was trapped inside the organ. Time-integrated activity 
coefficients, which are mathematically equal to the number of 
disintegrations occurring within the source organ, were 
calculated from these TACs by trapezoidal numerical 
integration as proposed in literature [6, 13] using MATLAB 
software version 7.12.0 (Mathworks, Natick, USA). Since CT-
based segmentation was not feasible for the urinary bladder 
and only a limited number of time points were available, 
urinary excretion scenarios with voiding every 4 h and a 
biological half-life of 3 h equal to those used in the preclinical 
study were modeled [4]. Additionally, pre-voiding of subjects 
was simulated by decreasing the voiding interval to 2 h for the 
same scenarios. PET-based VOI were created to estimate the 
activity present in the bladder content (using the 5 highest 
activity pixel inside the VOI), but were not used for dose 
calculations due to the limited number of time points and the 
low accuracy. Activity of organs that could not be clearly 
delineated was together with all unaccounted for activity 
assigned to the remainder of the body. The calculated time-
integrated activity coefficients were used for dosimetry 
calculations with OLINDA/EXM software to obtain total 
absorbed dose and the effective dose based on tissue 
weighting factors from ICRP publication 60 [14] for the 
standard 70 kg adult male model. Newer tissue weighting 
factors exist, which were published in ICRP publication 103 





S-factors for dose calculations are available as of yet [16]. 
Standard deviations (sample for injected dose, mass of drug 
and subject statistics; population for time-integrated activity 
coefficients and doses) across subjects were calculated using 
Excel (Excel 2010, Microsoft, Redmond, USA) and expressed 
as coefficients of variation (in percentage) for time-integrated 
activity coefficients and doses. Minimum and especially 
maximum values were displayed, since these are of special 
interest in dosimetry. Correlations between datasets were 
calculated using Pearson product-moment correlation 
coefficient in Matlab.  
III. RESULTS 
The biodistribution over time of [18F]UCB-H was 
determined for major organs in the five human male 
volunteers and is presented in percentage of injected activity, 
normalized to organ volumes of the 70 kg phantom in Fig. 1. 
 
The highest uptake was observed within the liver with an 
initial value of 19% of injected activity after 5 minutes 
followed by a rapid washout phase to 3.5% after 2 h. The 
brain showed an average uptake of 9.4% after 5 min with a 
washout phase to 1.2% after 2 h. The other significant uptake 
was in the heart with 2.3% after 1 minute and 0.5% after 2 h. 
The gallbladder was characterized by a low uptake compared 
to other organs but showed very slow clearance to increase of 
activity over the scan duration depending on the subject.  
Time-integrated activity coefficients of segmented organs 
were calculated and are shown in Table 2. The highest number 
of disintegrations per organ occurred in the bladder with an 
average time-integrated activity coefficient of 3.08E-01 h 
(voiding interval of 4 h, excretion fraction of 0.5) followed by 
the liver (2.28E-01 h) and the brain (1.01E-01 h). 
 
 
Fig. 2a illustrates whole body coronal plane images of a 
representative subject at different time points post 
administration of [18F]UCB-H and a 3D representation of the 
segmented CT image overlaid with the corresponding frame-
averaged PET image in Fig. 2b. Half of the skull in the CT 
images was removed for display purposes. The high initial 
uptake in the liver and in the brain can be observed as well as 
the prolonged uptake within the gallbladder. 
The average absorbed dose statistics across all subjects are 
shown in Table 3 including the standard deviation expressed 
as coefficient of variation (%CV) and the minimum and 
maximum value obtained. The highest absorbed dose was 
TABLE II 
AVERAGE TIME-INTEGRATED ACTIVITY 
COEFFICIENTS (h)  
*derived theoretically 
Organ Mean (n=5) %CV Minimum Maximum 
Brain 1.01E-01 16.0 8.25E-02 1.15E-01 
Gallbladder 1.37E-02 52.0 4.28E-03 2.22E-02 
Heart 2.98E-02 13.5 2.57E-02 3.58E-02 
Kidneys  3.21E-02 16.8 2.35E-02 3.61E-02 
Lung 5.95E-03 24.4 4.23E-03 7.93E-03 
Spleen 7.51E-03 18.8 6.44E-03 9.90E-03 
Liver 2.28E-01 10.7 1.93E-01 2.54E-01 
Testes 1.28E-03 16.1 1.04E-03 1.47E-03 
Bladder*  3.08E-01 0.0 3.08E-01 3.08E-01 
Remainder 1.91E+00 2.3 1.86E+00 1.97E+00 
 
 
Fig. 1.  a) Average interpolated TAC including physical decay in % of 




Fig. 2a) Whole body coronal image of representative subject at different time points post administration of [
18
F]UCB-H (same slice and activity scale, filtered 
with Gaussian kernel of 8 mm isotropic, injection equipment removed after fourth frame for quantification of remaining activity) and b) 3D representation of 
PET/CT image averaged over all frames 




received by the urinary bladder wall with 1.56E-01 ± 
0.00E+00 mGy/MBq followed by the gallbladder wall with 
3.66E-02 ± 1.13E-02 mGy/MBq and the liver with 3.26E-02 ± 
3.01E-03 mGy/MBq. The absorbed dose to the brain, which is 
the tracer’s main target of interest, was 1.89E-02 ± 2.07E-04 
mGy/MBq. The effective dose calculated using the tissue 
weighting factors from ICRP publication 60 was 1.98E-02 ± 
1.30E-0.4 mSv/MBq. 
 
Since the urinary bladder wall data was modeled, different 
bladder scenarios were implemented to clarify the impact on 
the bladder dose and the effective dose. Three different 
fractions of injected activity being cleared via the urinary 
excretion system were assigned and the absorbed dose for the 
urinary bladder wall and the effective total body dose are 
shown in Fig. 3. The urinary bladder wall absorbed dose 
decreased from 1.56E-01 mGy/MBq to 9.83E-02 mGy/MBq, 
when reducing the excretion fraction from 0.5 to 0.3. 
However, the assumption of a urinary excretion fraction of 
0.5, meaning that half of the injected activity is cleared via the 
urinary pathway, is a rather conservative approach and might 
be an overestimation. By pre-scan hydration of the patient the 
voiding interval could be decreased to 2 h, which would result 
in a decreased urinary bladder wall absorbed dose of 9.37E-02 
mGy/MBq for an excretion fraction of 0.5 (6.10E-02 
mGy/MBq for excretion fraction of 0.3). Activity data derived 
from PET based segmentation showed that an average of 4.32 
± 1.16 % of injected activity was present inside the urinary 
bladder across subjects after 110 minutes (data based on 5 
hottest pixel applied in kBq/cc to the urinary bladder content 
of 203 cc of the OLINDA phantom). 
 
Regarding the clinical safety assessment, two out of 5 
subjects reported treatment-emergent adverse events (viral 
infection and headache in 1 subject each) a few hours after 
study drug administration. The Investigator considered the 
adverse events to be mild in intensity and not to be related to 
the study drug. Both adverse events resolved and did not lead 
to premature discontinuation of the study. There were no 
clinically significant trends in any laboratory, vital sign, or 
ECG parameters following single iv bolus administration of 
[18F]UCB-H. There were no clinically relevant increases from 
baseline in the QTcB or QTcF electrocardiographic interval. 
IV. DISCUSSION 
This study is the first clinical trial to directly assess the 
biodistribution and whole body radiation dose given to 
humans by the compound [18F]UCB-H. The urinary bladder 
wall, whose dose was derived theoretically, received the 
highest absorbed dose followed by gallbladder, liver and 
kidneys. The highest %CV (30.7%) was obtained for the 
gallbladder, which is a result of different filling states of the 
organ across subjects. The significant uptake of [18F]UCB-H 
in the brain shows its potential for investigating the expression 
of SV2A in the normal or pathological central nervous system. 
If comparing the effective dose received by the 
OLINDA/EXM 70 kg adult male phantom to that of one of the 
most widely used PET tracers [18F]FDG, [18F]UCB-H with 
1.98E-02 mSv/MBq stays below the effective dose reported in 
literature for [18F]FDG, i.e. 2.1E-02 to 2.9E-02 mSv/MBq 
[17] and below limit recommendations of 10 mSv provided by 
the ICRP [5]. Additionally, guidelines of the Society of 
Nuclear Medicine propose for [18F]FDG brain PET scans an 
 
Fig. 3.  Impact of assigned excretion fraction on urinary bladder wall dose 
and effective dose (voiding interval of 4 h); AD = Absorbed dose, ED = 
Effective dose based on ICRP 60 
 
TABLE III 
ABSORBED DOSE ESTIMATES (mGy/MBq) FOR 





%CV Minimum Maximum 
Adrenals 1.34E-02 1.6 1.31E-02 1.36E-02 
Brain 1.89E-02 14.1 1.59E-02 2.13E-02 
Breasts 8.28E-03 1.0 8.21E-03 8.41E-03 
Gallbladder Wall 3.66E-02 30.7 2.16E-02 5.00E-02 
LLI Wall 1.54E-02 1.5 1.51E-02 1.57E-02 
Small Intestine 1.37E-02 1.2 1.35E-02 1.39E-02 
Stomach Wall 1.19E-02 0.9 1.18E-02 1.20E-02 
ULI Wall 1.35E-02 1.3 1.33E-02 1.37E-02 
Heart Wall 2.33E-02 9.6 2.10E-02 2.67E-02 
Kidneys 2.67E-02 12.6 2.14E-02 2.93E-02 
Liver 3.26E-02 9.2 2.83E-02 3.56E-02 
Lungs 7.13E-03 4.6 6.75E-03 7.56E-03 
Muscle 1.08E-02 1.1 1.06E-02 1.09E-02 
Ovaries 1.55E-02 1.2 1.53E-02 1.58E-02 
Pancreas 1.38E-02 1.5 1.35E-02 1.40E-02 
Red Marrow 1.03E-02 0.7 1.02E-02 1.04E-02 
Osteogenic Cells 1.56E-02 1.5 1.53E-02 1.59E-02 
Skin 8.05E-03 1.3 7.93E-03 8.20E-03 
Spleen 1.39E-02 10.3 1.28E-02 1.63E-02 
Testes 1.30E-02 6.0 1.22E-02 1.38E-02 
Thymus 1.03E-02 0.8 1.02E-02 1.04E-02 
Thyroid 9.99E-03 1.6 9.83E-03 1.02E-02 
Urinary Bladder Wall 1.56E-01 0.0 1.56E-01 1.56E-01 
Uterus 2.08E-02 1.1 2.05E-02 2.11E-02 
Total Body 1.18E-02 0.0 1.18E-02 1.18E-02 
Effective Dose ICRP 
60 (mSv/MBq) 






injected activity of 185 – 740 MBq depending on equipment 
limitations, specific application and patient compliance [18]. 
Assuming a similar use of [18F]UCB-H in brain PET scans for 
displacement studies, the high activity reaching the brain 
suggests that an injected activity of 200 MBq would be 
sufficient for the purpose of the tracer, which was confirmed 
by preliminary kinetic modelling studies performed in our lab. 
Therefore, the absorbed doses of organs as well as the 
effective dose will stay significantly below those of [18F]FDG 
for routine use in clinic. The herein used urinary excretion 
scenario with voiding every 4h and a fraction of 0.5 (0.5 to 0.3 
shown in Fig. 3) of total injected activity leaving via urinary 
excretion pathways within 6h results in an absorbed dose of 
1.56E-01 ± 0.00E+00 mGy/MBq to the urinary bladder wall. 
When comparing this theoretical estimation to derived 
absorbed doses in humans for [18F]FDG by Deloar et al. [17] 
using MRI/PET with 3.1E-01 ± 1.9E-01 mGy/MBq (only 
voiding post scan at approx. 80 min, physical decay assumed 
after), the radiation dose to the bladder from [18F]UCB-H 
remains below this value. However, the scenarios are different 
and whether speed of accumulation and amount of activity 
excreted via urinary pathways are similar is unknown. The 
average of 4.32 ± 1.16 % of injected activity present in the 
urinary bladder suggests that the assumed fraction of 0.5 is a 
conservative approach. Nonetheless, due to the limited amount 
of time points available and inaccurate PET based 
segmentation, the conservative approach should be used for 
calculating first injection doses in order to avoid over-
exposure of patients. 
For biomedical research in the USA the Food and Drug 
Administration (FDA) defined maximum exposures for single 
injections (SI) and annual total injections (ATI) limiting the 
dose received by whole body, active blood-forming organs, 
lens of the eye, and gonads to 30 mSv for single injection and 
50 mSv for annual exposure [19]. For other organs the limits 
are 50 mSv and 150 mSv, respectively. In accordance with 
these FDA dose limits the maximum single and annual 
injection dose of [18F]UCB-H is 321 MBq and 962 MBq, 
respectively, with the urinary bladder being the critical organ. 
For a urinary excretion fraction of 0.3 (as presented in Fig. 3) 
the urinary bladder wall remains the dose limiting organ with 
a maximum injected dose of 508 MBq (SI) and 1525 MBq 
(ATI). 
In Europe different guidelines exist for tracers depending on 
their societal benefit [5]. [18F]UCB-H is classified as a tracer 
with moderate societal benefit (Category IIb) due to its 
potential for “increases in knowledge leading to health 
benefit”. The maximum effective dose for ICRP category IIb 
is 10 mSv per single injection. This limit would be exceeded 
based on the ICRP 60 tissue weighting factors for an injection 
of 505 MBq for a urinary excretion fraction of 0.5 or 592 MBq 
for an excretion fraction of 0.3. 
However, when performing dual modality studies with 
PET/CT, the CT dose should be considered and the sum of 
both exposures should be kept as low as possible while still 
producing diagnostically useful images. When hypothesizing 
an administered activity of 200 MBq for a brain study, the 
average effective dose of the PET scan amounts to 3.96 mSv. 
In a typical brain PET study involving a single head scan for 
attenuation correction the CT exposure most likely stays 
below 1 mSv (depending on equipment and protocol), which 
keeps the total exposure of the patient far below radiation 
limits. 
A. Comparison of preclinical data (derived by organ 
harvesting in mice) and clinical data 
When comparing data derived by organ harvesting in mice 
[4] and the data derived from this study in humans large 
differences can be observed in lung, liver and brain regarding 
time-integrated activity coefficient as shown in Fig. 4. The 
preclinically determined time-integrated activity coefficient of 
the lung was overestimated by a factor of 10 compared to the 
clinical value, that of the liver by a factor of 1.9 and that of the 
brain by 1.7.  
 
A comparison of the preclinical and clinical dose estimates 
is presented in Fig. 5. The Pearson’s correlation coefficient 
between the mean animal derived dose estimates and mean 
human derived dose estimates was 0.969 with p-value ≤ 
0.0001 (based on all 27 values). 
 
 
Several explanations can be given for differences between 
human data predicted on the basis of animal data and real 
human data. The most general is the fact that the interspecies 
 
Fig. 5.  Comparison of mean human dose predicted from animal data and 
mean derived human dose ( ±SD) for major organs (both for 70kg adult 
standard male, urinary excretion fraction 0.5); TB = total body, ED = 
Effective dose based in ICRP 60 
 
Fig. 4.  Comparison of mean animal (organ harvesting in mice) derived time-
integrated activity coefficients and mean human derived time-integrated 
activity coefficients (±SD) (*Heart wall only) 
 




extrapolation method used does not account for differences in 
metabolism; it is only based on the ratio between organ to 
body weight in both species. The organs with the largest 
difference in time-integrated activity coefficients (brain, liver 
and lung) also have the largest difference in organ to body 
weight ratio indicating that the assumptions made for 
interspecies extrapolation after Kirshner [20] should be treated 
carefully. Moreover, these organs are highly perfused and 
when considering the activity injected per kg body weight 
(approx. 285 MBq/kg in mice vs. 2 MBq/kg in humans) it is 
clear that the activity remaining in the blood is higher in 
animals increasing the activity in organs. This is not the case 
for the human heart wall value derived from animal data, 
because prior to activity quantification with a gamma well 
counter the blood was removed from the heart chambers of the 
animals. Additionally, blood content and heart wall could not 
be separated in the human study leading to a higher value for 
the heart wall in the human study. Furthermore, the impact of 
anaesthesia on the animal’s metabolism for that specific tracer 
is unclear and it has been previously shown that e.g. in the 
case of [18F]FDG the type of anaesthesia can significantly alter 
the uptake of the tracer in the myocardium in mice [21]. 
V. CONCLUSIONS 
The novel radiotracer [18F]UCB-H meets standard criteria 
with regard to whole body distribution of radiation doses for 
human application. The maximum single injection dose was 
determined to be 321 MBq for practice in the USA and 587 
MBq in Europe. For both guidelines of biomedical research 
involving radiopharmaceuticals the urinary bladder wall 
followed by the liver and the gallbladder were the limiting 
organs. Due to the high uptake of the tracer in its target organ, 
the brain, an injection of 200 MBq (effective dose of 3.96 
mSv) is considered to be sufficient for brain studies 
investigating the role of SV2A in central nervous system 
diseases. Based on this consideration repeated scans in 
displacement studies are feasible with [18F]UCB-H. 
Depending on the radiation dose from the attenuation scan and 
as a function of which research guideline has to be followed, 
two to three consecutive scans keep radiation exposure below 
recommended limits. 
The comparison of previously published preclinical data 
derived from organ harvesting in mice for [18F]UCB-H and of 
human data suggests that, although the effective dose was 
overestimated by only 10% in animal data, precautions should 
be taken when using animal data to predict injection limits. 
Absorbed doses of single organs were significantly different 
between the studies. However for this tracer, most of the 
values were overestimated in data derived from animals 
therefore minimizing the risk of an overexposure in humans in 
this case.   
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Performance Evaluation and X-ray Dose
Quantification for Various Scanning Protocols
of the GE eXplore 120 Micro-CT
Florian Bretin, Geoffrey Warnock, André Luxen, Alain Plenevaux, Alain Seret, and Mohamed Ali Bahri
Abstract—The aim of this paper was to evaluate the perfor-
mance of the General Electric eXplore 120 micro-CT regarding
image quality and delivered dose of several protocols. Image
quality (resolution, linearity, uniformity, and geometric accu-
racy) was assessed using the vmCT phantom developed for the
GE eXplore Ultra, the QRM low contrast, and the QRM Bar
Pattern Phantom. All dose measurements were performed using
a mobileMOSFET dose verification system, and the
and the multiple-scan average dose (MSAD) were determined
with a custom-built PMMA phantom. Additionally, in vivo scans
in sacrificed rats with different weights were acquired to assess
dose, contrast, and resolution variation due to X-ray absorption
in surrounding tissue. The spatial resolution was determined as
between 95 and 138 m with a geometric accuracy of 0.1%. The
system has a highly linear response to the iodine concentrations
(0.937–30 mg/ml) for all protocols. The calculated
ranged from 20.15 to 56.79 mGy, and the MSAD from 27.98 to
77.45 mGy. The results were confirmed by in vivo scans in rats
with different weights, and no impact of body weight on delivered
dose could be observed. However, body weight had a slight impact
on image contrast and resolution.
Index Terms—Dosimetry, performance evaluation, X-ray
tomography.
I. INTRODUCTION
M ICRO-COMPUTED tomography (micro-CT) is ascaled-down CT-imaging modality for small animals.
Increased interest in in vivo preclinical imaging has promoted
huge technical developments, making micro-CT a useful tool
to study tissue morphology and disease status in small animals
such as rodents. Most of the current micro-CT scanners pro-
vide a set of scanning protocols designed to meet the image
quality requirements for particular study types, such as char-
acterization of bone structure and density in osteoporosis and
osteoarthritis, study of microvasculature anatomy, and tumor
or tissue visualization [1], [2]. These protocols mainly differ in
tube voltage and current, exposure time, binning of the detector
elements, and the number of projections. In order to reach the
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high resolution (typically 50–100 m) needed when imaging
small animals, the X-ray dose delivered must be high compared
to clinical scanners in order to improve signal-to-noise ratio,
which is achieved by increasing the tube current and the expo-
sure time per projection [3]. Since longitudinal studies, often
combined with other ionizing imaging modalities like positron
emission tomography or single photon emission tomography,
are increasingly used in preclinical imaging [4], [5], it is im-
portant to quantify the radiation delivered to the animals to
rule out any influence of the irradiation on the outcome of the
study [6]. A dose of 6 Gy is considered lethal to a mouse [7],
however some studies report that even low doses can affect
protein expressions [8] and alter signal transduction of neurons
in mouse hypothalamus [9]. On the other hand, a study con-
ducted by Detombe et al. found no radiation-induced effects on
pulmonary or myocardial tissue for a cumulative entrance dose
of 5.04 Gy over six weeks [10].
The aim of the present paper was to evaluate the performance
of the General Electric (GE) eXplore 120 micro-CT regarding
image quality and resulting X-ray dose for various protocols to
provide support in choosing the appropriate protocol to meet
requirements of a study type. Image quality was assessed using
the same methodology and image quality assurance vmCT
phantom developed by Du [11] for the GE eXplore Ultra. The
Quality Assurance in Radiology and Medicine (QRM) low
contrast [12] and Bar Pattern phantoms [13] were also used to
assess the contrast and resolution. The dose delivered by the
protocols that are used for live animal scans, which were also
part of the performance evaluation, was quantified bymeasuring
dose profiles and computing the CT dose index (CTDI), which
is routinely used in clinics [14] and has been shown to be a
promising parameter for quality assurance and dose assessment
in micro-CT [15]. The multiple-scan average dose (MSAD)
was computed, and it was, along with the CTDI, compared to
experimentally obtained in vivo dosimetry data in rats. Weight
and size of the rats were varied in order to investigate dose
deviations due to body weight. Additionally, the QRM Bar
Pattern phantom was used to evaluate resolution degradation
due to X-ray absorption in rats with different weights.
II. MATERIALS AND METHODS
A. Micro-CT
The eXplore CT 120 is the latest generation micro-CT
from General Electric (GE Healthcare, Amersham, U.K.
/GammaMedica, Northridge, CA, USA). The scanner is
0018-9499 © 2013 IEEE
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Fig. 1. Micro-CT images of (a) coil, (b) slanted edge, and (c) geometric accu-
racy sections.
equipped with a mammography X-ray tube and a CCD de-
tector, fiber-optically coupled to a phosphor screen, designed
for high-resolution (80 m resolution as stated by the manu-
facturer) and rapid high-contrast scanning in small animals.
The X-ray source is a high-power rotating-anode tube with
5 kW peak source power and a focal spot of 300 m and is able
to provide tube voltages between 70–120 kVp with a typical
current range from 20 to 50 mA. The only filtration used is
the inherent filtration of the tube housing (equivalent to about
1.5 mm Al). The CCD detector consists of 3500 2300 pixel
elements covering an active area of 110 75 mm . The source
and the detector, positioned opposite to each other at a fixed
distance of 450 mm, rotate on a gantry around a fixed carbon
fiber bed. Two beds were designed to cater for mouse (25 mm
width) and rat (75 mm width). The maximum axial field of
view (FOV) per rotation is 55 mm with a transaxial length of
85 mm. With overlapping FOVs and stitching of images, a
maximum axial scan length of 250 mm can be achieved [16].
The system operates with three different detector binning
modes (1 1, 2 2, and 4 4). No scatter or beam hardening
correction is implemented for the eXplore 120. Feldkamp’s
filtered backprojection algorithm [17] is used to reconstruct a
3-D volume image. The image matrix size and the isotropic
voxel size (25/50/100 m) depend on the selected number of
FOVs and the binning mode.
B. Phantoms
The design of the vmCT phantom (Fig. 1) and the associ-
ated methodology are fully described by Du et al. [11] and
Bahri et al. [16]. Briefly, the vmCT is a single phantom con-
sisting of six separate modular sections (resolution coils, slanted
edge, geometric accuracy, CT number evaluation, linearity, and
uniformity and noise) each designed to evaluate one aspect of
image quality. The sections are held together inside an acrylic
tube (inner diameter: 63 mm; outer diameter: 70 mm; length:
54 mm). The phantom fits within the scanners’ field of view, al-
lowing all quantitative information to be obtained from a single
scan.
The QRM low-contrast phantom is a resin cylinder (diameter:
32 mm; length: 40 mm). It contains small cylindrical inserts
(diameters: 1 and 2.5 mm; length: 40 mm) at a specified low
contrast with respect to the background. The contrast-to-noise
ratio was measured for the four inserts. The QRM Bar Pattern
phantom [13], which consists of two silicon chips containing
bar and point patterns of 5–150 m in diameter/line thickness
embedded in resin, was used to visually evaluate the spatial res-
olution and is displayed in Fig. 2 [18].
Fig. 2. QRM Bar Pattern phantom. (a) Full view and (b) structural chip
close-up [13].




For dosimetry measurements, a cylindrical poly(methyl
methacrylate) (PMMA; the most widely used material for
phantoms in dosimetry for CT [15], [19], [20]) phantom was
custom made. It was 200 mm in length with a diameter of 50
mm and had nine longitudinal boreholes with a diameter of
3 mm, of which eight were radially distributed (every 45 ) at
distances of 12.5 mm around the center hole as can be seen
in Fig. 3. The diameter of 50 mm was chosen to represent a
standard rat as in the NEMA NU42–2008 rat-like phantom.
For ease of manufacturing, the whole phantom was split into
4 50-mm parts, which were connected with two PMMA pins
at each interface to prevent any movement as displayed in
Fig. 3 [21].
C. Measurements
Six standard scanning protocols regularly used in our lab-
oratory (Table I) were studied using the three image quality
phantoms (vmCT and QRM). A set of bright- and dark-field
images were collected for each scan to correct for individual
detector gain and offset in the raw projection data. Projections
were reconstructed into 3-D volume images with a voxel size of
m . Resolution section data from the vmCT
phantom were also reconstructed with a voxel size of
m for protocols P3, P5, and P6. These three protocols have
a detector-binning mode of 2 2, which allows reconstruction
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of the projections at either 50 or 100 m. The data acquired with
the other protocols were recorded with the 4 4 detector-bin-
ning mode and could only be reconstructed with the largest
voxel size. Data analysis was performed using PMOD software,
version 3.3 (PMOD Technologies Ltd., Zurich, Switzerland),
and MATLAB software, version 7.7 (http://www.mathworks.
com).
1) Spatial Resolution: The spatial resolution was evaluated
qualitatively and quantitatively by computing the modulation
transfer function (MTF) from the coil and slanted edge section
[see Fig. 1(a) and (b)] of the vmCT phantom as described by
Du et al. [11]. The MTF is calculated for each aluminum coil
by the standard deviation (SD) inside regions of interest (ROIs)
placed on the coil, which is corrected by the SD inside the uni-
form region of the phantom, and the mean absolute difference
CT values of aluminum and plastic. From averaged slices and
therefore a noise reduced image of the slanted edge, an edge
spread function (ESF) was generated, which is the integral of
the line spread function (LSF). Calculating the modulus of the
Fourier transform of the LSF gives the presampled MTF of the
detector [16].
2) Geometric Accuracy: In the geometric accuracy section
of the vmCT phantom [Fig. 1(c)], four beads were positioned
at 35 mm distance in an ideal square, with one additional in
the center (24.75 mm from every other). Distance in number of
pixels between the centers of the beads was measured, and the
true physical pixel size was calculated by dividing the known
distance by numbers of pixels. The axial pixel spacing was mea-
sured on the image of the geometric accuracy section, removed
from the phantom and scannedwith its diameter toward the axial
direction.
3) Linearity: The linearity of the system was determined by
linear regression of the relation between signal intensity and io-
dine concentration (0.9375, 1.875, 3.75, 7.5, 15, and 30 mg/mL)
inside vials placed in the vmCT phantom.
4) CT Number: Measured CT numbers for air and eight
different materials (cortical bone-equivalent tissue-mimic,
a silicone-based vascular contrast compound, polytetrafluo-
roethylene, high-density polyethylene, fat-mimicking epoxy
resin, muscle-mimicking epoxy resin, polymethyl methacrylate
plastic, and water-equivalent epoxy resin) were compared to
the protocol specific values provided by the manufacturer. For
details on materials, see [11].
5) Uniformity: The variation of the signal intensity and the
average SD of a central and four peripheral ROIs in the uniform
region of the vmCT phantom was assessed. The uniformity-to-
noise ratio was calculated by dividing the average difference
in signal intensity from center to periphery and the average SD
noise.
6) Dosimetry: All dosimetric measurements [only for proto-
cols used for live animal scans: P1 to P4 (Table I)] were carried
out with a mobileMOSFET Dose Verification System (Best
Medical Canada, Canada) with standard-sensitivity MOSFET
sensors (14 mV/cGy for 40–120 kVp, isotropic response
with over 360 ) and calibration factors provided by the
manufacturer. At each of the nine transaxial positions of the
phantom (Fig. 3), the dose was measured (center , other
) from to mm longitudinally around the center
of an axial scan to be able to calculate the . Between
to mm and 20 to 50 mm, measurements were
made every 5 mm, whereas between 20 and 20 mm around
the scan center, the dose was measured every 2.5 mm. The
phantom remained fixed throughout all measurements on the
microCT bed; only the bed was moved in axial direction with
respect to the gantry. Using the axial dose profiles obtained, the
[15] [19] [20] was computed as follows:
(1)
where equals the axial dose profile along the scanner
axis . is defined in clinical scanners as the nominal
beamwidth at the axis of rotation with as the number of si-
multaneously acquired slices and the width of each slice [15].
The acquired FOV for a single acquisition is 55 mm for the
eXplore 120, which was set equal to the nominal beamwidth.
The mAs was computed based on the central dose
profile.
The experimentally acquired center dose profiles were used
to construct theoretical dose profiles for multiple field-of-view
(mFOV) scans for all protocols. When mFOVs are acquired
with the eXplore 120, an overlap of 15 mm exist between each
single field of view (sFOV), which is used to stitch images
together after reconstruction. Therefore, the first and the last
sFOV have an overlap region of 15 mm, and the inner sFOVs
a total overlap region of 30 mm. The MSAD was computed for
all protocols used for dosimetry, which represents the average
dose over one scan interval ( ) in the central portion of a mul-
tiple-scan ( ) dose profile. It was computed from the theoreti-
cally constructed mFOV dose profiles as follows [20]:
(2)
The center scan interval has a width of 55 mm, and the
number of acquired sFOV assumed was five (total scan length
of 155 mm) [21]. The dose length product (DLP) was not
provided, as it is a more appropriate unit for clinical systems
that do not acquire sFOVs with an overlap to obtain an mFOV
scan.
D. In Vivo Measurements
To quantify the in vivo X-ray dose delivered to animals, the
MOSFET sensors were placed in three sacrificed rats of 272,
415, and 610 g body weight. All animals were part of other
studies, which were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of Liège,
Liège, Belgium, and were sacrificed after completion of the
studies. The weight was varied to show the variation of the de-
livered dose due to attenuation inside matter. Four MOSFET
sensors were placed inside the skull, chest cavity, abdomen (in-
testines), and the anal cavity above the testes as illustrated in
Fig. 4.
Each location of the sensors was scanned twice as an sFOV
in each animal with the four protocols used for the phantom
dosimetry scan. For each protocol and each animal, an mFOV
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Fig. 4. Maximum intensity projection of exemplary rat including MOSFET
sensors.
Fig. 5. MTF for all protocols measured from the slanted edge and resolution
coil sections. The dotted line represents the 10% MTF.
scan covering all sensors was acquired to assess the increase
of dose in mFOV scans. Additionally, after conducting the
dosimetry evaluation, the QRM Bar Pattern phantom was
inserted into the abdomen of each animal. An sFOV scan was
acquired centered on the phantom with the same four protocols
to visually inspect the impact of scatter and reduced X-ray




The MTF of the system was determined over a frequency
range from 0 to 6 mm based on the analysis of the recon-
structed images of the coil and slanted edge sections for all
protocols (Fig. 5). The MTF obtained by the coil method
agreed well with the slanted edge results. The 10%MTF for the
slanted edge was in the range 3.6–4.8 mm ( ;
; ; and ), corresponding
to a spatial resolution between 95 and 138 m. Due to their
size, the coils did not allow assessment of the 10% MTF.
The spatial resolution of the system was not measured in the
-direction because the vmCT phantom was not designed for
this measurement. The QRM Bar Pattern phantom confirmed
the results, as the smallest visible objects were those of 100 m
(the other objects in this phantom have a size above 150 m or
below 50 m).
B. Geometric Accuracy
The nominal pixel spacing both in-plane and axial was within
0.1% of the manufacturer’s specification. For protocol-specific
nominal pixel spacing, see Table I.




C. Linearity and CT Number
A highly linear relationship between measured CT number
and iodine concentration (average )
was observed with a tube voltage dependent slope (Fig. 6). The
same behavior was also observed for the CT number evaluation
section for measured versus expected CT number with an av-
erage .
D. Uniformity
The central region of the polycarbonate uniformity section al-
ways exhibited a lower CT number and a higher noise than pe-
ripheral regions. This cupping effect was masked by the noise
when the images were reconstructed with the largest voxel size
(100 m) except for protocols designed for low noise (P3, P5,
and P6). At 50 m voxel size, the noise was greatly increased,
and the uniformity-to-noise ratio decreased, emphasizing the
cupping effect. The uniformity-to-noise ratios for all protocols
(from reconstructed images with protocol-specific voxel size)
are shown in Table II.
E. Contrast
The contrast-to-noise ratio (CNR) measured with the QRM
low-contrast phantom decreased with the diameter and true
contrast of the insert (Fig. 7). The best contrast discrimination
(highest CNR values) was observed for the P2 and P5 protocols.
F. Dosimetry
Axial dose profiles for all nine transaxial positions were ob-
tained for protocols P1–P4. The dose distribution in -, -, and
-direction is displayed in Fig. 8 for P1 and P2. In contrast to the
360 gantry rotation protocol P2, 192 rotation (P1) resulted in a
nonhomogeneous dose distribution across transaxial positions.
The of all transaxial positions was calculated, and
the central position including the transaxial average is shown in
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Fig. 7. CNR plots measured for all contrast inserts and for all protocols.
(RxLCn: is the diameter of the insert in millimeters, for the highest
true contrast and for the lowest true contrast).
Fig. 8. Spatial dose distributions as measured for (a) P1 and (b) P2.
Fig. 9. Dose profiles of (a) transaxial center position and (b) calculated mFOV
scan dose profiles of transaxial center position.
TABLE III
SUMMARY
Table III. The (center) per mAs of the X-ray tube was
also calculated for all protocols.
The dose profiles of the transaxial center position for all as-
sessed protocols are shown in Fig. 9(a). Collimation of the beam
was observed at 35 to 45 mm along the -axis around the
center of the scan.
In Fig. 9(b), the theoretically obtained mFOV scan dose
(5 sFOVs) profiles at the center of the dosimetry phantom are
displayed. Each image plane is marked by vertical lines and
horizontal arrows. Overlap between images for stitching of
Fig. 10. In vivo dose measurement summary for (a) single-field-of-view and
(b) multiple-fields-of-view scans; MSAD is a theoretical value, no SD.
TABLE IV
MSAD INCLUDING PEAK VALUE FOR CENTER POSITION IN PMMA PHANTOM
reconstructed images was taken into account, and the falling
edges outside of the imaging field of view are displayed.
In Table IV, the calculated MSAD of mFOV scans using the-
oretically obtained mFOV scan dose profiles is shown. Peak
values are included for comparison to in vivo whole-body scan
data in rats.
G. In Vivo Dosimetry
The averaged measured in vivo dose for all protocols for
sFOV and mFOV scans is shown in Fig. 10. Doses for specific
protocols were averaged across sensor position for each rat as
the position did not impact significantly on the measured dose.
The for sFOV measurements and the MSAD for
mFOV measurements were added for comparison.
Standard deviations for mFOV measurements proved to be
higher due to a less homogenous dose profile along the -axis.
Overbeaming resulted in a difference between CTDI, MSAD,
and the respective point in vivo measurements.
H. In Vivo Bar Pattern Phantom
In Fig. 11, exemplary in vivo images using P2
[Fig. 11(a) and (b)] and P3 [Fig. 11(c) and (d)] are displayed
with the QRM Bar Pattern phantom inside the abdomen of
rat 1 [Fig. 11(a) and (c)] and rat 3 [Fig. 11(b) and (d)]. For
comparison, an image acquired using P3 of the phantom in air
is provided [Fig. 11(e)]. When using P2, in vivo line structures
below 150 m cannot be resolved independently of the amount
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Fig. 11. In vivo bar pattern scan of (a) rat 1 using P2, (b) rat 3 using P2, (c) rat 1
using P3, and (d) rat 3 using P3, and (e) ex vivo in air using P3; all images from
500 to 2000 HU.
of attenuating tissue surrounding. In the images acquired with
P3, which uses a higher tube current and a longer exposure
time, lines with a thickness of 100 m are visible inside the
200-g-rat scan and point structures with a diameter of 150 m
in both scans. For both protocols, the amount of surrounding
tissue influences the contrast between the metal plate and the
rest of the phantom and therefore impacts on the calculated
X-ray density of the materials.
IV. DISCUSSION
In this study, the vmCT phantom, with related performance
tests, and two QRM phantoms were used to evaluate the
performance of the eXplore CT 120 scanner for various scan-
ning protocols. Image quality parameters that were evaluated
using the vmCT phantom in a single acquisition per protocol
included: spatial resolution, geometric accuracy, CT number
evaluation, linearity, and uniformity and noise. The results
calculated with the slanted edge indicate a 10% of MTF in the
range 3.6–4.8 mm corresponding to effective spatial resolu-
tion between 95 and 138 m. The QRM Bar Pattern phantom
confirmed these results, as the smallest visible objects were
those of 100 m in ex vivo scans. The MTF values provided by
the coils method at the four spatial frequencies (0.15, 0.2, 0.3,
and 0.5 mm) agreed well with the slanted edge, although the
values were slightly higher. The sensitivity of the slanted edge
method toward the noise and orientation [16] could explain
the difference in the MTF values between protocols as well as
between methods.
The geometric accuracy of the system in both transaxial and
axial directions was evaluated, and the nominal pixel spacing
was shown to be within 0.1% for all tested protocols. The eX-
plore CT 120 demonstrated a highly linear response over the
range of iodine solutions used. The same behavior was also
observed for the CT evaluation section. The signal uniformity
and noise were evaluated for all protocols. A cupping effect
was observed, which is masked by noise for protocols with a
voxel size of 100 m. The noise and the uniformity-to-noise
ratio were voxel-size (binning mode) dependent. The high level
of the noise may also explain the low values of CNR mea-
sured with the QRM low-contrast phantom. The implementa-
tion of beam-hardening corrections to improve the uniformity
of the system over the entire field of view would be a valu-
able improvement for this system. Du et al. [11], who used the
vmCT phantom to evaluate the performance of the GE eXplore
Ultra (GE Healthcare, London, ON, Canada), reported a 10%
MTF of 2.5 line pairs per millimeter (equal to a resolution of
200 m). The eXplore CT120 demonstrated a better resolution.
However, the GE eXplore Ultra showed better results for signal
uniformity [11].
The was measured using a custom-built PMMA
phantom with MOSFET sensors for protocols P1–P4. All cal-
culated showed standard deviations below 3%, with
the exception of two positions in the P3 for which deviations
were higher (8%–11%). This may be attributed to slight posi-
tioning errors of the micro-CT bed at the falling edges of the
dose profiles. This can be seen in Fig. 9(a) in the P3 data, where
deviations are higher on the collimated edges of the beam. Fur-
thermore, it was observed that the collimation of the beam had
an offset of 5 mm in the positive -direction relative to the
center of the axial scan. This might be the result of inaccu-
rate calibration of the micro-CT table with respect to the de-
tector. Since the acquired FOV (55 mm) is smaller than the
collimated beam (80 mm), large overbeaming takes place, in-
creasing the compared to the dose throughout the real
beamwidth [as can be seen in Fig. 10(a)]. The average dose over
the full collimated beamwidth can be obtained by multiplying
the , shown in Table III, with the factor of 0.6875.
The P1–P3 showed a deviation of 8%–9% in the cross-sec-
tional average . This is likely due to limitation to 192
rotation, leading to a transaxial gradient in the dose measured as
can be seen in Fig. 8(a) where the dose is highest on the lower
right side of the phantom. When the was analyzed per
mAs, a deviation of 5% across 70-kVp protocols was found,
with an average of mGy/mAs.
When comparing the result to different studies using other
microCT systems, it shows that the GE eXplore CT 120 delivers
a comparably low dose to the animals.Willekens et al. [22], who
investigated the radiation dose of the Skyscan 1178 (SkyScan,
Kontich, Belgium), measured a of 6.6 mGy/mAs
in a 2.7-cm-diameter water container (at 50 kV, 615 A and
121 s image acquisition). They derived average organ doses
around 400 mGy, which is approximately 10 times higher
than using the GE eXplore 120. However, by decreasing res-
olution, scan time, and number of projections, they achieved
a dose of 1.2 mGy/mAs. Hupfer [15], using a TomoScope
microCT (CT Imaging GmbH, Erlangen, Germany), reported a
inside a 32-mm cylindrical phantom of approximately
2.2 mGy/mAs (40 kV, 23 mAs). Kersemans [6], using a Bioscan
nanoSPECT/CT, measured a CTDI inside a 60-mm-diameter
cylindric PMMA phantom of 7.7 mGy/mAs (35 kV, 50 A,
400 ms, 180 projections) to 3.7 mGy/mAs (65 kV, 123 A, 2 s,
and 360 projections). When comparing literature values of dose
output, it should be noted that the size of the phantom as well as
the material have an impact on the measurement. Additionally,
the actual mAs used in a protocol should be considered, as it
determines the resulting dose received by the scan subject.
Using the experimentally obtained dose profiles inside the
center position of the PMMA phantom, the MSAD for the cen-
tral image plane of a five-fields-of-view scan was theoretically
computed. In comparison to an sFOV, the average dose in the
center of an mFOV scan using the GE eXplore 120 is approx-
imately doubled with steeply falling edges in the dose profile.
The results were confirmed by in vivo measurements in three
different rats, where sFOV scans centered on sensors in skull,
chest, abdomen, and anal cavity were performed including an
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mFOV scan with each protocol. Although the weight of the an-
imals varied from 272 to 602 g, little deviation of the sFOV
doses could be observed. Standard deviations for mFOV scans
were higher due to a less homogenous dose profile as can be
seen in Fig. 9(b), which increases the sensitivity of the mea-
surement toward sensor placement across subjects. Due to the
large overbeaming when only considering the acquired FOV of
55 mm, the and the MSAD predict a higher dose than
measured in single-dose point measurements. However, when
correcting the with the previously provided factor to
the whole beamwidth, agreement between sFOV measurements
and the is satisfactory.
When visually inspecting the in vivo scans of the QRM Bar
Pattern phantom inserted into the abdomen of rats with different
weights, a clear impact of the amount of surrounding tissue and
the different protocols can be observed on contrast and reso-
lution. The protocol depositing more energy (P3) could con-
firm ex vivo results and achieve a resolution of approximately
100 m in vivo, whereas low-energy protocols (P1, P2, and P4)
only can resolve structures of 150 m. However, for all low-en-
ergy protocols, the images appeared blurred. The amount of sur-
rounding tissue decreased the contrast between the plate inside
the phantom and the filling material of the phantom perceiv-
ably. Thus, a tradeoff between resolution/contrast and dose de-
livered must be made when planning experiments. Smaller an-
imals seem to be more suitable for experiments where resolu-
tion/contrast is of high importance. However, if high resolution
is not necessary and the contrast achieved is sufficient, low-en-
ergy protocols should be used for the sake of dose reduction.
In conclusion, the eXplore CT 120 achieved a mean effec-
tive spatial resolution in the range 95–138 m (10% MTF).
The system was shown to be linear and geometrically accurate.
The major difference between the protocols was the noise level,
which limits the detectability of low contrasts. The average dose
delivered by the protocols used for in vivo imaging ranged from
20.15 to 56.79 mGy for single-field-of-view scans and 27.98
to 77.45 mGy for multiple-fields-of-view scans depending on
tube settings. The high dose delivered especially by protocol
P3 should be taken into account when planning multimodality
scans in a longitudinal setup, where radiation effects might com-
promise the study. However, doses delivered by the GE eXplore
120 are equal to or lower than doses of other microCT systems
reported in the literature.
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Abstract- Small animals are increasingly used as translational 
models in preclinical imaging studies involving microCT in which 
the subjects can be exposed to significant amounts of radiation. 
While the radiation levels are generally sublethal, studies have 
shown that low level radiation can change physiological 
parameters in mice. In order to rule out any influence of the 
radiation on the outcome of the experiments, or resulting 
deterministic effects in the subjects, involved radiation levels 
need to be addressed. The aim of this study was to investigate the 
radiation dose delivered by the GE eXplore 120 microCT non-
invasively using Monte Carlo simulations in GATE and to 
compare results to previously obtained experimental values. 
Tungsten x-ray spectra were simulated at 70, 80 and 100 kVp 
using an analytical tool and their half-value layers were 
simulated for spectra validation against experimentally measured 
values of the real x-ray tube. A Monte Carlo model of the 
microCT system was set up and four protocols that are regularly 
applied to live animal scanning were implemented. The CTDI 
inside a PMMA phantom was derived and multiple field of view 
acquisitions were simulated using a PMMA phantom, a 
representative mouse and rat. Simulated half value layers agreed 
with experimentally obtained results within a 7% error window. 
The CTDI ranged from 20 to 56 mGy and closely matched 
experimental values. Derived organ doses in mice reached 459 
mGy in bones and up to 200 mGy in soft tissue organs using the 
highest energy protocol. Dose levels in rats were lower due to the 
increased mass of the animal compared to mice. Monte Carlo 
simulations proved a valuable tool to investigate the 3D dose 
distribution in animals from microCT. Small animals, especially 
mice due to their small volume, receive significant amounts of 
radiation from the GE eXplore 120 microCT, which might alter 
physiological parameters in a longitudinal study setup. 
  
Index Terms—microCT, Monte Carlo Simulations, small 
animal dosimetry, X-ray quantification  
I. INTRODUCTION 
mall animal imaging techniques, such as micro Computed 
Tomogrpahy (microCT) and micro Positron Emission 
Tomography (microPET), have gained significant importance 
in preclinical studies, since small animals are increasingly 
used as translational models for clinical disease and treatment 
research [1]. Both imaging techniques can deliver, especially 
in a longitudinal study setup, extensive amounts of radiation. 
In microPET imaging of mice the injected activity per kg can 
be 100 times higher than in humans in a clinical setup 
resulting in far higher absorbed doses in animals [2, 3]. In 
microCT imaging, since it is used for anatomical referencing 
 
 
or disease staging in longitudinal studies, the needed 
resolution is typically between 50 – 100 µm. To achieve such 
a high resolution with an adequate signal-to-noise ratio, the 
photon flux of the X-ray tube has to be high leading to a 
significant radiation burden. While the absorbed dose 
distribution (or the S-factors for calculations of absorbed 
doses) of several isotopes in small animal microPET imaging 
have been derived in literature [3-5] and can be applied to 
every microPET scan, the dose distribution resulting from 
microCT imaging is machine dependent and needs to be 
addressed for every machine. Most studies investigate dose 
point measures in vivo experimentally using TLD chips in or 
in the vicinity of organs [6-9]. Monte Carlo simulations 
(MCS) are a valuable tool to quantify the 3D absorbed dose 
distribution in microCT non-invasively [10, 11], especially in 
locations or organs that are difficult to assess in vivo 
accurately due to large sensor geometries. Experimentally, 
bone doses can only be investigated using surface entrance 
doses with sensors being placed on top of the bone. With MCS 
however, it is possible to obtain the spatial dose distribution 
within the bone. The aim of the study was to simulate the 
microCT GE eXplore 120 and quantify the computed 
tomography dose index over 100 mm (CTDI100) inside a 
PMMA phantom and the dose delivered to rats and mice by 
several protocols that are regularly applied to live animals. 
The results will be compared to values experimentally 
obtained in our lab available in literature [12]. 
II. MATERIALS & METHODS 
All simulations of the GE eXplore 120 microCT were 
performed using GATE v6.1 [13]. Since CT imaging and dose 
calculations involve low energy radiation, the simulations 
were performed using the low energy Penelope package for 
physics processes and interaction models (check 
http://geant4.web.cern.ch/geant4/G4UsersDocuments/UsersGu
ides/PhysicsReferenceManual/html/node64.html for details 
and all cross-sections) [14]. The following physical processes 
were implemented in all performed simulations: Photoelectric 
effect, Compton scattering, Rayleigh scattering, Electron 
Ionization, Bremsstrahlung and multiple electron scattering. 
For details on the implemented GE eXplore 120 microCT the 
reader is referred to [12, 15], only information relevant to 
dosimetry simulations will be repeated here. The inbuilt X-ray 
source of the GE eXplore 120 microCT is a Dunlee 
PX1483GS (Subdivision of Philips Healthcare, Amsterdam, 
Netherlands). Its rotating anode is made of tungsten and 
rhenium and has a focal spot with a diameter of 300 µm. The 
Monte Carlo simulations of the dose from 
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GATE 
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tube has a 5 kW peak source power and can provide tube 
voltages between 70-120 kVp with a tube current range from 
20 to 50 mA. Its inherent filtration is equivalent to 1.5 mm 
Aluminium. The CCD detector of the system is positioned on 
a rotating gantry opposite of the tube at a fixed distance of 450 
mm with a carbon fibre bed designed to cater for mouse (25 
mm width) or rats (75 mm width) in the centre of rotation. The 
maximum axial field of view (FOV) per rotation is 55 mm (85 
mm in transaxial direction). Via overlapping FOV’s (15 mm 
on each side of the FOV) and stitching of images the 
maximum axial field of view can be extended to 250 mm. The 
axial dose profile (collimation of the X-ray beam) was 
experimentally determined to have a full width half max 
(FWHM) of 74.5 mm at the centre of rotation [12]. 
 
A. Simulation geometry 
The X-ray tube was reduced for simplicity to its focal spot and 
was modelled as a circular disk with a radius of 150 µm. The 
opening angle of the X-ray beam was determined via 
trigonometric calculation to be 18.8008° using the 
experimentally determined FWHM of the axial dose profile 
(74.5 mm) and the distance of the tube to the centre of rotation 
(225 mm). A detector was modelled at the distance of 450 mm 
to the X-ray source. Since no images had to be reconstructed 
from simulated data and large numbers of small detectors are 
computationally expensive, the detector was not subdivided 
and was modelled as a single continuous element for the 
purpose of verifying spectra only. 
B. X-ray spectra and half-value layer 
For the simulation of the X-ray spectrum at 70, 80 and 100 
kVp the spectrum simulator provided by Siemens on their 
website (https://w9.siemens.com/cms/oemproducts/Home/X-
rayToolbox/spektrum/Pages/radIn.aspx) based on an algorithm 
by Boone et al. [16] was used. The algorithm was developed 
for Tungsten spectra only between 30 and 140 kV. Input 
parameters were 70, 80 and 100 kV peak voltages, air kerma 
of 0.1 Gy and 1.5 mm equivalent Al filtration according to the 
filtration of the microCT.  
In order to validate the spectra, the half value layer (HVL) was 
simulated and experimentally determined. The HVL 
represents the thickness of a material reducing the intensity of 
radiation by absorption and scattering by one half. In 
radiology it is usually measured using aluminium (Al) for 
beam quality control purposes. For the determination of the 
HVL using simulations, a 60 mm x 60 mm box of Al was 
inserted into the beam path at 60 mm distance to the X-ray 
source with varying thickness (0 – 6.5 mm, depending on 
kVp). An ideal single lead detector at a distance of 225 mm 
with a size of 80 mm x 80 mm x 1 mm was used for stopping 
and counting photons. For each simulation a total amount of 
6E+07 photons were simulated to determine the HVL of 
spectra at 70, 80 and 100 kVp.  
The HVL of the PX1483GS at 70, 80 and 100 kVp was 
experimentally determined with the X-ray quality control 
device Black Piranha of RTI Electronics (RTI AB, Mölndal, 
Sweden). The sensor was placed at the center of rotation of the 
gantry on the carbon fiber bed with the x-ray tube in stationary 
top position above the sensor. The tube was triggered with a 
tube current of 50 mA and an exposure time of 100 ms at the 
respective tube voltage with 5 measurements per tube voltage 
setting.   
 
C. Phantoms 
CT images in Analyze7.5 format were implemented into the 
rotational centre between source and detector and were rotated 
instead of the source-detector geometry according to the 
settings of the simulated protocol, which are displayed in 
Table 1. The images included the microCT bed as the 
attenuation inside the bed decreases the amount of X-ray 
quanta reaching the subject on the table. Three images shown 
in Figure 1 were used for dose calculations, which were down-
sampled for computational speed: the custom build phantom 
used in [12] (0.7109 mm x 0.7019 mm x 3.1999 mm voxel 
 
 
Fig. 1.  Down-sampled, segmented CT input images of Phantom: (a) transversal, (b) sagittal and (c) coronal plane; rat: (d) transversal, (e) sagittal and (f) coronal 






size), a representative mouse (0.3996 mm x 0.3996 mm x 
0.3996 mm voxel size) and a representative rat (0.7992 mm x 
0.7992 mm x 0.7992 mm voxel size). Images were segmented 
and the ranges of arbitrary pixel values (PV) of segmented 
structures were related to either existing materials or newly 
implemented materials in the material database of GATE. 
Since the soft tissue contrast between organs (apart from lung) 
in mouse and rat was poor, organs were not fully segmented 
but spheres were manually placed in the centre of organs. The 
PV ranges inside the spheres in the respective organ were 
derived and the spheres were used for dose readouts from the 
dose maps of the simulations.  
 
D. Dose simulations 
Four different acquisition protocols (P1 to P4), which were 
also experimentally investigated in [12], were implemented 
and simulated using all three above mentioned phantoms 
(PMMA, mouse, rat). In the starting position (0° rotation) of 
each simulation the X-ray source was located in the top 
position over the various phantoms. The phantoms were then 
rotated anti-clockwise during the simulation according to 
protocol settings. A total amount of 6E+07 photons/sec were 
simulated in each simulation. The output of simulations was a 
co-registered Analyze7.5 image of the spatial dose distribution 
with the same size and resolution as the original input CT 
image. Single field of view (sFOV) acquisitions and multiple 
fields of view (mFOV) acquisitions were simulated. The 
mFOV simulations consisted of several independently 
performed sFOV simulations with the source translated in 
axial direction according to machine settings of the GE 
eXplore 120 microCT. The overlap between images of 15 mm 
on each side used for stitching images together was taken into 
account. The dose maps of all sFOV building the mFOV 
acquisition were then added up numerically to one dose map. 
For the PMMA phantom one sFOV simulation was performed 
with each protocol and one mFOV consisting of 5 sFOV 
simulations using P1. Due computer memory issues, the 
resolution of the image of the PMMA phantom had to be 
decreased to a voxel size of 1.4218 mm x 1.4218 mm x  
3.1999 mm for simulations using P2. For rodent simulations 
mFOV scans were performed with 3 sFOV for mice and 5 
sFOV for rats. Organ doses in mice were derived for all 
protocols (P1 to P4) and for rat P1 and P3 were used. 
E. Scaling of dose maps and CTDI/MSAD calculation 
Since only a fraction of the real amount of photons emitted by 
the X-ray source was simulated to decrease simulation time, 
the resulting dose maps were scaled using experimentally 
obtained data. Eight axial dose profiles D(i) along the scanner 
axis z were extracted from the unscaled dose map of the 
PMMA phantom around the centre hole inside the phantom, 
which were averaged and then used to compute the CTDI 















N · T is usually defined as the nominal beam width, but was 
set equal to the width of the acquired FOV of 55 mm as in 
[12]. The dose map was then scaled by the ratio between the 
computed CTDIsim based on simulated data and the 
experimentally obtained CTDIexp available in [12] in the same 
centre position, similar to Taschereau et al. [10]. The obtained 
scaling factors fs were applied to all simulations of the 











For all sFOV simulations of the PMMA phantom the CTDI 
was computed in 9 transaxial positions as described above. 
Additionally, the FWHM of all extracted dose profiles was 
determined. The MSAD of P1 was calculated using the mFOV 

















where I equals the width of the central sFOV of 55 mm. Organ 
and bone doses were derived from the scaled dose maps of 
mice and rats using the co-registered VOIs of the input images 
shown in Figure 1. 
 
III. RESULTS 
A. Simulated X-ray spectra 
 
In Figure 4 the X-ray spectra at 70, 80 and 100 kVp tube 
voltage simulated using the Siemens X-ray tool are displayed. 
The spectra were simulated for a pure Tungsten anode, 





















Fast scan 220 (P1) 70 32 16 220 192 
Fast scan 360 (P2) 70 32 16 360 360 
Soft tissue fast scan (P3) 70 50 32 220 192 
Soft tissue step & shoot (P4) 80 32 16 220 192 
 





B. Half-value layer 
The half value layer of the spectra of the x-ray tube 
PX1483GS was measured experimentally and the results are 
displayed in Table 2. The tube current and the exposure were 




The half layer value at 70 kVp was determined by simulation 
to be 4.28 mm Al, 5.04 mm Al at 80 kVp and 6.22 mm Al at 
100 kVp. The simulation of the HVL showed a highly linear 
relation between the percentage of detected photons of all 
emitted photons and the thickness of the aluminium box inside 
the beam path with R2 > 0.999 for all tube voltages (as can be 
seen in Fig. 3). The differences between experimentally 
obtained values and simulated values amounted to 1.33% for 
70 kVp, 3.21% for 80 kVp and 6.69% for 100 kVp. 
C. Dose simulation 
In Table 3 the PV of materials inside the phantoms obtained 
by segmentation of the Analyze7.5 input images are displayed 
along with the assigned materials of the material database of 
GATE. PV of all organs (apart from lung) overlapped and 
were summarized as soft tissue. Bone structures could not be 
resolved due to the limited resolution of the images and the 
whole skeleton was summarized as bone. A material definition 
from the MOBY phantom [17] of lung tissue was assigned to 
the lung pixel value range of mouse and rat. All other material 
compositions were taken from the material database of GATE. 
TABLE II 
EXPERIMENTAL MEASUREMENT OF HVL 
Tube voltage (kVp) 70 80 100 
Measured tube voltage (kVp) 70.60 ± 0.06 79.92 ± 0.07 96.99 ± 0.08 
Measured exposure (ms) 93.93 ± 1.50 94.64 ± 0.42 94.84 ± 0.55 
Measured dose (mGy) 0.51 ± 0.01 0.73 ± 0.00 1.22 ± 0.01 
Measured HVL (mm Al) 4.22 ± 0.02 4.88 ± 0.01 5.80 ± 0.01 
 
 
Fig. 3.  Simulation of HVL for 70, 80 and 100 kVp including fit and 






Fig. 4.  Simulated average dose profiles of P1 in PMMA phantom with (a) Center position sFOV, (b) simulated dose  map including positions for data extraction 









In Table 4 the scaling factors fs (ratio between 
experimentally derived CTDI100 and the CTDI100 obtained 
from unscaled simulated dose maps), the scaled and averaged 
CTDI100 of the center position including the transaxial average 
for P1 to P4 are displayed. The averaged MSAD including the 
transaxial average was only simulated for P1. The highest 
radiation was delivered by P3, followed by P2. Standard 
deviation for 192° gantry rotation in the transaxial average 
CTDI100 is increased compared to the 360° rotation protocols. 
 
 
In Figure 4 simulated dose profiles inside the PMMA 
phantom of P1 are displayed. The CTDI100 was determined to 
be 20.25 ± 0.44 mGy and the MSAD (5 sFOV acquisition) 
was 28.75 ± 1.32 mGy. Peak dose point value in the mFOV 
acquisition was 37.9 mGy. Dose profiles in positions on the 
left side of the phantom (position 4 to 8) showed higher 
maximum dose values due to the limited 192° anti-clockwise 
rotation of the gantry for sFOV and mFOV acquisitions.  
 
In Figure 5a and 5b a comparison of sFOV (P1 to P4) and 
mFOV (P1) dose profiles of the center position inside the 
PMMA phantom derived experimentally taken from [12] and 
by simulations is presented. In Figure 5c the CTDI100 of all 
protocols obtained experimentally and by simulations are 
displayed for the centre position and the transaxial average. 
All derived values agreed within an error range of 2%. Figure 
5d to 5f display dose depositions outside the phantom 
boundaries in air that were observed in mFOV acquisitions. 
Fig. 5. Experimental (exp) and simulated (sim) data of (a) center position 
inside PMMA phantom for all protocols and sFOV, (b) mFOV using P1 and 
(c) CTDI of all protocols for centre position and the transaxial average (TA), 
– sFOV average dose profiles in transaxial center position inside PMMA 
phantom extracted from mFOV acquisition of P1 with (d) leftmost 
acquisition, (e) center acquisition and (f) rightmost acquisition; for positions 
1 to 9 see Figure 4e 
TABLE IV 
SCALING FACTOR, CTDI100 AND MSAD DERIVED 
BY SIMULATION IN PMMA PHANTOM 
  P1 P2 P3 P4 
Scaling factor fs 9816.1 12642 13547.8 14228.1 
CTDI100 center (mGy) 20.25 ± 0.44 30.09 ± 0.29 55.81 ± 0.48 28.56 ± 7.41 
CTDI100 transaxial (mGy) 20.12 ± 2.59 30.94 0.19 55.58 ± 7.82 28.13 ± 3.71 
MSAD center (mGy) 28.75 ± 1.32 - - - 
MSAD transaxial (mGy) 28.76 ± 4.05 - - - 
 
TABLE III 





















































          *from GATE material database 






In Figure 6 organ doses including the whole-body dose 
simulated in the mouse phantom using P1 to P4 and the rat 
phantom using P1 and P3 are displayed. Analogue to the 
phantom results, P3 delivered the highest amount of radiation. 
The largest dose was received by the bones with an average of 
459.13 ± 96.37 mGy from P3 in mice (166.37 ± 35.49 mGy 
from P1, 351.00 ± 61.29 mGy from P2, 219.43 ± 46.49 mGy 
from P4). The average whole body dose in mice was 188.70 ± 
112.05 mGy from P3 (68.39 ± 40.89 mGy P1, 143.80 ± 84.91 
mGy from P2, 91.28 ± 53.55 mGy from P4). Doses absorbed 
by rats are slightly lower compared to mice and the total body 
dose from P1 was 43.07 ± 25.79 mGy and 118.89 ±  71.09 
mGy from P3 (highest dose in bones of 108.20 ± 33.32 mGy 
for P1 and 298.69 ± 91.87 mGy for P3).  
 
IV. DISCUSSION 
In this study we investigated the radiation dose delivered by 
the GE eXplore 120 microCT using Monte Carlo simulations. 
X-ray spectra for a tungsten anode were simulated with a 
publicly available tool provided by Siemens based on an 
algorithm by Boone et al. [16] and validated with 
experimental measurements and simulations of the HVL. 
Although the x-ray source PX1483GS contains tungsten and 
rhenium and the simulated x-ray spectra at 70, 80 and 100 
kVp tube voltage were based on data for tungsten anodes only, 
the experimentally obtained HVL and simulated data agreed 
closely. Differences in the HVL of 1.33% at 70 kVp, 3.21% at 
80 kVp and 6.69% at 100 kVp could be observed, which is in 
the range of the inaccuracy of ± 10% or ± 0.2 mmAl provided 
by the manufacturer of the sensor for 70 and 80 kVp. Yet, the 
error between experimental data and simulated data increased 
with tube voltage for two reasons. First, the simulated x-ray 
spectra are for tungsten anodes only, and the material 
characteristic peaks in an x-ray spectrum become more 
apparent at higher tube voltages as can be seen in Figure 2. 
The peaks characteristic for rhenium are slightly different than 
for tungsten explaining the larger difference at higher tube 
voltages. Second, the experimentally measured output tube 
voltage at 100 kVp was 96.99 ± 0.08 kVp with a sensor 
inaccuracy of ± 1.5%, while the simulated spectrum was 
simulated for 100 kVp possibly causing a further mismatch at 
100 kVp between experimentally obtained HVL and simulated 
data. However, since no experimental data for 100 kVp 
protocols was available, no scaling factor could be derived and 
consequently the radiation dose at 100 kVp could not be 
investigated but will be part of future studies. 
Deriving pixel value ranges of structures or organs inside 
the low-contrast microCT images by segmentation proved 
challenging. Many structures contained similar pixel values 
and overlapped. All segmented organs apart from the lung had 
to be summarized as soft tissue inside the image. All bone 
structures including the bone marrow were assigned the same 
material composition due to overlapping pixel values and the 
low resolution of the down-sampled phantoms. The material 
composition of spine bone, which is implemented in the 
material database of GATE, was assigned to the whole 
skeleton, since its density of 1.42 g/cm3 represented an 
approximate average of all bone densities implemented in 
GATE. Analytical phantoms instead of voxelized phantoms, 
such as the MOBY and ROBY phantom [18], would have 
enabled to differentiate between more structures, but are 
commercial products nowadays and were not available to us.  
The derived CTDI100 values inside the PMMA phantom 
(see Table IV) confirmed experimentally obtained values 
available in [12]. Although the center CTDI100 could not be 
different to the experimental value due to scaling of the dose 
maps to that particular value, the transaxial averages of 192° 
and 360° rotation protocols agreed as well (see Figure 5c) 
proving that the simulated dose deposition inside the phantom 
reflects the measured situation. Standard deviations were 
slightly higher in the simulated transaxial averages compared 
to experimental transaxial averages, which could be related to 
noise originating from simulating only a fraction of the total 
amount of photons emitted and scaling afterwards. 
Simulations with the real photon flux of the x-ray tube might 
improve results due to a higher signal-to-noise ratio; however, 
long computation times are to be expected. The simulated 
mFOV dose profile of protocol P1 in the center position of the 
PMMA phantom matched the experimentally determined dose 
profile from [12] closely. The experimentally obtained dose 
profile was derived by measuring a sFOV dose profile using 
MOSFET sensors inside the PMMA phantom, which was then 
used to theoretically construct the mFOV dose profile by 
superposition and shifting of the sFOV dose profile. The 
agreement between both mFOV dose profiles confirmed the 
assumptions of the additive nature of the dose profiles inside 
the homogenous medium and makes phantom measurements 
and simulations of mFOV acquisitions in phantoms redundant, 
since the mFOV dose profile can be obtained by simple 
superposition of sFOV dose profiles. The calculated MSAD 
based on simulations in the center FOV consequently matched 
the experimental value within an error range of 5%. It is to be 
expected, that simulated mFOV acquisitions would produce 
similarly accurate results for all other protocols due to the very 
close agreement of sFOV dose profiles of all protocols. The 
mFOV acquisitions of protocols P2 to P4 were therefore not 
simulated to save computation time. However, the simulated 
mFOV dose profile of protocol P1 showed dose deposition 
peaks on either side of the profile outside of the phantom 
boundaries in air (see Figure 5b). They originate from the first 
 
Fig. 6.  Organ doses derived from mFOV acquisitions with P1 to P4 in mice 







and last sFOV acquisition in axial scanner direction 
(translation of the source in axial direction of ±8 cm), where 
the beam is directed at the boundary between air and PMMA 
as can be seen in Figure 5d and 5f. Even when the source is 
located in the center (corresponding dose profile in Figure 5e) 
dose is deposited in air outside of the phantom boundaries. 
The artifacts could be related to edge effects on material 
boundaries and scatter from inside the phantom. There was no 
impact from the artifacts on the calculation of the MSAD, 
since the MSAD was calculated in the central portion (central 
sFOV) of the dose profile. 
The derived doses from the animal phantoms of mouse and 
rat showed that significant doses are inflicted on both species 
in a typical microCT acquisition. Especially smaller animals, 
such as mice, receive a large amount of radiation due to their 
small volume with bone doses of 459.13 ± 96.37 mGy (P3). 
The whole body received a total amount of radiation of 68.39 
± 40.89 mGy (mouse, P1) and 43.07 ± 25.79 mGy (rat, P1), 
which is far more than predicted by the MSAD for P1 (3 
sFOV for mouse: 28.49 ± 1.36 mGy; 5 sFOV for rat: 28.75 ± 
1.32 mGy). This is related to the difference in volume between 
the PMMA phantom, the mouse and the rat. The PMMA 
phantom has a total volume of 392.69 ccm, the rat 258.18 ccm 
and the mouse 18.76 ccm. Boone et al. [19] performed Monte 
Carlo simulations with a homogenous small animal model of 
different diameters (5 to 40 mm) and also found that the dose 
increases with a decreasing animal diameter. Derived rat organ 
doses are therefore closer to the MSAD due to the more 
similar volume. The average soft tissue organ dose in mice 
was 159.42 ± 43.91 mGy and 128.02 ± 36.67 mGy using P3. 
High energy protocols such as P3 with longer exposure and a 
larger tube current compared to P1 result in higher radiation 
burdens. The large standard deviations in all derived organ 
doses might be a result of the 192° gantry rotation only, which 
results in higher doses on one side of the animal (analogue to 
dose profiles in the PMMA phantom for P1 shown in Figure 
4d). Another factor might be simulating only a fraction of the 
photons and scaling afterwards, which results in a higher 
signal-to-noise ratio as if the real number of photons would 
have been simulated. Analytical animal models, where 
different material compositions can be easily assigned to 
different organs, might improve the accuracy of the results and 
they should be implemented for future studies.  
When comparing the herein derived mouse doses for the 
360° rotation protocol P2 to data of a 70 kVp protocol (2 mm 
Al filtration, 360 x 0.5s exposures and 0.5 mA) derived by 
Taschereau et al. [10] for another microCT, absolute total 
body doses delivered by the GE eXplore 120 microCT are 
slightly larger, but the dose per mAs is lower (total body dose 
of 0.78 mGy/mAs vs. 1.03 mGy/mAs from Taschereau et al.). 
The protocols are different and the GE eXplore uses a much 
higher current while the exposure per projection is much 
shorter compared to the machine simulated by Taschereau et 
al.. The higher absolute doses might be also a result of the soft 
beam of the GE eXplore as it has 0.5 mm Al less filtration. 
In future studies an analytical small animal model should be 
used to be able to assign different material compositions to all 
organs and to derive more organ doses, especially to the 
radiosensitive bone marrow. Simulations with the appropriate 
photon flux of the respective x-ray tube might increase the 
signal-to-noise ratio in dose maps and produce more accurate 
results. 
In conclusion, we established a valid Monte Carlo 
simulation model of the GE explore 120 microCT for tube 
voltages of 70, 80 and 100 kVp. Simulated dose profiles and 
consequently the CTDI100 and MSAD in a PMMA phantom 
agreed closely with published experimentally derived results. 
Monte Carlo simulations proved a valuable tool to derive non-
invasively organ doses in rats and mice. Researchers using the 
GE eXplore 120 microCT can expect significant radiation 
doses in mice from a single acquisition with total body doses 
of 189 mGy using P3. Especially bones in mice are exposed to 
high radiation burdens of up to 459 mGy. The additional 
radiation from microCT in longitudinal dual modality studies 
should always be taken into account in order to avoid 
overexposures of animals that might compromise the outcome 
of the study. 
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